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Summary
To investigate the role of the carboxyl terminal in the regulation of the prostacyclin (IP) 
receptor, chimeric receptors expressing the carboxyl termini of either the thyrotropin- 
releasing hormone-1 (TRH) receptor or the P2 -adrenoreceptor (p2 -AR) were generated. 
Furthermore, C-terminally green fluorescent protein (GFP)-tagged forms of the 
receptors were built and stably expressed in HEK293 cells, thus enabling direct 
visualisation of receptor localisation and trafficking in intact cells.
Pharmacological analysis of the receptor-GFP fusion proteins demonstrated that each 
bound [^H] iloprost with similar affinity and coupled to increased cAMP production. 
Sequestration studies revealed that iloprost-induced internalisation of the prostacyclin 
receptor was augmented by the addition of the TRH carboxyl tail. Conversely, the p2 - 
tailed chimeras exhibited internalisation properties comparable to those of the full- 
length prostacyclin receptors. The receptors’ internalisation kinetics were unaffected by 
the addition of the GFP moiety.
Agonist-mediated sequestration of the constructs was abolished by treatments inducing 
clathrin depletion. In addition, sequestered receptors were found to colocalise in 
endosomes containing transferrin, as determined by confocal microscopy. Visual 
assessment of the dynamic interaction between p-arrestins and the receptor proteins 
demonstrated that sequestration of the full-length receptor proceeded primarily via an 
arrestin-independent mechanism. Switching of the receptor’s carboxyl domain for the 
equivalent P2 -AR sequence did not confer p-arrestin sensitivity to the receptor. In 
contrast, the TRH-tailed receptors exhibited an increased binding affinity for p- 
arrestins, internalising in complexes with p-arrestin 2. In a cellular milieu deficient of p- 
arrestins and GRKs, the prostacyclin receptor and its chimeric forms retained the ability 
to undergo agonist-mediated sequestration.
Analysis of receptor regulation revealed that the GFP-tagged IP receptor elicited rapid 
signal attenuation in response to iloprost challenge. A less striking desensitisation 
response was evident with receptors expressing the different carboxyl tails. During 
desensitisation of the receptor-GFP proteins, iloprost challenge induced rapid receptor
XXI
phosphorylation which was, in part, mediated by the second messenger kinases PICA 
and PKC. PKA was demonstrated to be a major desensitising kinase of the receptors 
while PKC phosphorylation was identified as a possible determinant for receptor 
sequestration. Upon agonist withdrawal, the internalised GFP-tagged full-length 
receptor recycled rapidly back to the plasmalemmal surface, which was followed by the 
restoration in receptor responsiveness. By comparison, the agonist-activated chimeric 
receptors failed to recycle, and therefore resensitise, after agonist removal. 
Subsequently, the intracellularly retained chimeric receptors were sorted predominantly 
via a degradative pathway. Taken together, these data highlight the importance of the 
carboxyl terminal domain in prostacyclin receptor function.
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Chapter 1 
Introduction
1.1 Cell Signalling
Communication between individual cells is an essential prerequisite for the co-ordinated 
functioning of a multicellular organism. Cells have the ability to process vast amounts 
of information provided to them by extracellular signals (such as hormones, 
neurotransmitters, and growth factors) and physical signals (such as light). Most of 
these signals do not enter the cell, but affect membrane-bound receptors which are 
dedicated to the recognition of such messenger molecules. The most abundant receptor 
family is the G protein-coupled receptor (GPCR) family. In vertebrates, this family 
contains 1 0 0 0 - 2 0 0 0  members, thus constituting one of the largest protein families in 
nature.
GPCRs are involved in the recognition and transduction of messages as diverse as light, 
Ca^  ^ ions, odorants, small molecules such as nucleotides, amino acid residues, and 
peptides, as well as proteins. GPCRs characteristically activate one or more members of 
the guanine-nucleotide-binding signal transducing proteins (G proteins) that convey the 
information received by the receptor to cellular effectors such as enzymes and ion 
channels. These effectors influence levels of second messengers that regulate a wide 
variety of cellular processes including cell growth and differentiation.
1.1.1 GPCRs and G proteins: Historical perspective
In 1957, Sutherland and Rail described the basic properties of an enzyme now known as 
adenylyl cyclase, its activators adrenaline, glucagon, and sodium fluoride, and its 
product cAMP (Rail et al  ^ 1957; Sutherland and Rail, 1958). At this stage, G proteins 
and hormone receptors were unknown. Ten years later the hormone-sensitive enzyme 
was still thought of as a protein complex in which its catalytic activity was regulated 
allosterically by the direct binding of a hormone ligand to a specific site on a regulatory 
subunit. By the end of the 1960s, however, studies of fat cell adenylyl cyclase by 
Bimbaumer and Rodbell (1969) determined that hormone receptors and adenylyl 
cyclase are distinct entities. A few years later the separateness of receptor and cyclase 
was directly demonstrated by Orly and Schramm (1976), and in 1981, the purification
of a (3-adrenergic receptor (p-AR) was reported, the first GPCR to be characterised 
(Shorr et 1981).
Further study of the molecular mechanisms governing hormonal activation of adenylyl 
cyclase revealed a critical role for GTP in the process (Rodbell and Bimbaumer, 1971), 
A GTP-binding protein was subsequently separated from the enzyme complex by 
Pfeufer and Helmreich in 1975, and by 1977 Ross and Gilman reported that activation 
of a GTP-insensitive cyclase could be restored by the addition of a 40 kDa GTP-binding 
protein which is now known as Gsa.
In the late 1970s, Cassel and Selinger (1978) first noted the GTPase activity of Gsa 
when adrenaline was used to stimulate adenylyl cyclase activity. They postulated that 
interaction of the hormone-activated receptor with Gs triggered the release of bound 
GDP and subsequent GTP binding. The hydrolysis of bound GTP to GDP led to Gs 
inactivation and the completion of the cycle. They also noted that hormone-stimulated 
GTPase activity could be inhibited by cholera toxin-catalysed ADP-ribosylation of Gsa 
resulting in constitutive activation of adenylyl cyclase.
Further research showed that Ga proteins formed complexes with two other proteins, 
which became known as the p (35-36 kDa) and y (6-10 kDa) subunits. The p and y 
subunits were found to be tightly bound together to function as a Py dimer, py dimers 
have since been shown to be involved in the activation of signalling pathways within 
cells independently of the Ga subunit (Clapham and Neer, 1997). Using cDNA cloning 
techniques, by the late 1980s, an array of G« subunits had been identified including the 
Gi proteins (which are associated with inhibition of adenylyl cyclase). Go (which are 
involved in ion channel activation), and transducin (the G-protein coupling rhodopsin to 
cGMP phosphodiesterase in rod photoreceptors) (Spiegel, 1987). In 1990 the Gq family 
(which regulate phospholipase C activity) were reported (Strathmann and Simon, 1990).
1.1.2 Structural features of GPCRs
Nearly 2000 GPCRs have been reported since bovine opsin was first cloned in 1983 and 
the p-AR receptor in 1986. The superfamily has been classified into over 100
subfamilies according to sequence homology, ligand structure, and receptor function. 
All GPCRs share a common structural homology which comprises an extracellular N- 
terniinal segment, seven transmembrane spanning domains which are linked by three 
extracellular and three intracellular loops, and an intracellular C-terminal segment 
(Figure 1.1a).
The N-terminal segment of most GPCRs exhibit at least one consensus sequence (Asn- 
X-Ser/Thr) for N-linked glycosylation, although for some receptors there may also be 
predicted glycosylation sites in the first and second extracellular loops. In some 
receptors glycosylation seems to be functionally important for cell surface expression 
(George et al, 1986). The secretin/vasointestinal peptide GPCR sub-family, which bind 
neuropeptides and peptide hormones, possess a relatively large N-terminus with at least 
6  highly conserved cysteine residues which are thought to be involved in ligand binding 
(Strader et al, 1995). Members of the metabotropic glutamate receptor family possess 
the longest N-terminal segments which not only provides the ligand binding site but is 
also involved in receptor activation (Takahashi et al, 1993).
The seven transmembrane (TM) spanning domains are thought to form a barrel shape, 
orientated roughly perpendicular to the plane of the membrane in an anti-clockwise 
fashion with three extracellularly and three intracellularly connecting loops, forming a 
ligand binding pocket (Figure 1.1b). Sequence analysis has shown that each of the TM 
domains comprise 20-25 predominantly hydrophobic amino acids. By extrapolation 
from the stmcture of rhodopsin these stretches are predicted to form a-helical 
membrane spanning domains of unequal length which can extend beyond the lipid 
bilayer (Unger et al, 1997). The orientation of the TMs imposes a stereo- and geometric 
specificity on a ligand’s entry into and binding to the TM core. The core primarily 
contains TMs II, III, V, and VI (which are extremely hydrophobic) whereas TMs I, IV, 
and VII (which are more hydrophilic) are more exposed to the bilayer (Sealfon et al, 
1997). Hydrogen bonds and salt bridges between residues of the same TM as well as 
other TMs are critical for maintaining a tightly packed TM core (Pebay-Peyroula et al., 
1997).

Figure 1.1
a) Schematic representation of the general structure of GPCRs.
GPCRs comprise 7 a-helical transmembrane domains which are linked by 3 
intiacellular and 3 extracellular loops. The N-terminal region contains sites for 
glycosylation and the C-terminal region contains sites for lipid modification and 
phosphorylation.
b) Arrangement of the transmembrane domains of a prototypical GPCR in the 
lipid bilayer.
The 7 transmembrane regions are arranged in the plasma membrane as a closed loop 
in an anti-clockwise direction from TMl to TM7. The stability of the structure is 
maintained by intramolecular disulphide bonds and salt bridges.
Figure 1.1
a)
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Two conserved cysteine residues in extracellular loops 1 and 2 are known to be linked 
by a disulphide bond in bovine rhodopsin, the thyrotropin-releasing hormone (TRH) 
receptor, the thromboxane receptor, and the gonadotropin-releasing hormone (GnRH) 
receptor. This disulphide linkage is thought to constrain the loops and receptor, 
specifically pulling the second extracellular loop over and thus preventing the opening 
of the TM core on the extracellular side (Ji and Ji, 1995), Substitution of cysteine 
residues in the first and second extracellular loops of the P2-AR receptor (Cys^^  ^and 
Cys^ ®"^ ) induced destabilisation of the tertiary structure and alterations in the receptor’s 
ligand binding properties (Dohlman et a l, 1990). The first or second extracellular loops 
may also contain sites for N-linked glycosylation.
The intracellular loops are predicted to be between 10 and 40 amino acids in length with 
the notable exception of the third intracellular loop, which can be more than 150 
residues long. The intracellular loops are involved in the interaction of the receptor with 
the heterotrimeric G proteins. Both the second and the third intracellular loops have 
been reported to be crucial for coupling to G„ subunits. The amino acid sequence of the 
second intracellular loop is among the most highly conserved in the GPCR superfamily 
and substitutions in some of its highly conserved residues has been shown to severely 
impair G protein coupling. The amino and carboxyl terminal portions of the third 
intracellular loop in the muscarinic and catecholamine receptors appear to be critical 
determinants of G protein coupling and activation (Wess et aL, 1990; Cotecchia et a l,
1992). The third intracellular loop is also a target for phosphorylation by G protein 
receptor kinases (GRKs), and in case of the P2 -AR, second messenger kinases such as 
cAMP-dependent protein kinase (PKA) (Benovic et a l, 1985).
The intracellular C-terminal tail varies considerably in length (12-359 amino acids) with 
the exception of the mammalian GnRH receptor which completely lacks an intracellular 
C-terminal domain (Sealfon et a l, 1997). A fourth cytoplasmic loop can be formed 
when the C-tail is pahnitoylated. The C-tail is usually rich in serine and threonine 
residues that are potential sites for phosphorylation by GRKs and second messenger 
kinases for receptor desensitisation (Freedman and Lefkowitz, 1996).
1.1.3 Ligand binding and receptor activation
Ligand binding and receptor signalling are clearly dissociable functions involving 
distinct interactions of the ligand with several domains of the GPCR. The regions of the 
receptor responsible for binding and activation is dependent on the GPCR subfamily as 
well as the size and structure of the ligand.
The binding of biogenic amines to their receptors is characterised by a complex of 
interactions involving key residues in TMs III, V and VI (Strader et a l, 1987). In these 
receptors, the amine of the ligand interacts with the carboxyl group of an aspartate 
residue in TM III, whereas the catechol ring interacts with residues in TMs V and VI. 
Interactions of the ligand with TMIII are important for binding, while interactions with 
TMs V and VI are more important for receptor activation (Strader et a l, 1997).
Photo-affinity labelling and mutational analysis showed that the P-ionone ring of retinal 
associates with TMs III, V, and VI of rhodopsin, in particular TM VI Trp^^  ^ and Tyr^^  ^
(Han, 1997). Light absorption causes an 2i\\-trans isomérisation of retinal and as a result, 
key hydrogen bonds and salt bridges between TMs III and VI are broken, leading to a 
rearrangement of TMs III, VI, and VII, thereby generating a signal (Han, 1997).
Small peptides, such as angiotensin, bind to regions of the first extracellular loop and 
TMs II-VII, highlighting the role of both extracellular and TM domains in ligand 
binding and receptor activation. The C-terminal part of the ligand enters the TM core 
and the C-terminal carboxyl group pairs with Lys^^  ^in TM V, while the N-terminal part 
of the ligand ion pairs with the His^ *  ^of the second extracellular loop and Asp^^  ^ of the 
third extracellular loop. Mutational studies suggest the interaction with the aspartate 
residue is necessary for signal generation (Noda et a l, 1995; Feng et a l, 1995)
For glycoprotein hormone receptors, which characteristically possess a 350-400 residue 
amino terminus, the N-terminal region is solely capable of high affinity ligand binding. 
Leucine-rich repeats in the N-terminus are thought to be important in the ligand 
binding, whereas contact with the extracellular loops and/or membrane-associated 
domains are required for receptor activation (Ji and Ji, 1995).
For the metabotropic glutamate receptors, the ~300 amino acid amino-terminal half of 
N-terminal segment not only functions as the ligand binding site, but also mediates the 
signal specificity for effector stimulation i.e. phospholipase C activation or inhibition of 
adenylyl cyclase (Takahashi et aL, 1993).
1.2 Heterotrimeric G Proteins
1.2.1 Introduction
GPCRs characteristically bind G proteins that in turn act as mediators of receptor- 
stimulated effector activation. Upon receptor activation, bound GDP, in the guanine 
nucleotide-binding site of the GTPase domain of the G« subunit, is released and 
exchanged for GTP (due to high intracellular concentrations of GTP). GTP binding 
promotes a-subunit dissociation from the py dimer, which in turn allows both the G« 
subunit and the py dimer to activate effectors. G protein deactivation is rate-limiting for 
turn off of the cellular response and occurs when the intrinsic GTPase activity of the Ga 
subunit hydrolyses the GTP to GDP, and the G« subunit subsequently reassociates with 
the Gpy unit (Figure 1.2).
1.2.2 Ga subunit
To date, more than 20 different Ga subunits have been identified corresponding to 16 
gene products, which have been divided into 4 subfamilies according to their sequence 
homology (Figure 1.3). The Gs family includes Gsa and Goif which mediate adenylyl 
cyclase activation and the closure of Ca^  ^ ion channels. The G; family includes Giai-s, 
which function mainly to inhibit adenylyl cyclase activity, Gt (at and a t2 ) which 
stimulate cGMP phosphodiesterase. Go (aoA and aob) which are involved in Ca^  ^ ion 
channel closure (Hsu et aL, 1990) and the Ggust and G% proteins. Ggust is expressed in the 
taste buds and is thought to couple to cGMP phosphodiesterase. Gz is expressed in 
neuronal cells where it inhibits adenylyl cyclase (Taussig and Gilman, 1985). The Gq 
family (Gq«, Gna, Gi4«, Gi5a, and Giea) predominantly couples to phosphoinositide 
turnover (Strathmann and Simon, 1990). The G 12/G13 family is ubiquitously expressed

Figure 1,2
The G protein cycle.
Activated receptors (R*) associate with the trimer (a-GDPpy) triggering dissociation 
of GDP. GTP then binds with the trimer in its “empty” state (aePy) and induces a 
conformational change which leads to the dissociation of a-GTP from the complex, 
releasing Py. After GTP hydrolysis, a-GDP reassociates with py.
Figure 1.2
R*
a-GDPpy
R*aePy GTP
R*
a-GTP

Figure 1.3
G protein a  subunit family.
Four distinct classes of G» have been identified. The a  subunits are grouped 
according to their shared amino acid identity.
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and has been shown to be involved in the regulation of Na^ /KT^  ion exchange in cells 
(Hooley et aL, 1996) and the maintenance of the cell cytoskeleton through the activation 
of the small GTPase Rho (Klages et aL, 1999).
1.2.3 Gpy subunit
The Gpy complex comprises two polypeptides Gp and Gy which function as a monomeric 
unit. As with the G« subunits, there are multiple p and y proteins. At present, genes 
encoding 6  p and 12 y subunits have been identified. Most Gpy pairs are functional 
although there are exceptions. The yi protein (and all the other y proteins) can combine 
with pi but is unable to pair with p2 . The region on the y subunit which determines this 
specificity for Pi over P2 is located in a 14 amino acid sequence on the y subunit (Spring 
and Neer, 1994). Evidence that py units could regulate effectors came from studies of 
cardiac atrial cells where py dimers were shown to activate a ion channel (Logothetis 
et aL, 1987). Py proteins have since been demonstrated to regulate numerous effectors 
including activation of phospholipase Cp isoforms (Camps et aL, 1992), inhibition of 
adenylyl cyclase type I, stimulation of adenylyl cyclase types II and IV (Tang and 
Gilman, 1991), GRK regulation (Pitcher et aL, 1992) and MAP kinase activation 
(Crespo etaL, 1994).
1.2.4 Structural features of G proteins
Ga subunits contain two domains, a domain involved in binding and hydrolysis of GTP 
that is structurally homologous to the GTPases of monomeric G proteins and elongation 
factors, and a unique helical domain which buries the bound GTP in the protein core. 
The GTPase domain consists of 5 a  helices surrounded by 6  p strands which bind the 
phosphate and the guanine moiety of GTP. Also present in the core is a binding site for 
Mg^  ^ions which are essential for catalysis (Sprang, 1997). Substantial rearrangement of 
three segments of the a  subunit occurs upon GTP hydrolysis. These are designated 
Switch I (the loop between the first a  helix and the second p strand), Switch II (the loop 
preceding the second a  helix) and Switch III (the loop between the third a  helix and the 
fifth p strand) (Lambright et aL, 1994). When GTP is bound, basic residues in Switch II
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form ionic interactions with residues in Switch III. Upon GTP hydrolysis, these linkages 
are broken as Switch II and III collapse. Switches II and III are the proposed effector- 
binding regions in activated Gs« (Sprang, 1997).
The p subunit of heterotrimeric G proteins comprises an N-terminal helix followed by a 
7 membered P-propeller structure based on its 7 WD-40 repeats (Sondek et aL, 1996). 
The y subunit contains two helices but no inherent tertiary structure. The y subunit 
interacts with p through an N-terminal coiled-coil, whereas the remainder interacts 
extensively with the p propeller (Sondek et aL, 1996).
The interaction of the G« with the Gpy unit involves the G« N-terminal helical domain 
binding to the propeller structure of the p subunit (Lambright et aL, 1996). Upon 
receptor activation and the exchange of GDP for GTP, conformational changes in the 
Ga subunit cause a reduction in the a  helical content of the G« (Lambright et aL, 1996) 
which leads to separation of the py dimer from the a  subunit.
1.2.5 Lipid modification of G proteins
All Ga subunits undergo covalent modification at or near their N-termini by the 
attachment of the fatty acids myristate and/or palmitate. N-myristoylation, which occurs 
in members of the Gi family, is a co-translational modification of the glycine residue at 
the extreme N-terminus after the removal of the initiating methionine residue (Gordon 
et aL, 1991). All G protein a  subunits, with exception of at, can be palmitoylated. 
Palmitate is attached through a labile, reversible thioester bond to a cysteine residue 
near the N-terminus (Parenti et a l, 1993). Gy subunits are covalently modified by the 
fixture of the 2 0 -carbon isoprenoid geranylgeranyl, or in the case of retinal-specific yi, 
the 15-carbon isoprenoid farensyl. Prénylation occurs via a stable thioether bond to a 
cysteine residue located in the C-terminal “CAAX” motif. Following covalent 
modification the C-terminal three amino acids are removed by proteolysis and the new 
C-terminus is carboxymethylated (Higgins and Casey, 1994). Although non-prenylated 
y mutants have been shown to form stable dimers with p, prénylation of y is essential for 
normal py function.
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For G proteins, lipid modification acts as a hydrophobic membrane anchor. Both 
palmitoylation and myristoylation are thought to contribute to membrane association, 
with palmitoylation providing a stronger interaction with the lipid bilayer due to its 
greater hydrophobicity. Non-palmitoylated mutants of Gs« (which are not 
myristoylated) have been reported to exhibit a markedly decreased capacity to associate 
with the membrane (Wedegaertner et aL, 1993). py dimers also help guide a  subunits to 
membranes and prénylation of the y chains is a prerequisite for correct targeting of the 
py to the membrane (Silvius and F Heureux, 1994), and indeed binding of py to the a  
subunit, receptors and effectors (Casey et aL, 1994).
1.3 Receptor/G protein coupling
1.3.1 Structural features of GPCRs important for coupling
Considering the general structure of GPCRs, receptor-G protein coupling domains lie 
within the intracellular portion of the receptor which include the loops, the distal parts 
of the TM domains, and the C-terminal tail.
Deletion studies of the p2 -AR demonstrated the importance of the regions of the amino 
and carboxy segments of the third intracellular loop and the N-terminal segment of the 
cytoplasmic tail as being critical for p2 -AR activation of adenylyl cyclase (O’Dowd et 
aL, 1988).
For the ml and m2 muscarinic receptors, mutational analysis revealed that the aspartate 
and arginine residues of the highly conserved DRY motif located at the beginning of the 
second intracellular loop are crucial for efficient coupling (Wess, 1993).
Studies of the rhodopsin receptor identified residues 143-150 of the second intracellular 
loop and residues 236-239 and 244-249 of the third intracellular loop as domains 
essential for the activation of transducin (Konig et aL, 1989). In addition, a synthetic 
peptide from the fourth intracellular loop (created by palmitoylation of a cysteine 
residue in the C-tail) was capable of interacting with transducin (Konig et aL, 1989).
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Investigations of the porcine calcitonin and murine GnRH receptors revealed the first 
intracellular loop to be of importance in G protein coupling. In the former (which is Gs 
and Gq/ii-coupled), substitution of the first intracellular loop with the equivalent 
sequence from a human receptor isoform (containing a unique insertion of 16 amino 
acids) completely abolished the production of inositol phosphates, while the cAMP 
signalling of the porcine receptor remained unaffected (Nussenzveig et aL, 1994). In 
contrast, residues in the first intracellular loop of the murine GnRH receptor, which are 
critical for cAMP signalling, were found not to be essential for Gq/n signalling (Arora et 
aL, 1998).
For the EP3 prostanoid receptor, the C-terminal tail seems to be the critical determinant 
in the coupling to G proteins. The EP3 receptor comprises 4 splice variants which differ 
only at their C-terminal tails (Namba et aL, 1993). EP3A activates the G; family, while 
both EP3B and EP3C activate Gs, and EP3D couples to G,, Gs, and the Gq families.
1.3.2 Structural features of the G protein important for coupling
The most important region within the a  subunit for coupling to the receptor appears to 
be the extreme C-terminus. ADP-ribosylation of Gi« on a cysteine residue close to the 
C-terminus was shown to uncouple the G protein from the receptor (West et aL, 1985). 
A proline to arginine mutation at the sixth amino acid from the C-terminus of Gsa 
abolished adenylyl cyclase activation upon receptor stimulation (Sullivan et aL, 1987).
The development of chimeric G  proteins further highlighted the role of the extreme C- 
terminus of G« in receptor coupling. Replacement of the native C-terminal sequence of 
Gqa with the corresponding residues of Gia created a chimera that mediated stimulation 
of phospholipase C by receptors otheiwise coupled exclusively to G, (Conklin et aL,
1993). Moreover, antibodies directed against the extreme C-terminus of G« subunits 
were found to be capable of inhibiting receptor-mediated activation of G  proteins 
(Simonds et aL, 1989).
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1.3.3 Diversity in signalling
GPCRs can couple to more than one Ga subunit and hence activate multiple effectors. 
Studies have shown that mutations can abolish the signalling output through one class 
of G protein while the coupling to other families remains unaffected, thus highlighting 
the fact GPCRs selectively interact with G proteins at distinct sites within their 
structure.
In human thyroid cells, activated TSH receptors can signal through all the four classes 
of G  protein (Laugwitz et aL, 1996). Substitution of a tyrosine residue in TM V (Tyr^ ®^ ) 
resulted in a loss of agonist-induced inositol phosphate production, yet unchanged 
cAMP generation (Biebermann et aL, 1998) therefore demonstrating the role of this 
tyrosine residue in the coupling to G q/n.
In the case of the Gs- and Gq/u-coupling luteinismg-hormone receptor, point mutations 
in Asp^*  ^ in the third intracellular loop decreased cAMP formation whereas agonist 
binding and inositol phosphate hydrolysis remained unaltered (Gilchrist et aL, 1996).
For the p2-AR, coupling can switch from Gs to Gi upon receptor phosphorylation. 
Agonist-induced phosphorylation by c AMP-dependent protein kinase (PKA), 
subsequently allowed the recruitment of Gi which appears to be involved in initiating 
MAP kinase signalling by the receptor (Daaka et aL, 1997).
1.4 Adenylyl Cyclases
1.4.1 Introduction
Despite the discovery of numerous second messengers since Sutherland and Rail (Rail 
et a l, 1957; Sutherland and Rail, 1958) discovered the role of cAMP in hormone 
signalling, the adenylyl cyclases have continued to play a pivotal role in signal 
transduction. Principally, adenylyl cyclases catalyse the conversion of ATP to cAMP 
(Table 1.1). This enzyme family consists of 9 isoforms of -120 kDa with increased 
diversity produced by splice variants of some of the isoforms (Taussig and Gilman,
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1995). Krupinski and coworkers (1989) were able to purify the first adenylyl cyclase 
(AC) isoform (AC I) using a forskolin affinity matrix. From the deduced cDNA 
sequence of the full length protein, PCR reaction and low affinity hybridisation 
techniques allowed a further 6  full length isoforms to be isolated (AC II-VI, and VIII) 
(Feinstein et aL, 1991; Bakalyar and Reed, 1990; Gao and Gilman, 1991; Katsushika et 
aL, 1992; Premont et aL, 1992a; Yoshimura and Cooper, 1992; Cali et aL, 1994). AC 
VII was isolated as a partial sequence of novel isoforms (Krupinski et aL, 1992).
1.4.2 Structure of adenylyl cyclases
The nine cloned isoforms share a common structure comprising a short cytoplasmic 
amino terminus followed by a transmembrane domain (Ci) of six a  helices (Mi) then a 
large cytoplasmic domain (Ci) which is followed by a further six transmembrane 
spanning region (M2) and another cytoplasmic domain (C2) (Hurley, 1999; Taussig and 
Gilman, 1995, Figure 1.4). Within the AC family, it is the cytoplasmic domains which 
are the most highly conserved (up to 93% homology). The Ci and C2 domains are 
further subdivided into Cia, Cib, and C2 &, C2b- It is these regions which are responsible 
for the catalytic site of the enzyme. The catalytic activity of the enzyme depends on the 
heterodimerisation of Cia and C2 . The substrate binding site is formed by ionic 
interactions between C2 and the purine ring of ATP. The Ci domain plays a more 
supporting role in substrate binding (Liu et aL, 1997). The ATP binding site is 
surrounded by hydrophobic residues (contributed by C2) that pack the purine ring and 
ionic interactions contributed by both Ci and C2  stabilise the phosphate groups (Liu et 
aL, 1997).
1.4.3 Activation and regulation of adenylyl cyclases
All mammalian adenylyl cyclases are activated by the diterpene forskolin except type 
IX. Forskolin binds the catalytic core and activates the enzyme by “gluing together” the 
two domains Ci and C2  using hydrophobic and hydrogen bond interactions (Zhang et 
aL, 1997). Type IX is non-responsive to forskolin due to differences in amino acid 
sequence in the binding pocket, unlike types I-VIII where this sequence is conserved.
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Figure 1.4
Diagrammatical representation of the structure of membrane adenylyl cyclase 
isoforms.
The putative adenylyl cyclase structure has been deduced from sequence analysis 
implying 12 tiansmembrane helices. Functional studies have revealed the catalytic 
and regulatory sites within the intiacellular regions of the enzyme (adapted from 
Taussig and Gilman, 1995).
Table 1.1
Differential regulation of the adenylyl cyclase isoforms.
Summaiy of the biochemical characteristics of each AC isoform.
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N, amino-terminal domain; Mi, first set of membrane-spanning regions; Cia and Cib, the 
first large intracellular cytoplasmic domain; M2 , second set of transmembrane spanning 
regions; and C2a and C2b, second large intracellular domain.
Table 1.1
Response to cAMP si]snalling
AC
Isoform
Gsa G|a Gpy Forskolin Protein
Kinases
1 Î (CAM or 
Forskolin- 
stimulated)
i Î Î  (CAM)
4- (CAM
Kinase IV)
T PKC (weak)
4" CAM Kinase 
IV
2 Î T (when 
stimulated 
by Gs„)
Î T PKC
3 t 4. T T (CAM, in 
vitro)
i  (CAM 
Kinase II)
T PKC (weak) 
4- CAM Kinase 
II
4 t T T t  PKC
5 Î 4. 'I' (P1Y2) Î 4- (<l|iM) i PKA TPKC
6 t i 4- (I'lYi) Î ■i’ (<I]iM) i PKA, PKC
7 t t Î T PKC
8 t 4^ (Ca^  ^rises) T t  (CAM) - >  PKC
9 T i T (weak) ■i’ (caicineurin)
T, positive response; 4-, negative response; — neutral response
All cyclase isoforms are activated by GTP-bound Gsa- GTP-Gsa binds to a crevice on 
the outside of C2 and the N-terminal portion of Ci. GTP-Gsa can activate cyclase by the 
same mechanism as forskolin but it can also stimulate catalysis by inducing a 
conformational change in the enzyme to allosterically regulate it (Yan et al, 1997).
Gia selectively inhibits AC V and VII. Mutational analysis suggests that Gja binds to the 
catalytic core on a groove similar to the Gsa binding groove (Yan et aL, 1997). In 
association with Gsa, Py subunits can bind to AC isoforms and regulate them. The 
binding site of Py is adjacent to the Gsa site, consistent with the observation that type II 
is activated by Gpy when Gs« is bound (Chen et aL, 1995).
Changes in the intracellular Ca^  ^ ion concentration can profoundly affect types I and 
VIII. These isoforms are activated by nanomolar concentrations of Ca^Vcalmodulin. At 
higher concentrations of Ca^  ^(100-1000pM) inhibition occurs as a result of competition 
with Mg^  ^ions in the active site, which are essential for catalysis (Hurley, 1999).
The possibility for PKA-mediated phosphorylation being a negative feedback on 
adenylyl cyclase activity has been investigated but evidence for such a mechanism 
remains flimsy (Premont et aL, 1992b). However, regulation by phosphorylation of AC 
isoforms has been demonstrated by PKC. PKC activates AC type II by phosphorylation 
on Thr^ *^ ^^  (Bol et aL, 1997). Jacobowitz and coworkers (1993) observed moderate 
phosphoiylation of AC V by PKC in vivo.
1.5 GPCR Desensitisation
1.5.1 Introduction
Agonist activation of GPCRs initiates a series of reactions which result in the “turn off’ 
of the GPCR signal. This process is known as desensitisation and is characterised by the 
waning of a stimulated response in the presence of continuous agonist exposure. This 
attenuation of GPCR responsiveness to agonist represents an important mechanism that 
protects against both acute and chronic receptor stimulation.
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The phenomenon of desensitisation can be subdivided into agonist-specific 
(homologous) and agonist-non-specific (heterologous) events. Homologous 
desensitisation refers to the situation whereby only the activated GPCRs desensitise, 
while heterologous desensitisation refers to the situation whereby activation of one 
GPCR leads to the desensitisation of responses initiated by another, heterologous 
GPCR. Homologous desensitisation occurs as a consequence of G protein uncoupling in 
response to phosphorylation by GRKs and second messenger kinases. GPCR 
phosphorylation promotes the binding of p-arrestins, which not only uncouple receptors 
from heterotrimeric G proteins but also target GPCRs for internalisation in clathrin 
coated vesicles (Ferguson and Caron, 1998; Figure 1.5). Prolonged agonist exposure 
can also result in downregulation of receptor levels as a result of reduced receptor 
mRNA and protein synthesis, as well as both the lysosomal and plasma membrane 
degradation of pre-existing receptors (Doss et al., 1981; Hadcock and Malbon, 1988; 
Valiquette et ah, 1990, 1995; Jockers et al., 1999; Pak et al., 1999). These processes 
occur over time periods ranging from seconds (phosphorylation) to minutes 
(endocytosis) and hours (downregulation).
The level of desensitisation varies from complete termination of receptor signalling, as 
observed in the visual and olfactory signals, to the reduction in agonist potency and 
maximal responsiveness. Desensitisation of the photoreceptor rhodopsin in response to 
light, and the response to hormone by the p2 -AR, are the best studied systems of this 
process (Hausdorff et al., 1990; Hargrave and McDowell, 1992). In order to perceive 
continuous light changes, desensitisation of rhodopsin was found to occur in less than 1 
second following light stimulation, thereby preventing a flash of light as being seen as 
continuous illumination (Schleicher et al, 1989). For the p2 -AR, within a few minutes of 
agonist exposure, cAMP accumulation was observed to plateau or return to basal levels 
(Shear et al., 1976; Su et al., 1979; Sibley et al., 1987). For the p2-AR, this 
desensitisation was demonstrated to be induced by a distinct effect on the receptor and 
not the G protein since isolated desensitised p2-ARs were unable to stimulate adenylyl 
cyclase in reconstituted systems (Strulovici et al., 1984).
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Figure 1.5
Schematic representation of GPCR desensitisation.
For GPCRs including the P2 -AR, receptor activation leads to receptor 
phosphorylation by GRKs facilitating the translocation and binding of P-arrestins to 
the receptor thereby uncoupling GPCR/G protein interactions. p-Arrestins then 
target receptors for endocytosis via clathrin coated pits. Figure adapted from 
Ferguson and Caron, 1998.
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1.5.2 Role of phosphorylation in GPCR desensitisation
The discovery of light-dependent phosphorylation of the rhodopsin in vivo correlated 
well with the loss of cGMP phosphodiesterase activity (Bownds et ah, 1972). The 
kinase responsible was identified as rhodopsin kinase (or GRK 1) which phosphorylates 
the light activated receptors at multiple serine and threonine residues (Bownds et ah, 
1972). The subsequent cloning of rhodopsin kinase showed that it is predominantly 
expressed in the retinal cones and rods (Lorenz et al., 1991). Studies in vivo mapped the 
phosphorylation sites of rhodopsin to residues in the C-terminal region, namely Ser^ '^^ , 
Ser^ ^^ , and Ser^ "^  ^ (Ohguro et al., 1995). The role of phosphorylation in inactivating 
rhodopsin was further demonstrated using transgenic mice expressing a C-terminally 
truncated mutant of rhodopsin. In such mice, abnormally long responses were detected 
in the retinal rods (Chen et al., 1995).
The role of phosphorylation in P2 -AR desensitisation was originally suggested upon 
notice that the kinetics of P2 -AR phosphorylation mimicked those of desensitisation 
(Stadel et al., 1983a). GRKs were first implicated in agonist-specific phosphorylation 
when it was observed that desensitisation of the P2-AR still occurred in kin" S49 
lymphoma cells (which lack PKA) (Green and Clark, 1981). A partially purified 
preparation of a kinase from the supernatant of kin” S49 cells was capable of 
phosphorylating P2 -AR in vitro (Benovic et al., 1986). Subsequent cDNA cloning of the 
kinase identified it as a novel GRK termed p-adrenergic receptor kinase, PARK (or 
GRK 2) (Benovic et al., 1989). Further studies identified Ser Ser and Ser"^ ®^  and 
T h^^ as the sites of pARK phosphorylation of the human P2 -AR (Fredericks et al.,
1996).
1.5.3 G protein-coupled receptor kinase family
pARK and rhodopsin kinase were found to be part of a GRK family when pARK 2 
(GRK 3) and GRKs 4-7 were cloned from cDNA libraries (Benovic et al., 1991; 
Ambrose et al, 1992; Kunapuli and Benovic, 1993; Benovic and Gomez, 1993; Weiss et 
al., 1998). GRKs are 62-80 kDa proteins that are members of the large family of 
serine/threonine kinases. Like GRK 1, expression of GRK 4 and GRK 7 are tissue-
2 1
specific (testis and retinal rods respectively) while the other GRKs are more 
ubiquitously expressed. The GRKs share similar structural features with each 
possessing a central catalytic domain, an amino-terminal domain which contains an 
RGS-like domain thought to be important for substrate recognition, and a carboxyl- 
terminal domain that is required for targeting of the kinase to the plasma membrane 
(Figure 1.6 and Table 1.2).
1.5.4 GRK targeting and regulation
It has emerged that lipid modification or interactions may be important for membrane 
localisation and activity of GRKs. Upon agonist activation of GPCRs, cytosolic GRKs 
1-3 translocate to the membrane-bound receptors. For GRK 1, plasma membrane 
association is facilitated by post-translational famesylation on it its C-terminus (Inglese 
et aL, 1992). For GRKs 2 and 3, plasma membrane targeting is aided by 
phosphatidylinositol 4,5-bisphosphate binding to their carboxyl-terminal pleckstrin 
homology domains (Pitcher et aL, 1995a). In unstimulated cells GRKs 4, 5, and 6  all 
exhibit substantial membrane localisation. Both GRKs 4 and 6  are palmitoylated 
(Stoffel et al., 1994; Premont et al., 1996; Stoffel et al., 1998) which seems to be 
essential for their localisation to the plasma membrane. GRK 5 forms electrostatic 
interactions between 46 basic residues in the carboxyl terminus of the protein and the 
phospholipids from the bilayer (Kunapuli et ah, 1994)
Apart from lipid modification, other factors regulate GRK activity. GRK 1 activity can 
be inhibited by the Ca^^-binding protein recoverin (lacovelli et a l, 1999), while GRKs 
2, 5, and 6  appear to be negatively regulated by Ca^Vcalmodulin (Pronin et a l, 1997) 
with the inhibitory effects being most significant with GRK 5. A calmodulin-binding 
domain has been located within the N-terminal domain of GRK 5 (Pronin et a l, 1997). 
Studies have demonstrated that an important regulator of GRKs 2 and 3 are the Gpy 
subunits (Daaka et a l, 1997; Pitcher et a l, 1992). The binding site for the Py proteins to 
the kinase was localised to the pleckstrin homology domain within the C-terminus 
(Koch et a l, 1993). It may be that Gpy provides a signal for the docking of GRK 2 and 3 
to the membrane. GRKs 2 and 5 are also substrates for phosphoiylation by PKC
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Figure 1.6
Diagrammatical representation of the structure of GRKs 1-7.
The amino terminal domain of the GPCR-binding domain of each GRK contains a 
conserved RGS domain. The carboxyl terminal domains of the GRKs mediate their 
targeting to the plasma membrane. GRKs 1 and 7 are famesylated at “CAAX” 
motifs in their carboxyl termini. GRKs 2 and 3 contain py-subunit binding that 
exhibits sequence homology to a pleckstrin homology domain. GRK5 contains a 
stietch of 46 basic amino acids that mediate interactions with the phospholipids in 
the plasma membrane. GRKs 4 and 6  are palmitoylated at cysteine residues.
Table 1.2
Molecular properties of the GRKs.
Overview of the characteristics and biochemical regulation of the GRKs.
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Figure 1.6
GBK: |-q!#-CO;CH,
Carboxyl terminai
domain
Catalytic Domam
Table 1.2
GRK Size
(kDa)
Polypeptide
Variants
Covalent
Modification
Activators Inactivators
1 63 ND Famesylation Polycations Recoverin
2 79 ND ND Gp^PIPz, 
PKC, c-Src
MAPK
3 80 ND ND Gb,,PIP2 ND
4 66 4 Palmitoylation ND ND
5 68 ND ND Polycations,
PIP2
PKC,
calmodulin
6 66 Yes Palmitoylation Polycations ND
7 62 ND Famesylation ND ND
ND, not determined
(Chuang et a l, 1995; Pronin and Benovic, 1997). For GRK 2, PKC phosphorylation 
activates the enzyme, whereas PKC reduces GRK 5 activity.
1.5.5 Role of GRKs in GPCR desensitisation
There is an abundance of evidence to suggest that desensitisation of GPCRs is 
associated with GRK phosphorylation. Coexpression of GRKs with GPCRs in cells 
resulted in augmented desensitisation of receptors including the p2 -adrenergic (Pippig et 
ah, 1993), pi-adrenergic (Freedman et aL, 1995), am-adrenergic (Diviani et al., 1996), 
oi2 -adrenergic (Jewell-Motz and Liggett, 1996), angiotensin IIia (ATia) (Opperman et 
al., 1996), A3 adenosine (Palmer et al., 1995), m2 muscarinic (Schlador and Nathanson, 
1997), histamine H2 (Shayo et al., 2001) and m3 muscarinic (Willets et al., 2001) 
receptors.
A few GPCRs show preference for phosphorylation by a particular GRK, such as the 
endothelin receptors which are phosphorylated only by GRK 2 in HEK293 cells 
(Freedman et al., 1997) while thrombin receptors (Ishii et al., 1994) are specifically 
phosphorylated by GRK 3. Conversely, there are GPCRs which can be phosphorylated 
by several GRKs, including the ATia (Opperman et a l, 1996), p2 -adrenergic (Premont 
et a l, 1995), and muscarinic m2 and m3 (Richardson et a l, 1993; Debburman et a l, 
1995) receptors.
Deletions or mutations in putative phosphorylation sites in GPCR cytoplasmic domains 
have been shown to reduce desensitisation due to the loss of receptor phosphorylation, a 
phenomenon which has been observed for GPCRs including the a 2A-adrenergic (Liggett 
et a l, 1992), thrombin (Ishii et a l, 1994), m2 muscarinic (Pals-Rylaarsdam et a l, 
1995), |3 2 -adrenergic (Bouvier et a l, 1988), and the am-adrenergic (Lattion et a l, 1994) 
receptors. Similarly, coexpression of dominant negative GRK mutants (which lack 
kinase activity) with GPCRs was found to inhibit desensitisation of the m2 muscarinic 
(Pals-Rylaarsdam et a l, 1995), ATia (Opperman et a l, 1996), p2 -adrenergic (Kong et 
al, 1994), Pi-adrenergic (Freedman et a l, 1995), am-adrenergic (Diviani et a l, 1996), 
Ô-opioid (Pei et a l, 1995) and A2 adenosine (Mundell et a l, 1997) receptors.
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In vivo studies using transgenic mice have also given some insight into GRK activity in 
different tissues. Mice engineered to overexpress GRK 2 in cardiac myocytes displayed 
a reduction in their responsiveness to p-AR agonists and angiotensin II, while mice 
overexpressing the C-terminal portion of GRK 2 (consequently inhibiting GRK 2 by 
sequestering the Gpy pool) exhibited increased sensitivity to such agonists (Koch et aL, 
1995; Rockman et aL, 1996). Similarly, long term exposure with p-AR agonists or 
antagonists in mice induced GRK 2 upregulation and downregulation respectively 
(laccarino et aL, 1998).
1.5.6 Other kinases which phosphorylate GPCRs
GPCRs are also substrates for phosphorylation by other kinases apart from GRKs 
and/or second messenger kinases. Studies have revealed that casein kinase l a  can 
phosphorylate the m3 muscarinic receptor on the third intracellular loop (Tobin et aL,
1997) although receptor mutants lacking the potential casein kinase l a  phosphorylation 
sites still underwent agonist-mediated desensitisation (Budd et al., 2000). The 
phosphorylation of TRH receptor on its C-terminal tail by casein kinase II (Hanyaloglu 
et al., 2 0 0 1 ) was deemed to be important for receptor internalisation but not 
desensitisation. Tyrosine phosphorylation of agonist-occupied p-opioid receptors (Pak 
et al., 1999) has been suggested to be an important signal for downregulation of the 
receptor. For the bradykinin B2  receptor, tyrosine kinase inhibitors blocked bradykinin- 
mediated prostaglandin E2 production, indicating that tyrosine kinase phosphorylation 
of the receptor is critical for its signal transduction (Jong et al., 1993).
1.5.7 The role of visual arrestin in rhodopsin desensitisation
Phosphorylation by GRKs of rhodopsin has been shown to be insufficient to promote 
complete desensitisation of the receptor. It was observed that full inactivation of the 
receptors required an additional interaction with an “arresting” protein. The 
identification of arrestin was first made in the rod photoreceptor cells where a 48 kDa 
protein, originally called S-antigen, was demonstrated to regulate rhodopsin signal 
transduction (thus it is now known as visual arrestin) (Pfister et a i, 1985).
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Visual arrestin was shown to translocate from the cytoplasm to the membrane following 
light activation of rhodopsin (Kuhn et a l, 1984) and the protein was subsequently 
purified from the retinal rod membranes via its light-dependent binding to 
phosphorylated rhodopsin (Wilden et al., 1986a). The cDNA sequence of visual arrestin 
revealed it to encode a 404-amino acid protein (Shinohara et aL, 1987) and that its 
expression was localised to the retinal tissue (Lohse et aL, 1990a). More recently, 
another retinal-specific arrestin was cloned and found to share ~50% sequence 
homology with visual arrestin. With expression being primarily localised to the cone 
photoreceptors, the protein was named cone arrestin (Craft et aL, 1994; Murakami et 
aL, 1993).
Receptor activation and phosphorylation is an absolute requirement for the binding of 
visual arrestin to rhodopsin. In vitro studies revealed that there was a 10-12- fold 
increase in the binding of visual arrestin to rhodopsin when the receptor was 
phosphorylated and light-activated, compared to when it was phosphorylated dark 
rhodopsin or light-activated (non-phosphorylated) rhodopsin (Gurevich and Benovic, 
1992).
The complete quenching of the cGMP phosphodiesterase activity of activated rhodopsin 
receptors occurred only when visual arrestin bound to the receptor, indicating that 
phosphorylation alone is not sufficient to produce full desensitisation (Wilden et aL, 
1986b). Phosphorylation alone reduced coupling to transducin by 30-50% (Krupnick et 
aL, 1997). Visual arrestin produces full quenching of the signal by acting as a physical 
barrier to prevent transducin coupling to the phosphorylated activated receptors. 
Binding studies using purified arrestin and transducin have demonstrated that the two 
proteins compete for binding to phosphorylated light-activated rhodopsin (Krupnick et 
aL, 1997).
1.5.8 The role of non-visual arrestins in GPCR desensitisation
Evidence for the existence of other arrestin proteins involved in the desensitisation of 
other GPCRs besides rhodopsin originated from the observation that a partially purified 
pARK preparation inhibited up to 80% of p-AR signally in vitro, whereas a more highly
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purified pARK only inhibited signalling modestly (Benovic et al., 1987). This cofactor 
in the pARK preparation >vas subsequently cloned and termed p-arrestin (Lohse et ah, 
1990a, Table 1.3). P-Arrestin ’was found to be a 418 amino acid protein which shares a 
59% sequence homology to visual arrestin. Another non-visual arrestin, called p- 
arrestin 2 was cloned (Attramadal et al., 1992) and encodes a 409 amino acid protein. 
The expression of the p-arrestins is ubiquitous, but they are predominantly localised in 
the neuronal tissues and in the spleen (Attramadal et ah, 1992). A third class of arrestins 
has been identified, namely D- and E-arrestin (Craft et al., 1994). Although the mRNAs 
for D- and E-arrestin are expressed in many tissues, it is unclear whether such proteins 
exist and if they are functional (Craft et a l, 1994).
As with visual arrestin, in vitro studies with the p-arrestin proteins has greatly enhanced 
the understanding of their interactions with GPCRs. Translated P-arrestin 1 was found 
to bind to the m2  muscarinic receptor in a phosphorylation-dependent manner, with the 
highest binding occurring with an agonist-activated phosphorylated form of the receptor 
(Gurevich et a l, 1993). Furthermore, purified p-arrestin 1 was observed to bind 
preferentially to ligand-activated, phosphorylated pz-ARs, with a Kd of ~2nM and a 
stoichiometry of 1 P-arrestin molecule per receptor (Sohlemann et a l, 1995). However, 
unlike visual arrestin, substantial binding of the p-arrestins to phosphorylated non­
activated forms of the m2 muscarinic receptor and pz-AR, as well as agonist-activated 
non-phosphorylated forms of the receptors was detected (Gurevich et ah, 1995). 
Furthermore, in vitro studies with the p2 -AR showed that p-arrestin 1 works in concert 
with pARK to effect agonist-specific desensitisation of the receptor. It was observed 
that pARK phosphorylation, but not PKA phosphorylation, greatly enhanced p2 -AR 
desensitisation (Lohse et a l, 1992), an observation which was in accord with the 
finding that p-arrestins preferentially bind GRK-phosphorylated as opposed to second 
messenger kinase-phosphorylated receptors (Lohse et a l, 1990a, 1992).
The role of P-arrestins in desensitisation in vivo has been studied for an array of GPCRs. 
In cells expressing receptors such as the p2-adrenergic, pi-adrenergic, am-adrenergic 
and m2 muscarinic receptors, coexpression of P-arrestin 1 or P-arrestin 2 was found to
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increase desensitisation (Pippig et a l, 1993; Freedman et aL, 1995; Diviani et al., 1996; 
Schlador and Nathanson).
1.5.9 Structure and function of the arrestin proteins
Alternative splice variants have been identified for visual arrestin and the p-arrestins. 
Bovine visual arrestin is expressed as a 404 amino acid residue protein, as well as p44 
(for which the last 35 amino acids are replaced by alanine) and another that lacks 
residues encoded by exon 13 (Yamaki et al., 1990; Smith et at., 1994). The p44 splice 
variant is specifically localised to the rod outer segment and is more potent at inhibiting 
rhodopsin signalling than the M l length form, thus demonstrating that the carboxyl 
terminal domain of arrestin is not essential for binding to rhodopsin. Like visual 
arrestin, the p-arrestins express at least two alternative spliced forms. The variant form 
of P-arrestin 1 has an eight amino acid insertion between residues 333 and 334 (Parruti 
et al., 1993) and the alternate p-arrestin 2 has an eleven amino acid insert between 
residues 362 and 363 (Steme-Marr et al., 1993). No differences in activity of the p- 
arrestin splice variants have been reported.
The observation that arrestins preferentially bind to phosphorylated, ligand-activated 
receptors suggests that there is a domain(s) that makes specific contacts with GPCRs in 
the active state (Figure 1.7). Initial investigations to locate the activation-recognition 
region suggested that it was present in the N-terminal half of the protein (residues 1- 
191) as a truncated visual arrestin containing residues 1-191 retained its ability to bind 
light-activated state of rhodopsin (Gurevich and Benovic, 1992). Moreover, it had been 
previously shown that the p44 visual arrestin mutant binds with high affinity to 
rhodopsin (Palczewski et al., 1994). Further mutagenesis studies mapped the 
phosphorylation-recognition site to a discrete region within the N-terminus. Arrestin 
truncated at residue 185 bound to phosphorylated light-activated rhodopsin and 
phosphorylated dark rhodopsin, while arrestin truncated at residue 158 exhibited a 
reduction in its ability to detect the phosphorylated form of the receptor, thus focusing 
the location of the phosphorylation-recognition region to between residues 158 and 185 
(Gurevich and Benovic, 1993). Mutagenesis of individual residues within region 158- 
185 of arrestin identified several basic residues, namely Arg^^\ Arg and Lys^^ ,^
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Figure 1.7
Structure of the arrestin proteins.
Crystallographic and mutagenesis studies have identified that the arrestin proteins 
comprise an amino regulatory domain (residues 1-24), a receptor activation domain 
(residues 24-180), a phosphate sensor domain (163-182), a secondary receptor- 
binding domain (residues 180-330), and a carboxyl terminal domain (residues 330- 
404). The black box highlights the clathrin- and p-adaptin-binding domains that are 
conserved among non-visual arrestins.
Table 1.3
Characteristics of the arrestin proteins.
Summary of the molecular properties of the members of the arrestin family.
29
Figure 1.7
N Domain C Domain
RI, amino regulatory domain; A, receptor activation domain; P, phosphate sensor 
domain; S, secondary receptor-binding domain; R2, carboxyl terminal regulatory 
domain
Table 1.3
Name Size
(residues)
Polypeptide
Variant
(residues)
Substrate Phosphorylation Function
Visual
arrestin,
bovine
404 390, 370 
(p44)
rhodopsin > 
P2 -AR > m2 
muscarinic 
receptor
PKC
Ca^^-camodulin
Desensitisation
Cone
arrestin,
human
388 ND ND ND Desensitisation
P-arrestin 1, 
rat
418 410 P2 -AR > m2 
muscarinic 
receptor »  
rhodopsin
MAPK Desensitisation,
Endocytosis,
Signalling
P-arrestin 2, 
rat
410 399 P2 -AR > m2 
muscarinic 
receptor »  
rhodopsin
Casein kinase II Desensitisation,
Endocytosis,
Signalling
ND, not determined
which were crucial for phosphate binding (Gurevich and Benovic, 1995). Furthermore, 
Ai’g^ ^^  was suggested to function as a phosphorylation-sensitive trigger, since mutation 
of this residue to a neutral or acidic amino acid resulted in constitutive binding of 
arrestin to non-phosphorylated light-activated rhodopsin (Gurevich and Benovic, 1995). 
The N-terminal segment of the p-arrestins also retained the ability to recognise agonist- 
activated receptors, indicating that the activation-recognition region of all arrestins was 
contained within the N-terminal half (Gurevich et a l, 1995).
Visual arrestin undergoes a conformational change upon its binding to light-activated 
phosphorylated rhodopsin. This was first implied when it was noticed that the arrestin 
molecule became more sensitive to limited proteolysis when bound to activated 
rhodopsin (Palczewski et a l, 1991). Further studies confirmed that the conformational 
change was driven by the primary interactions of the activation-recognition and 
phosphorylation-recognition regions with corresponding contact sites on the receptor. 
These interactions lead to a conformational change that exposes a secondary 
hydrophobic binding site (between residues 191 and 365) for high affinity binding 
(Gurevich and Benovic, 1993). The involvement of hydrophobic interactions in high 
affinity binding of the arrestin to the receptor was further demonstrated from the 
observation that salt promoted the interaction of arrestin with the activated receptor 
(Gurevich and Benovic, 1993).
The selectivity of visual arrestin for binding to phosphorylated light activated receptors 
is mediated by an intramolecular interaction between the basic N-terminus and acidic C- 
terminus (Gurevich et a l, 1993; 1995). The rigid structure of the arrestin C-terminus is 
maintained until the receptor is activated and the intramolecular arrestin interactions are 
replaced by contacts with the receptor. The lack of discrimination of C-terminal 
truncated arrestin mutants for phosphorylated light-activated rhodopsin therefore 
indicated that such mutants were unable to form a rigid structure leading to an increased 
availability of the hydrophobic region to the receptor for binding (Gurevich et a l,
1994).
Visual arrestin/p-arrestin chimeras have been important tools used in the discovery of 
the regions of arrestins which are critical for determining GPCR binding specificity.
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Two large central domains in visual arrestin (residues 48-365) and p-arrestin (residues 
45-367) have been identified as being important for determining specificity of GPCR 
binding (Gurevich et a l, 1995). Switching the N- and C-terminal domains of visual 
arrestin with the complementary p-arrestin domains did not prevent the binding of the 
chimeric arrestin to activated rhodopsin. Similarly, a chimeric p-arrestin, which 
possessed the N- and C- terminal regions of visual arrestin, was still able to bind to 
agonist-occupied, phosphorylated m2 muscarinic and Pi-ARs (Gurevich et a i, 1995). 
Such observations were consistent with the assumed roles of the N- and C-termini of the 
arrestins in regulation of their conformation.
More recently, the resolution of visual arrestin crystal structure has provided further 
understanding of arrestin/rhodopsin interactions (Granzin et al., 1998). The solution of 
the visual arrestin structure confirmed the presence of the different arrestin domains 
which had aheady been identified in mutagenesis studies: a receptor activation domain 
(residues 24-180), a secondary receptor binding domain (residues 180-330), a phosphate 
sensor domain (163-182), an N-terminal regulatory domain (residues 1-24) and a 
carboxyl regulatory domain (residues 330-404) (Granzin et al., 1998; Hirsch et al., 
1999). Taken together, the crystallographic and mutagenesis studies of arrestin have 
demonstrated that its molecular structure is designed to resist agonist- and 
phosphorylation-independent interactions with receptors.
1.6 GPCR internalisation
1.6.1 Introduction
An important aspect of GPCR regulation is the internalisation of agonist-activated 
receptors. Studies have demonstrated that many GPCRs translocate from the cell 
surface to intracellular membrane compartments upon exposure to agonist.
The discovery of GPCR internalisation originated from the observation that there was a 
rapid distribution of P2 -ARS from the cell surface upon agonist treatment of bullfrog 
erythrocytes. It was noticed that the loss of cell surface receptors corresponded with an
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increase in intracellular P2-ARS (Chuang and Costa, 1979). Subsequently, early ligand 
binding studies were able to distinguish cell surface receptors from internalised P2 -AR 
binding sites using differential sedimentation on sucrose gradients or by the use of 
hydrophobic and hydrophilic ligands for the receptor (Harden et aL, 1980; Staehelin and 
Simons, 1982). The internalised receptors were found to be associated with a “light 
vesicle” fraction that could be separated from a “heavy vesicle” plasma membrane 
fraction that was associated with the cell surface receptors (Harden et al., 1980). 
Similarly, the internalised receptors were not accessible to hydrophilic ligands but were 
accessible to hydiophobic ligands (Staehelin and Simons, 1982). More recently, 
immunocytochemical staining of epitope-tagged p2-ARs, as well as the use of green 
fluorescent protein (GFP) tagged p2 -ARs, has permitted the visualisation of receptor 
trafficking in real time in live cells (von Zastrow and Kobilka, 1992; Barak et al., 
1997a).
1.6.2 The role of phosphorylation in GPCR internalisation
Early studies into the role of phosphorylation in receptor endocytosis were inconclusive 
as p2 -AR mutants lacking sites for both PKA- and GRK-mediated receptor 
phosphorylation showed no significant difference in internalisation compared to the 
wild-type P2 -AR (Bouvier et al., 1988; Hausdorff et al., 1989). Similarly, PKA and 
GRK inhibitors were unable to inhibit internalisation of the P2-AR in A431 cells (Lohse 
et al., 1990b).
Despite these original studies with the P2 -AR, evidence was accumulating that 
phosphorylation might be important for the internalisation of other GPCRs. A Ser/Thr- 
rich sequence was suggested to be a crucial factor in the sequestration of the m l, m2 , 
and m3 muscarinic receptors (Moro et al., 1993). Mutation of the serine and threonine 
residues within the third intracellular loop of the m2  muscarinic receptor reduced the 
rate of internalisation (Moro et al., 1993). Moreover, overexpression of GRK 2 
enhanced the rate of m2  muscarinic receptor internalisation, whereas expression of a 
dominant-negative GRK 2 mutant led to a decrease in receptor phosphorylation and 
internalisation in COS 7 cells (Tsuga et al., 1994). Further evidence to support the role 
of phosphorylation in internalisation was highlighted in studies with the thrombin
32
receptor (Shapiro et al., 1996). Truncation or mutation of the Ser/Thr residues in the C- 
terminus of the thrombin receptor reduced both agonist-induced phosphorylation and 
sequestration. In addition, C-terminal deletions or point mutations of Ser/Thr residues in 
the C-terminus of the Ô-opioid receptor significantly reduced its agonist-induced 
internalisation (Trapaidze et al., 1996).
The direct role of phosphorylation of the pz-AR in its sequestration was eventually 
demonstrated using a phosphorylation- and internalisation-defective mutant, pz-AR- 
Y326A (Ferguson et al., 1995). Overexpression of GRK 2 enhanced both the 
phosphorylation and internalisation of the receptor mutant. Likewise, overexpression of 
GRKs 3-6 also enhanced phosphorylation and sequestration of pz-AR-Y326A with the 
agonist-dependent restoration of phosphorylation correlating with the rescue of 
internalisation (Menard et al., 1996). In addition, the phosphorylation and 
internalisation of the wild-type pz-AR in HEK293 cells was reduced by overexpression 
of a dominant negative GRK 2 mutant (Ferguson et al., 1995). GRK 2 phosphorylation 
has been shown to mediate internalisation of other GPCRs including the ATia (Smith et 
al., 1998), endothelin A (Bremnes et al., 2000), D2 dopamine (Itokawa et al., 1996) and 
the chemokine receptors CCR-5 (Aramori et al., 1997) and CXCRl (Barlic et al.,
1999).
1.6.3 The role of p-arrestins in GPCR internalisation
GRK-mediated phosphorylation is not an absolute necessity for internalisation (Bouvier 
et al., 1998; Hausdorff et al., 1989) but instead promotes the interaction of the GPCR 
with other cellular proteins. It has now become evident that the ability of GRKs to 
promote GPCR endocytosis is dependent on the binding of p-arrestins to the receptor. In 
addition to uncoupling receptors from G proteins, p-arrestins act as endocytic adapters 
targeting GPCRs for internalisation into clathrin-coated vesicles (CCVs) (Zhang et al., 
1996). Overexpression of both p-arrestin 1 and p-arrestin 2 alone with the Pz-AR- 
Y326A mutant augmented receptor sequestration even in the absence of GRKs 
(Ferguson et al., 1996). Moreover, P-arrestins promoted internalisation of C-terminal 
tail truncated pz-ARs and mutants lacking putative GRK phosphorylation sites.
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The relationship between GRK-mediated phosphorylation and p-arrestin recruitment is 
likely dependent upon the receptor subtype and the cell type in which it is expressed. 
Different GPCR subtypes have different requirements for internalisation. For example, 
internalisation of the chemokine receptors CCR-5 and CXCRl in HEK293 cells 
required overexpression of both GRKs and P-arrestins (Aramori et ah, 1997; Barlic et 
ah, 1999). For the m2 muscarinic receptor, internalisation required GRK 
phosphorylation but not P-arrestin, depending on the cellular environment in which it 
was expressed (Tsuga et ah, 1994; Schlador and Nathanson, 1997; Werbonat et ah,
2000). Studies of pz-AR sequestration have shown that there is significant correlation 
between the endogenous complement of GRKs and p-arrestins in the cell types and the 
kinetics of pz-AR agonist-induced internalisation in such cells (Menard et ah, 1997). 
Similarly, for the CXCRl receptor, sequestration could be detected in the GRK- and p- 
arrestin-rich RBL-2H3 cells, but not in HEK293 cells in which expression of these 
proteins is lower (Barlic et ah, 1999).
1.6.4 p-Arrestin interactions with clathrin in GPCR endocytosis
The first evidence that P-arrestins direct GPCRs for endocytosis into CCVs originated 
from the study of the effects of p-arrestin and dynamin dominant-negative mutants on 
Pz-AR and ATiaR internalisation (Zhang et ah, 1996). The large GTPase dynamin is 
involved in the pinching off of CCVs from the plasma membrane (Damke et ah, 1994). 
The expression of a GTPase-deficient dynamin mutant (K44A) effectively inhibited 
both pz-AR and ATiaR sequestration (Zhang et ah, 1996). Furthermore, 
immunofluorescence analysis by Goodman et ah (1996) demonstrated that Pz-ARs and 
p-arrestin colocalise with clathrin in coated pits.
Recent studies have shown that p-arrestins directly interact with components of the 
endocytic machinery involved in the formation of clathrin-coated pits (Goodman et ah, 
1996; Laporte et ah, 1999, 2000, Figure 1.7). p-Arrestins bind to both the clathrin heavy 
chain and the p2-adaptin subunit of the heterotetrameric AP-2 adapter complex 
(Goodman et ah, 1997; Laporte et ah, 1999, 2000). The clathrin p-arrestin binding 
domain lies between residues 89-100 of the amino-terminal globular region in the
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terminal domain of the clathrin heavy chain which is located at the distal portion of each 
clathrin triskelion (Goodman et al., 1997). Amino acid residues 373-377 in the carboxyl 
terminus of p-arrestin 2 are involved in clathrin binding (Krupnick et al., 1997). The P~ 
arrestin domain responsible for binding to the p2-adaptin subunit of the AP-2 adapter 
complex is also localised to the C-termini of the p-arrestin proteins (Laporte et al., 
1999). More specifically, in vitro studies have revealed that residues Arg^ '^^  and Arg^^  ^
in p-arrestin 2 are required for p2-adaptin binding (Laporte et al., 2000). The interaction 
of P-arrestins with the AP-2 adapter, rather than clathrin, is essential for the initial 
translocation of receptors to coated pits (Laporte et al., 2000). Immunocytochemical 
studies demonstrated that p-arrestin mutants lacking the P-arrestin clathrin binding site 
motif retained the ability to redistribute with the pz-AR to coated pits whereas mutation 
of the p-arrestin p2-adaptin binding site blocked the targeting of receptors to CCVs 
(Laporte et al., 2000).
1.6.5 p-Arrestin regulation and signalling
The use of GFP-tagged p-arrestins has shown that cytosolic p-arrestin translocates to 
the plasma membrane upon GPCR activation and subsequently associates with the 
receptors in clathrin-coated pits (Barak et al., 1997b). The underlying mechanism of this 
receptor-mediated response remains undetermined. However, feedback regulation of p- 
arrestins has been demonstrated. Pz-AR activation leads to phosphorylation of p-arrestin 
1 on serine residue 412 by extracellular signal-regulated kinases (ERKs) (Lin et al., 
1998, 1999). p-Arrestin 1 appears to be dephosphorylated upon its recruitment to the 
plasma membrane-bound receptors, while cytoplasmic p-arrestin 1 is primarily in the 
phosphorylated form (Lin et al., 1998). Hence, a S412D P-arrestin 1 mutant was found 
to function as a dominant negative of Pz-AR endocytosis. However, the mutant had no 
apparent affect on receptor desensitisation (Lin et al., 1998). The dephosphorylation of 
p-arrestin- 1 does not seem to be a prerequisite for the redistribution of p-arrestin 1 to 
the membrane (Oakley et al., 2000). It has been suggested that ERK-mediated 
phosphorylation contributes to the regulation of P-arrestin 1/p-adaptin interactions (Lin 
et al., 1999). For p-arrestin 2, there is no conserved serine residue for phosphorylation.
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Therefore, ERK-mediated phosphorylation either occurs at a different site or P-arrestin 
2  regulation is mediated by an alternative mechanism.
p-Arrestin activity is also regulated by phosphoinositides, particularly IP  ^(Gaidarov and 
Keen, 1999; Gaidarov et a l, 1999). Residues 233-251 of P-arrestin 2 form the 
phosphoinositide-binding site. Mutation of residues within this domain produced a p- 
arrestin mutant defective in stimulating pz-AR internalisation in COS 1 cells. 
Furthermore, the mutant did not localise to clathrin coated pits. Thus, these observations 
suggest that phosphoinositide binding may be involved in the routing of receptor/p- 
arrestin complexes to the clathrin-coated pits.
As well as functioning as adapter proteins regulating GPCR desensitisation and 
internalisation, p-arrestins have recently been shown to play important roles in the 
localisation of signalling proteins to agonist-activated GPCRs (Miller and Lefkowitz,
2001), It has been revealed that the interaction of p-arrestins with molecules such as 
Src, Raf, and JNK3 appears to regulate signalling pathways which result in the 
activation of MAP kinases. For the pz-AR, the recruitment of Src was found to be 
essential for both receptor-mediated activation of the ERK cascade and receptor 
internalisation. Src-induced phosphorylation of components of the endocytic machinery, 
such as dynamin and clathrin, appear to be critical for the internalisation process (Miller 
et al., 2000; Ahn et al., 1999).
1.6.6 Alternative GPCR endocytic pathways
It is now recognised that not all GPCRs internalise via a P-arrestin- and clathrin- 
dependent route. This was first suggested from experiments of ATiaR internalisation in 
COS 7 cells and HEK293 cells (Zhang et al., 1996). In COS 7 cells, in which the 
endogenous level of GRKs and p-arrestin is relatively low, the maximal extent of 
receptor internalisation was the same as in HEK293 cells which express much higher 
levels of the proteins. In contrast, pz-AR internalisation was markedly reduced in COS 7 
cells (Zhang et al., 1996). Other experiments have shown that the effects of dominant 
negative mutants of p-arrestin and dynamin on GPCR endocytosis varies depending on 
the receptor studied (Zhang et al., 1996; Vogler et al., 1999). For the ATia and m2
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muscarinic receptors, coexpression of either dominant-negative p-arrestin or dynamin 
mutants did not inhibit agonist-stimulated internalisation (Zhang et al., 1996; Vogler et 
al., 1999), whereas P-arrestin-mediated sequestration of the ATiaR was blocked 
completely by the expression of a dominant-negative dynamin mutant (Zhang et al., 
1996). Taken together, these observations suggest that the internalisation of some 
GPCRs, at least in the presence of dominant-negative inhibitors of clathrin-mediated 
endocytosis, use an alternative endocytic mechanism. This idea may be of significance 
since the overexpression of dynamin mutants is reported to stimulate an increase in 
activity of alternative internalisation pathways, such as pinocytosis (Damke et al.,
1995).
The likelihood of a clathrin-dependent pathway being involved in the normal 
sequestration of the ATia and m2  muscarinic receptors is supported by the observation 
that a dynamin dominant-negative mutant exhibiting mutations of all three dynamin 
GTPase domains abolished internalisation of both receptors (Werbonat et al., 2000). 
Furthermore, the K44A-dynamin mutant trapped ATiAR/p-arrestin complexes in coated 
pits and prevented the co-intemalisation of p-arrestin with the receptor into endosomes 
(Anborgh et al., 2000). However, these observations do not rule out the possibility of 
alternative pathways for GPCR internalisation.
Internalisation of GPCRs in non-coated vesicles has also been reported as an alternative 
pathway for endocytosis. The internalisation of the pz-AR in A431 cells is believed to 
be in association with small microdomains of plasma membrane rich in cholesterol and 
glycosphingolipids known as caveolae. Electron microscopy of A431 cells showed that 
pz-ARs internalised via microdomains with the caveolae marker protein caveolin-1 
(Raposo et al., 1989). A clathrin-dependent pathway for internalisation was shovm to be 
functional in these cells since transferrin receptors were endocytosed in clathrin coated 
pits (Daukas and Zigmond, 1985). The identification of the Pz-AR’s caveolin-binding 
motif was unexpectedly localised to residues within the extracellular portion of the 
seventh transmembrane domain (Raposo et al., 1989; Watson and Arkinstall, 1994; 
Couet et al., 1997). Such findings indicated that the receptor’s caveolin binding motif 
was inaccessible to caveolin and therefore was unlikely to be involved in the 
internalisation of the pz-AR. Caveolae have also been implicated in the internalisation
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of the endothelin A receptor in transfected COS cells (Chun et al., 1994) and in the 
sequestration of muscarinic receptors in human fibroblasts (Raposo et al., 1987). The 
putative caveolin-binding motifs in the muscarinic receptor family (Watson and 
Arkinstall, 1994) and endothelin A receptor (Watson and Arkinstall, 1994; Bremnes et 
al., 2 0 0 0 ) were also found to be in receptor domains that are inaccessible to caveolin 
thus ruling out the interaction of caveolin with such domains.
1.6.7 Receptor determinants for endocytosis
Multiple receptor domains appear to contribute to the internalisation properties of 
GPCRs. For many GPCRs the second and third intracellular loop domains are 
functionally important in GPCR internalisation. For the m2 muscarinic receptor, the 
determinants for internalisation are found within a serine/threonine rich domain of the 
receptor’s third intracellular loop (Moro et al., 1993). Presumably, these residues are the 
sites of GRK phosphorylation that are critical for inducing receptor endocytosis (Tsuga 
et al., 1998). As well as the third intracellular loop, the conserved DRYXXV/IXXPL 
sequence of the second intracellular loop domain is also involved in the internalisation 
of some GPCRs including the ml muscarinic and GnRH receptors. Specifically, 
mutation of the motif’s leucine residue led to a reduction in internalisation of both 
receptors (Moro et al., 1994, Arora et al., 1995).
Many investigators have examined the role of GPCR C-terminal tails and putative GRK 
phosphorylation sites in regulating agonist-stimulated GPCR internalisation. Although 
the internalisation of the Pz-AR is P-arrestin-dependent, neither the truncation of the Pz- 
AR carboxyl tail nor the mutation of potential GRK phosphorylation sites was found to 
inhibit pz-AR internalisation (Hausdorff et al., 1989; Ferguson et al., 1995). 
Conversely, truncation of the C-tail or mutation of putative GRK sites of the ATiaR 
blocked its internalisation (Thomas et al., 1995; Zhang et al., 1996; Smith et al., 1998). 
Both positive and negative regulators of agonist-stimulated internalisation have been 
identified within the GPCR carboxyl terminal tail. A dileucine motif within the C-tail of 
the Pz-AR is involved in receptor internalisation (Gabilondo et al,, 1997) whereas a 
carboxyl-terminal tail dileucine motif negatively regulates lutropin/choriogonadotropin
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receptor sequestration since mutation of the motif was revealed to increase agonist 
stimulated receptor internalisation (Nakamura and Ascoli, 1999).
1.6.8 The role of internalisation in receptor desensitisation
GPCR internalisation was originally thought to be the principal mediator of receptor 
desensitisation due to the physical separation of the receptor from its effectors (Sibley 
and Lefkowitz, 1985). However further studies showed that receptor desensitisation 
occurs more rapidly than receptor endocytosis and the majority of sequestered receptors 
are phosphorylated and thus already desensitised. Furthermore, treatments such as 
hypertonic sucrose and concanavalin A that inhibit GPCR internalisation were 
demonstrated not to affect the Pz-AR’s ability to desensitise (Pippig et al., 1995). In 
analysis of truncated C-tail receptors and phosphorylation-deficient mutants, many 
studies have reported that desensitisation and internalisation are distinct processes. This 
has been demonstrated for receptors including the ATia (Thomas et al., 1995), D 1 
dopamine (Ng et al., 1995), m2 muscarinic (Pals-Rylaarsdam et al., 1995) and H2 
histamine (Fukushima et al., 1997) receptors.
1.6.9 The role of internalisation in resensitisation
Although GPCR internalisation may not a play a critical role in agonist-induced 
desensitisation, recent studies have highlighted the importance of internalisation in the 
recovery from desensitisation (a process also known as resensitisation). The 
mechanisms of GPCR resensitisation are thought to involve the internalisation of 
agonist-activated receptors into endosomal compartments which contain a GPCR- 
specific phosphatase. Endosomal acidification promotes the association of the receptor 
with the GPCR phosphatase and dephosphorylation of the receptor. Dephosphorylated 
GPCRs are subsequently recycled back to the cell surface where they can be again 
activated by agonist (Figure 1.8).
The role of internalisation in resensitisation was first observed in studies of the pz-AR. 
Following agonist exposure, pz-ARs were found to endocytose and subsequently 
recycle back to the plasma membrane (Staehelin and Simons, 1982; Morrison et al..
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Figure 1.8
Schematic representation of GPCR resensitisation.
GPCR resensitisation is achieved by the dephosphorylation of internalised receptors 
by a receptor phosphatase and subsequent recycling of receptors back to the cell 
surface. Alternatively, sequestered receptors are retained intracellularly and/or 
targetted for downregulation in lysosomes. In this instance, resensitisation is 
mediated by the mobilisation of an intracellular pool of naïve receptors and/or de 
novo receptor synthesis. Figure adapted from Ferguson and Caron, 1998.
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1996). Furthermore, sequestered pz-ARs were capable of stimulating adenylyl cyclase 
in reconstituted systems (Stadel et al., 1983b; Strulovici et al., 1983). The use of 
internalisation inhibitors such as sucrose and concanavalin A also blocked pz-AR 
resensitisation while G-protein coupling and desensitisation were unaffected (Pippig et 
al., 1995; Yu and Lefkowitz, 1993). It was subsequently proposed that 
dephosphorylation of internalised receptors in the endosomes followed by recycling 
back to the cell surface was responsible for restoring pz-AR function (Pippig et al.,
1995). This model was actually intimated in earlier studies when it was noticed that 
sequestered pz-ARs exhibited a reduced phosphorylated state (-0.75 mol/mol 
stoichiometry) compared to the whole cellular pool of pz-ARs (-2.1 mol/mol 
stoichiometry), and that the “light vesicular” fractions (endosomes) were enriched with 
a GPCR-specific phosphatase (Sibley et al., 1986; Pitcher et al., 1995a). The critical 
importance of both phosphatase activity and receptor recycling in Pz-AR resensitisation 
was further demonstrated by the ability of calyculin A, an inhibitor of protein 
phosphatases, and monesin, an inhibitor of intracellular trafficking, to block receptor 
resensitisation (Pippig et al., 1995). Sequestration has been reported to be critical for the 
resensitisation of many other GPCRs including the m3 muscarinic (Edwardson and 
Szekeres, 1999), neurokinin 1 (Garland et al., 1996), Ô-opioid (Hasbi et al., 2000), and 
endothelin A (Bremnes et al., 2000) receptors.
1.6.10 Receptor downregulation
Receptor downregulation involves a loss in the total cellular complement of a particular 
GPCR in response to prolonged or repeated agonist stimulation. Downregulation occurs 
as a consequence of both increased lysosomal degradation of pre-existing receptors and 
reduced mRNA and protein synthesis. Initial studies with the pz-AR revealed that long 
term exposure of cells to agonist resulted in a form of the pz-AR that was undetectable 
by radioligand binding but, nonetheless, retained its primary amino acid structure. The 
undetectable receptors appeared to be retained until agonist was removed, whereupon 
they became detectable by radioligand binding within a tyz of about 36 hours in the 
presence of cycloheximide (Doss et a l, 1981). Incubation of DDT I MF-2 hamster vas 
deferens cells with p-adrenergic agonists resulted in a time- and concentration- 
dependent decrease in P-adrenergic receptor mRNA. In downregulated cells, the
41
addition of an antagonist was able to restore receptor mRNA levels to 90% of the 
control value within 12 hours. Full recovery of steady-state pz-AR mRNA was achieved 
within 60 hrs (Hadcock and Malbon, 1988). Significant levels of mRNA 
downregulation could also be observed in cells treated with cell permeable analogues of 
cAMP or by activators of adenylyl cyclase (Bouvier et ah, 1989).
Mutational analysis of the human pz-AR highlighted residues Tyr^ *^^  and Tyr^ "^^  as being 
important in receptor downregulation. This mutation dramatically decreased the ability 
of the pz-AR to undergo agonist-induced downregulation. However, the substitution of 
Tyr^^  ^and Tyr^^  ^did not affect agonist-induced sequestration of the receptor (Valiquette 
et al., 1990) suggesting that sequestration is not linked to downregulation. Blocking pz- 
AR endocytosis with chemical treatments or by expressing a dominant negative mutant 
of dynamin could not prevent receptor downregulation indicating that this process may 
occur at the plasma membrane (Jockers et al., 1999).
Contrary to this, some studies have shown that Pz-AR downregulation is linked with 
sequestration. Using immunocytochemical techniques to label epitope-tagged pz-ARs, 
agonist treatment induced redistribution of the receptors in punctate accumulations 
within the cells. While the majority of internalised receptors were recycled back to the 
plasma membrane, a small fraction of the internalised receptors were sorted in 
endosomes for degradation in lysosomes (von Zastrow and Kobilka, 1992). The 
development of a Pz-AR conjugated with green fluorescent protein (Pz-AR-GFP) 
provided the opportunity for more extensive optical analysis of Pz-AR sequestration, 
downregulation and recycling in cells. Time-dependent colocalisation of pz-AR-GFP 
with rhodamine-labeled transferrin and rhodamine-labeled dextran following agonist 
exposure demonstrated receptor distribution to early endosomes (sequestration) and 
lysosomes (downregulation) respectively (Kallal et al., 1998). In HEK293 cells, the 
dynamin-K44A mutant profoundly inhibited agonist-induced internalisation and 
downregulation of the pz-AR, suggesting that receptor internalisation was critical for 
downregulation in these cells. Moreover, a dominant-negative mutant of P-arrestin, p- 
arrestin-(319-418), also inhibited both agonist-induced receptor internalisation and 
downregulation illustrating that downregulation of the pz-AR is in part due to 
trafficking of the receptor via clathrin coated pits (Gagnon et al., 1998). More recently,
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immunofluorescence microscopy has been used to directly visualise the localisation of 
Pz-ARs with the lysosomal protease cathepsin D following prolonged agonist exposure 
(Moore et ah, 1999).
1.7 Prostaglandin Receptors 
1.7.1 Prostaglandins
Prostaglandins (PCs) were initially discovered in the 1930s when von Euler (1934) and 
others identified a smooth muscle-contracting and vasodepressor activity in seminal 
fluid as a lipid soluble acid. They called the substance “prostaglandin” because it was 
believed, erroneously, that it came only from the prostate gland. It was not for a further 
20 years before technical advances allowed the purification of the first PGs, PGEi and 
PGFia (Bergstrom and Sjovall, 1957) which demonstrated that PGs were in fact a 
family of lipid compounds of unique structure. Further research showed that the PG’s 
were part of a diverse family, being named alphabetically from PGAz to PGHz, of 
which PGAz, PGBz, and PGCz are prone to extraction artefacts (Schneider et aL, 1966). 
PGGz and PGHz are unstable intermediates in the synthesis of other members of the 
family (Hamberg and Samuelsson, 1973). PGs are biosynthesised from three fatty acid 
precursors namely dihomo-y-linolenic acid, arachidonic acid, and eicosapentaenoic acid, 
which generate 1-, 2-, and 3-series PGs respectively (van Dorp et al., 1964); the 
numerals referring to the number of carbon double bonds present. In animals, 
arachidonic acid is the main precursor and therefore the 2-series PGs are the most 
abundant. The synthesis of second-series PGs from arichidonate is catalysed by 
cyclooxygenases which convert arachidonate to PGHz. In turn, PGHz serves as a 
substrate for cell-specific isomerases and synthases to generate five primary bioactive 
prostanoids: PGEz, PGFza, PGDz, PGIz, and thromboxane Az (TXAz). By the late 1970s 
it was becoming evident that prostanoids are capable of mediating a broad array of 
physiological responses and were becoming under increased scrutiny as possible 
therapeutic agents and drug targets (Figure 1.9).
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Figure 1.9
Diagrammatical representation of the prostanoids.
The chemical structure of the five primary bioactive prostanoid metabolites: PGEz, 
PGDz, PGFza, TXAz and PGIz.
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1.7.2 Prostaglandin Receptors
By virtue of their lipid nature, PGs were originally thought to mediate their actions by 
diffusion across the cell membranes. However, despite this, in the 1970s work began to 
identify and classify prostanoid receptors in an attempt to rationalise the many and 
varied actions of prostanoids. Preliminary research demonstrated that both natural and 
synthetic prostanoids showed different rank orders of agonist activity over a wide range 
of isolated smooth muscle preparations (Andersen and Ramwell, 1974; Andersen et al., 
1980; Gardiner and Collier, 1980). In 1982, on the basis of functional studies with both 
natural and synthetic agonists, and some antagonists, Kennedy and coworkers outlined a 
comprehensive classification of receptors (Kennedy et at., 1982; Coleman et a l, 1984). 
The receptors were classified into the DP, EP, FP, IP, and TP receptors which were 
specific for the five primary prostanoids, PGs Dz, Eg, Fa, la, and TXAa respectively. 
From the functional data it was evident that at each receptor, one of the natural ligands 
was at least one order of magnitude more potent than any of the other four. Further 
diversity in the prostanoid receptor family has since been uncovered with the discovery 
of subdivision within the EP receptor family. Four EP receptor subtypes have been 
identified, termed EPi, EPa, EP3, and EP4.
The prostanoid receptors belong to the family of GPCRs which include receptors for 
autacrine, paracrine, and endocrine factors such as tripeptides, pituitary hormones, 
glycoprotein hormones, opioids and platelet-activating factor. The family overall shares 
a 20-30% sequence identity, with 65 amino acid residues conserved among the family. 
Of these residues, 34 are identical across the prostanoid receptor family. Most of these 
conserved residues lie within the transmembrane regions, although a considerable 
number of the conserved amino acids is present in the second extracellular loop (Audoly 
and Breyer, 1997a). Functional analysis has demonstrated that these domains are 
important in ligand binding. Another characteristic of the prostanoid receptor family is 
the existence of alternatively spliced variants of the TP, FP, EPi, and EP3 receptors. In 
each instance, the alternative splicing sites are found within the intracellular carboxyl 
tail of the receptor.
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1.7.3 TP receptor
Thromboxane is a potent agonist at the TP receptor mediating platelet aggregation as 
well as proliferation of smooth muscle cells and vasoconstriction. Upregulation of 
thromboxane biosynthesis has been suggested in cardiovascular diseases including acute 
myocardial ischaemia (Oates et al., 1988), heart failure (Castellani et ah, 1997), and 
renal disorders (Spumey et al., 1992). Thus, antagonists of thromboxane have potential 
therapeutic benefits.
The thromboxane receptor, TP, was the first eicosanoid receptor to be cloned and was 
found to encode a 343 amino acid protein (Hirata et al., 1994). Two alternatively 
spliced variants of the TP receptor have since been identified and named TPa and TPp 
(Raychowdhury et al., 1994). The original TP receptor cloned was termed TPa and the 
subsequent 407 amino acid variant, which possesses a longer intracellular tail, was 
designated TPp.
Mutational analysis of the TP receptor indicated that Trp^^  ^ in TMVII was a critical 
determinant of ligand binding selectivity. A W299L receptor mutant bound the 
synthetic agonists I-BOP and U-46619 but was unable to bind the antagonist SQ29548 
(Funk et al., 1993). Ligand binding and receptor signalling were abolished by mutation 
of the universally conserved Arg^^  ^ in TMVII (Funk et al., 1993), an observation that 
has been reported for other members of the prostanoid family (Audoly and Breyer, 
1997b). The extracellular loops have also been implicated in ligand binding as mutation 
of cysteine residues in these regions impaired ligand interaction with the receptor, 
suggesting that there are essential disulphide bonds in the receptor structure (D’Angelo 
etal., 1996).
Thromboxane receptors couple primarily to the Gq class of G proteins, activating the 
Ca^^/DAG effector signalling. More recently it has been shown that the receptor can 
also activate the Gn, Gn, and G13 proteins (Kinsella et al., 1997; Becker et al., 1999; 
Offermanns et al., 1994). Although both splice variants can bind ligands and couple to 
G proteins equally well, the TPp variant has been shown to exhibit an increased ability 
to internalise compared to the a  variant (Parent et al., 1999). In HEK293 cells, the TPP
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receptor was observed to traffic via a P-arrestin-, GRK- and dynamin-dependent 
pathway (Parent et al., 1999) suggesting that the longer tail of the TPp receptor is a 
target for phosphorylation and arrestin binding, and thus acts as a regulator of 
internalisation. The TPa splice variant, but not TPp, can undergo prostacyclin- 
activated PKA phosphorylation, indicating that the TPa variant may be of importance in 
the maintenance of thromboxane/prostacyclin-mediated vascular homeostasis (Walsh et 
al, 2 0 0 0 ).
1.7.4 FP receptor
PGFza receptor cDNA was cloned from a human kidney cDNA library (Abramovitz et 
a l, 1994) and it encodes a 359 amino acid protein. Alternative spliced variants of the 
ovine FP receptor were identified which differ only at their C-terminal tails. The FPa 
receptor has an additional 46 amino acid residues after the splice site, whereas the FPb 
receptor has only one residue distal to the splice junction. Mutation of His^  ^ in TMII of 
the rat FP receptor was shown to abrogate ligand binding. It was suggested that an 
interaction between His*  ^ and the conserved Arg residue in TMVII is responsible for 
ligand binding (Rehwald et a l, 1999).
FP receptor expression in corpora lutea has been shown to be crucial in parturition 
(Sugimoto et a l, 1997) as determined with knockout mice lacking FP receptor 
expression. The human FP receptor, when expressed in oocytes, was found to elicit a 
Ca^^-dependent CF ion current, thus demonstrating that FP receptor signalling mediates 
increases in intracellular Ca^ *^  concentration (Abramovitz et a l, 1994). Ovine FP 
receptors have also been observed to effect phosphoinositide turnover and Rho 
activation (Pierce et a l, 1999). The different splice variants of the ovine FP receptor 
exhibit different levels of agonist-mediated phosphorylation. The longer form has 
multiple PKC phosphorylation sites, and has been observed to undergo PKC-mediated 
phosphorylation in cell culture (Fujino et a l, 2000). Differential phosphorylation of the 
FP receptor variants has been suggested to induce desensitisation of the longer form but 
not of the FPb variant.
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1.7.5 EPi receptor
A 402 amino acid protein is encoded by the cloned human EPi receptor cDNA (Funk et 
al., 1993). An alternative variant of the rat EPi receptor has been reported which 
comprises an alternative 49 amino acids from the middle of TMVI to the carboxyl 
terminus (Okuda-Ashitaka et al., 1996). The human receptor signals via the Gq/n class 
of G  protein, stimulating IP3 generation and increasing the concentration of intracellular 
Ca^  ^ ions. The variant rat EPi receptor does not appear to signal although it is still 
capable of binding ligand (Okuda-Ashitaka et al., 1996). It has been suggested that the 
short EPi variant may inhibit the signalling of the rat EPi receptor as Ca^  ^mobilisation 
induced by the longer EPi receptor was attenuated by the shorter variant when they 
were coexpressed in cells. Antagonists of the EPi receptor appear to have analgesic 
properties. Therefore agents which block EPi receptor activation would provide pain 
relief without producing the side effects which are associated with cyclooxygenase 
inhibitor drugs (Hallinan etal., 1994).
1.7.6 EP2  receptor
The human EP2 receptor cDNA encodes a 358 amino acid polypeptide which couples to 
Gs. (Regan et al., 1994a). EP2 receptor expression in the uterus has been linked to 
embryonic implantation (Hizaki et al., 1999) and in the lung it is suggested to play an 
important role in bronchodilation (Pavord et al., 1991).
The EP2 receptor shares the greatest sequence homology with the DP and IP receptor 
subtypes. Mutagenesis studies of the receptor revealed that Leu^ ®"* in TMVII is critical 
in ligand binding selectivity as a L384Y receptor mutant gained the ability to bind the 
IP selective agonist, iloprost (Kedzie et al., 1998). Ligand binding was abolished by 
mutation of an adjacent conserved arginine residue, Arg^ ®^ , further highlighting the 
importance of this region in ligand binding for the prostanoid receptor family. 
Pharmacological analysis of the receptor demonstrated its inability to undergo short­
term agonist induced desensitisation. It was suggested the short C-tail of the EP2 
receptor is a poor substrate for kinase phosphorylation thereby reducing that rate of 
receptor desensitisation (Nishigaki etal., 1996).
48
1.7.7 EP3 receptor
A unique feature of this prostanoid receptor family member is the existence of multiple 
alternative spliced forms which differ at their carboxyl tails (Schmid et ah, 1995). The 
splice variants encode proteins of between 40 and 45 kDa (Regan et al., 1994b) which 
bind PGEa with similar affinity. Mutagenesis studies on the conserved arginine, Arg^^ ,^ 
in the EP3 receptor have proposed that there is a non-ionic interaction between the C-1 
carboxylate of the prostanoid and the conserved residue (Audoly and Breyer, 1997a,b). 
The conserved sequence in the second extracellular loop has also been shown to be 
important in ligand binding properties of the EP3 receptor. A P200S substitution in this 
region led to a reduction in the binding selectivity for prostanoid agonists (Audoly and 
Breyer, 1997a).
The EP3 splice variants exhibit differences in receptor phosphorylation and 
desensitisation, intracellular trafficking, and G protein coupling. The variants generally 
inhibit cAMP production through coupling to G;, though signalling through Gs and Ca^  ^
release has also been observed and appears to be mediated by the different C-tails 
(Namba et al., 1993), Rho activation via the EP3 receptors has also been suggested 
recently. Activation of the bovine EP3 in PC 12 cells caused neurite retraction which 
could be blocked by tyrosine kinase inhibitors upstream and downstream of Rho (Aoki 
etal., 1999).
1.7.8 EP4 receptor
The human EP4 receptor cDNA encodes a 488 amino acid polypeptide (Bastien et al., 
1994). As with the EP2  receptor, the EP4 couples to Gg. The EP4 receptor is widely 
expressed and its activation has been reported to be important in inducing vasodilation 
of blood vessels (Coleman et al., 1994). It has also been suggested to function in the 
closure of the pulmonary ductus arteriosus in new-boms as demonstrated by studies of 
knockout mice lacking EP4 receptor gene expression (Segi et al., 1998).
Unlike the EP2 receptor, the EP4 receptor has a long (156 amino acids) C-tail which 
contains 38 serine and threonine sites which are potential phosphorylation targets. As 
mentioned above, the EP2  receptor, which has a short C-tail, is insensitive to agonist
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mediated desensitisation whereas the EP4  receptor rapidly undergoes phosphorylation 
and G protein uncoupling (Nishigaki et ah, 1996). Deletion studies identified a stretch 
of six serines in the tail which are thought to be sites of kinase action and thus be 
important in receptor desensitisation (Bastepe and Ashby, 1999). The two receptors Gg- 
coupled EP receptors, EP2 and EP4, may therefore mediate different physiological 
responses in the presence of agonist.
1.7.9 DP receptor
The human DP receptor is the most recent prostanoid receptor to be cloned and it 
encodes a 359 ammo acid protein that binds PGD2 with high affinity (Boie et a l, 1995). 
PGD2  is involved in hypersensitivity reactions, being the major prostanoid released 
from mast cells after IgE challenge (Lewis et a l, 1982). It has also been shown to be an 
important regulator of the sleep-wake cycle (it induces sleep) and body temperature (it 
produces hypothermia) in rats (Urade and Hayaishi, 1999; Sri Kantha et a l, 1994). In 
peripheral tissues, PGD2  has been show to affect vascular tone, as well as inhibiting 
platelet aggregation (Giles et a l, 1989). The receptor couples to Gg, stimulating 
adenylyl cyclase. It shares the most sequence homology with the IP receptor. DP/IP 
receptor chimeras in which the first and second intracellular loops of the IP receptor 
containing the third transmembrane domain were replaced with the corresponding 
regions of the DP receptor gained the ability to bind PGD2 , thus highlighting the role of 
the TMIII domain in conferring the selective binding of PGD2 to the DP receptor 
(Kobayashi et a l, 2000).
1.7.10 IP receptor
The human IP (prostacyclin) receptor, which is the focus of this study, was cloned in 
1994 (Boie et a l, 1994) and encodes a 386 amino acid protein with a predicted 
molecular weight of 41 kDa (Figure l.IO). IP receptor mRNA is predominantly 
expressed in neurons of the dorsal root ganglia and vascular tissue including aorta, 
pulmonary artery, and renal afferent arterioles (Oida et a l, 1995),
Ligand binding studies of the IP receptor using stable analogues of PGI2 have shown 
that the most selective agonist of the IP receptor is iloprost. Displacement binding
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Figure 1.10
The human prostacyclin receptor.
The primary structure of the human IP receptor and its predicted configuration in the 
membrane. Figure adapted from Smyth et al., 1996.
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Figure 1.10
studies have produced a rank order of agonist potencies at the IP receptor as iloprost ^ 
cicaprost > carbacyclin > PGE2  > > PGFaa, PGD2 . Of the prostanoid receptor family, 
the IP receptor is the least discriminating in terms of ligand binding selectivity, being 
capable of binding PGEi analogues with high affinity. The receptor, however, binds 
PGE2 analogues with much lower affinity. Using IP/DP receptor chimeras in which IP 
receptor residues spanning from TMVI to the carboxyl terminus were replaced with the 
corresponding domains of the DP receptor, an increased PGE2 binding was observed 
while the binding of iloprost and PGEi remained unaltered. Thus, TM regions VI and 
VII determine the specificity of PGEi binding over PGE2  (Kobayashi et al. 2000). The 
generation of further IP/DP receptor chimeras identified the IP receptor’s TMI and first 
extracellular loop as important determinants in the binding selectivity of the prostanoid 
ring between the two receptors (Kobayashi et al. 2000).
Most studies suggest that the activated IP receptor signals through increased cAMP. 
Coexpression of the cloned IP receptor in Xenopus oocytes with the cystic fibrosis 
transmembrane conductance regulator (cAMP-activated Cl“ ion channel) and 
subsequent challenge with iloprost induced a specific inward CF ion current, 
demonstrating that the receptor couples to cAMP production (Boie et al., 1994). IP 
receptors couple to adenylyl cyclase via Gs as originally demonstrated in mouse 
mastocytoma P-815 cells where the dissociation of bound [^H] iloprost fi'om the cell 
membranes was specifically enhanced by guanine nucleotides. Furthermore, iloprost 
dose-dependently enhanced the activity of adenylyl cyclase in a GTP-dependent manner 
(Hashimoto et al., 1990). Many other fimctional studies of the IP receptor have 
confirmed its ability to activate Gs (Nilius et al., 2000; Lawler et al., 2001; Smyth et al., 
1996,1998, 2000; Hayes et al., 1999).
At relatively high concentrations of agonist, the IP receptor has been shown to stimulate 
phosphoinositide turnover (Namba et al., 1994) in transfected CHO cells. A 10,000-fold 
higher agonist concentration was required to stimulate PIP2  hydrolysis in the cells 
compared to the concentrations required to activate adenylyl cyclase. PGI2  analogues 
have also been shown to evoke smooth muscle contraction via increases in intracellular 
Ca^  ^ ion concentrations (Lawrence et al., 1992). Furthermore, iloprost-stimulated 
increases in intracellular Ca^  ^ion concentration in the human erythroleukaemia cell line
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were mediated by a pertussis-toxin sensitive G protein (Schwaner et al., 1992). HEK293 
cells stably expressing IP receptors also exhibited substantial agonist-mediated inositol 
phosphate production (Smyth et a l, 1996, 1998, 2000) but this may be an artefact of the 
transfection system. More recently, it has been reported that murine IP receptors can 
switch their coupling from Gs to Gi and Gq upon agonist-induced PKA phosphorylation 
of the receptor (Lawler et a l, 2001).
A feature of the IP receptor that may be unique among GPCRs is that it is isoprenylated 
(Hayes et a l, 1999). Isoprenylation occurs as a post-translational lipid modification to 
the first cysteine residue in the CSLC motif at the C-terminal sequence of the receptor. 
Disruption of this motif resulted in a receptor with defects in coupling to adenylyl 
cyclase and phospholipase C, indicating that lipid modification of the receptor is crucial 
for efficient signal transduction. In addition, a number of studies have confirmed that 
the IP receptor undergoes agonist induced phosphorylation, internalisation and 
downregulation in human platelets, NG108-15 neuronal cells, and HEK293 cell lines 
(Smyth et a l, 1998, 2000; Leigh and MacDermot, 1985; Krane et a l, 1994; Giovanazzi 
e ta l, 1997).
Prostacyclin plays a key role in many physiological processes and pathological states. 
Prostacyclin is mainly produced by the vascular endothelium where it acts as a potent 
inhibitor of platelet aggregation and as a vasodilator (Vane et a l, 1995). Thus, 
prostacyclin causes relaxation of arterial smooth muscle and inhibition of platelet 
aggregation, degranulation and shape change and is, therefore, thought to be important 
in maintaining vascular homeostasis. In unstable angina, prostacyclin synthesis is 
increased during ischaemic attack to function as a homeostatic regulator of platelet- 
vascular interactions in atherosclerotic plaque ruptures. Prostacyclin has also been 
reported to confer a cytoprotective effect against tissue injury during acute myocardial 
ischaemia or in response to hypoxia (Sakai et a l, 1990). The actions of prostacyclin 
generally counteract those of TXAz and thus the relative levels of these two prostanoids 
in the circulation are important in the local control of vascular homeostasis. Imbalances 
in TXAz or prostacyclin levels have been reported to be a major contributing factor in 
the development of a number of cardiovascular disorders including thrombosis, 
myocardial infarction, unstable angina, stroke, and atherosclerosis (Vane et a l, 1995; 
Lefer et a l, 1990; Rasmanis et a l, 1995). In addition to its central role in the
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cardiovascular system, prostacyclin may be important in the regulation of renal blood 
flow (Negishi et al., 1995); it also acts as a negative feedback regulator of histamine 
release from mast cells (Holgate et aL, 1980) and as a lipolytic agent in adipocytes 
(Chatzipanteli et ah, 1992). Moreover, transgenic mice lacking IP receptor expression 
exhibited reduced pain perception, thus establishing prostacyclin as a mediator of 
nociception (Murata et ah, 1997). The development of selective PGIz mimetics or 
antagonists may therefore serve as possible therapeutic agents in certain disease states.
1.8 Research Objectives
The aims of this project were to study the functional significance of the carboxyl 
terminal domain of the prostacyclin receptor in the following processes:
• Sequestration
• Desensitisation
• Resensitisation
Receptor chimera models were used to investigate these events.
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Chapter 2 
Materials and Methods
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2.1 Materials
All reagents used were of the highest grade possible and were obtained from the 
following suppliers.
2.1.1 General reagents
BDH, Lutterworth, Leicestershire, UK
Sodium di-hydrogen orthophosphate, potassium hydroxide, potassium chloride, glacial 
acetic acid, trichloroacetic acid, ethanol, methanol, isopropanol, chloroform, microscope 
slides, 2 2 mm coverslips.
Calbiochem, CN Biosciences UK, Nottingham, UK
H89, GF109203X, geneticin sulphate (G418).
Duchefa, Haarlem, The Netherlands
Yeast extract, tryptone, agar.
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK
Ammonium sulphate, glycine, HEPES, sucrose, SDS, potassium acetate, potassium di­
hydrogen orthophosphate, calcium chloride, HCl, sodium bicarbonate, manganese 
chloride, mercaptoethanol.
Interactiva, Ulm, Germany
Oligonucleotides for PCR reactions.
Invitrogen BV, Groningen, The Netherlands
NuPage® Novex pre-cast bis-tris gels, XCell Surelock™ mini-cell gel tank, XCell II™ 
blot module, MOPS running buffer, MES running buffer.
Konica Europe, Hohenbrunn, Germany
X-ray film
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Molecular Probes, Eugene, Oregon, USA
Texas Red® transferrin
Pierce, Perbio Science UK Ltd., Tattenhall, Cheshire, UK
Supersignal® west pico chemiluminescent substrate, EZ-Link^*  ^ Biotin-LC-Hydrazide, 
Streptavidin-HRP conjugate.
Promega UK Ltd., Southampton, UK
Restriction endonucleases, pfu polymerase, calf intestinal alkaline phosphatase, DNA 
purification kits- Wizard^^ Plus SV Minipreps and Wizard '^'  ^ Plus SV Maxipreps 
systems.
Quiagen, Crawley West Sussex, UK 
QIAquick gel extraction kit.
Roche Diagnostics Ltd., Lewes, East Sussex, UK
Complete™ mini-protease inhibitor cocktail tablets, Ikb DNA ladder, T4 DNA ligase, 
bovine serum albumin (fraction V).
Sigma-Aldrich Company Ltd., Poole, Dorset, UK
Alumina, agarose, gelatin (porcine, type A), magnesium chloride, sodium chloride, 
sodium hydroxide, sodium acetate, DTT, di-sodium pyrophosphate, di-sodium 
orthophosphate, tris, Dowex-50W, EDTA, bromophenol blue, deoxycholic acid, 
rubidium chloride, imidazole, Triton X-100, DMSO, glycerol, Tween 20, ethylene 
glycol, paraformaldehyde, ampicillin, DMEM (powder), Protein G-Sepharose, ethidium 
bromide, ATP, cAMP, IBMX, concanavalin A, PMA, gelatin (bovine, 2% solution), 
bovine albumin (essentially globulin-free), MOPS, Ponceau S, forskolin, mineral oil, 
sodium tartrate, sodium m-periodate.
Whatman International Ltd., Maidstone, UK
3mm-filter paper, chromatography paper, GF/C Glass fibre filters
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2.1.2 Tissue culture plastic ware & reagents
American Tissue Culture Collection, Rockville, USA
HEK293 cells
Bibby Sterilin Ltd., Stone, Staffordshire, UK.
15ml and 50ml centrifuge tubes
Costar, Cambridge, MA., USA
5ml, 10ml, and 25ml pipettes, 75cm^ tissue culture flasks, 25cm^ tissue culture flasks, 
60mm and 1 0 0 mm dishes, 6 , 12, 24, and 96 well plates, cryovials, cell scrapers.
Gibco BRL, Life Technologies Ltd., Paisley, UK
Lipofectamine™ transfection reagent, OPTIMEM-1, L-glutamine (200mM), NBCS, 
DMEM without sodium pyruvate.
Sigma-Aldrich Company Ltd., Poole, Dorset, UK
DMEM, 0.25% Trypsin-EDTA, Poly-D-Lysine.
2.1.3 Radiochemicals
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
[2-^H] Adenine (25 Ci/nunol)
[^ H] Iloprost (17 Ci/mmol) (supplied with 2mg unlabelled compound)
NEN^  ^Life Science Products, Hounslow, UK
[^ ^P] Orthophosphoric acid (285.5Ci/mg, lOmCi/ml)
2.1.4 Antisera
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK
Goat anti-mouse IgG-HRP conjugate 
Donkey anti-rabbit IgG-HRP conjugate
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Donkey anti-sheep IgG-HRP conjugate
Molecular Probes, Eugene, Oregon, USA
Alexa® 594 goat anti-mouse IgG conjugate 
Anti-P-arrestin 1 monoclonal mouse IgG
Roche Diagnostics Ltd., Lewes, East Sussex, UK
12CA5 monoclonal mouse IgG, binds to haemagglutinin (HA) epitope-tagged proteins. 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK
Anti-Flag® M2 monoclonal mouse IgG, binds to proteins which contain a FLAG 
epitope.
A sheep polyclonal anti-GFP antibody, which recognises proteins that are GFP-tagged, 
was generated in house.
2.2 Buffers
2.2.1 General buffers
Phosphate Buffered Saline (lOx)
137mMNaCl, 2.7mMKCl, 1.5 mMKH2P0 4 , 1 0 .2 mMNa2HPO4 ,pH 7.4 
This was diluted 1:10 to make a Ix stock which was stored at 4®C.
Tris-EDTA (TE) Buffer
lOmM Tris, O.lmM EDTA, pH 7.5 
This was stored at room temperature.
Laemmli Buffer (2x)
0.4M DTT, 0.17M SDS, 50mM Tris, 5M Urea, 0.01%(w/v) Bromophenol Blue.
This was stored in aliquots at -20°C.
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2.2.2 Molecular Biology Solutions
TAE buffer (50x)
For 500mls:
40mM Tris 12 Ig
ImM EDTA 5Omis of 0.5M (pH 8 ) stock
Glacial acetic acid 28.55ml
This was diluted 1:50 prior to use.
DNA Loading Buffer
For 10ml:
Bromophenol Blue (2%) 1.25ml
Sucrose 4g
This was dissolved in water and stored in aliquots at -20°C.
Liquid Broth (LB)
For 1 litre:
Yeast Extract 5g
Tiyptone lOg
NaCl lOg
This was dissolved in deionised water, pH adjusted to 7, and then sterilised by 
autoclaving at 126°C.
2.3 Molecular Biology Protocols
2.3.1 LB ampicillin agar plates
This has the same composition as LB but with 1.5% (w/v) agar added. After 
autoclaving, it was left to cool before ampicillin was added to a final concentration of 
50pg/ml. The liquid agar was poured into 10cm diameter petri dishes, and allowed to 
solidify before storing at 4°C. LB agar plates can be stored for up to 3 weeks without 
any loss of antibiotic activity.
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2.3.2 Preparation of competent bacteria
The uptake and expression of foreign DNA into E. Coli is known as transformation. 
Before transformation can take place, the E. Coli strain, which in this case was DH5a, 
has to be made receptive, or competent, for the uptake and expression of the pcDNAS.l 
(+) vector containing a particular cDNA insert. Competent E.Coli cells are made using 
the following procedure.
Solution 1 (for 100ml)
IM Potassium acetate 3ml
IMRbCk 1 ml
IM CaCl2  1 ml
IM MnCl2 5ml
80% (w/v) glycerol 18.75ml
This was pH adjusted to 5.8 with lOOmM acetic acid and made up to a final volume of 
100ml with deionised water. The solution was filter-sterilised and stored at 4®C.
Solution 2 (for 40ml)
lOOmM MOPS pH 6.5 4ml
IM CaCl2  3ml
IM RuCl2  0.4ml
80% (w/v) glycerol 7.5ml
This was pH adjusted to 6.5 with HCl and made up to a final volume of 40ml with 
deionised water. The solution was filter-sterilised and stored at 4°C.
DH5a cells were streaked out on a minimal agar plate (no antibiotics) and grown 
overnight at 37®C. A single colony from the plate was chosen and cultured overnight in 
5ml of LB at 37°C. The 5ml culture was then added to 100ml fresh LB and grown until 
the OD5 5 0  was 0.48. The culture was chilled on ice for 5 min and then spun at 3000rpm 
for 10 min at 4°C in 50ml sterile tubes. The pellets were resuspended in 20ml of 
solution 1, then chilled on ice for 5 min and spun as before. The pellets were then 
resuspended in 2ml of solution 2 and chilled on ice for a further 15 min. Cells were 
aliquoted and stored at -80°C.
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2.3.3 Transformation of competent bacterial cells with plasmid DNA
Between 10-50ng of plasmid DNA was incubated with 50p,l of competent bacterial cells 
on ice for 20 min. The mix was then heat shocked for 90 seconds at 42°C and placed 
back on ice for a further 2 min. 1ml of LB was added and the cells were allowed to 
recover by incubation at 37°C for 1 hour in a shaking incubator. 200pl of this mix was 
spread out on a LB agar ampicillin plate. Plates were then incubated overnight at 37°C. 
Colonies picked from the plates were cultured in 5ml LB containing 50pg/ml 
ampicillin.
2.3.4 Plasmid DNA preparation
Plasmid DNA was purified from bacterial cultures using the Promega Wizard™ Plus 
SV Minipreps and Wizard™ Plus SV Maxipreps systems. For minipreps, a 5ml culture 
of transformed bacterial cell was first set up. 3ml of the culture was spun down and the 
cell pellet was resuspended in resuspension solution (50mM Tris-HCl pH 7.5, lOmM 
EDTA, lOOug/ml RNase A), followed by lysis with lysis solution (0.2M NaOH, 1% 
SDS). Neutralising solution (4.09M guanidine hydrochloride, 0.76M potassium acetate, 
2.12M glacial acetic acid, pH 4.2) was added to the lysate to precipitate the bacterial 
chromosomal DNA. This was spun down and the resulting supernatant was transferred 
to a DNA purification column. The column was washed twice with column wash 
(60mM potassium acetate, lOmM Tris-HCl pH 7.5, 60% ethanol) and the DNA was 
eluted from the column with sterile water. From each column a lOOpl plasmid DNA 
solution with a concentration of 0.1-0.4pg/p,l was yielded. For maxipreps, a similar 
method of purification was used but on a much larger scale. 500ml cultures were used 
to generate approximately 1ml of plasmid DNA at a concentration between 0.5-2pg/pl.
2.3.5 Quantification of DNA
The concentration of plasmid DNA generated from maxipreps and minipreps was 
determined by measurement of the absorbance at 260nm of a 1:50 dilution of the DNA 
sample. An A2 6 0  value of 1 unit was assumed to be equivalent to 50pg/ml of double 
stranded DNA. The A2 8 0  value of the solution was also measured to assess the purity of 
the DNA solution. A DNA solution with an A2 6 0 /A2 8 0  ratio of between 1.7 and 2.0 was 
considered pure enough for use.
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2.3.6 Digestion of DNA with restriction endonucleases
Restriction digests of DNA were carried out for the subcloning of DNA fragments into 
plasmid vectors. The digests were set up using the conditions recommended by the 
manufacturer. In brief, Ipg of DNA was digested in lOpl of a buffered solution 
containing 1 unit of the appropriate enzyme for a minimum of 2 hours at 37°C.
2.3.7 DNA gel electrophoresis
Digested DNA fragments were separated and analysed using agarose gel 
electrophoresis. Samples were mixed with 6 x loading buffer to make a final Ix 
concentration. DNA fragments between 0,4 and 5kb were separated using 1% (w/v) 
agarose gels containing TAE buffer and 2.5mg/ml ethidium bromide. The gels were run 
at 75mA in horizontal gel tanks containing TAE buffer. Ultraviolet light was used to 
analyse the separated DNA fragments on the gels. The size of each DNA fragment was 
calculated by comparison with a Ikb ladder.
2.3.8 DNA purification from agarose gels
Purification of DNA fragments from agarose gels was carried out using the Quiagen 
QIAquick gel extraction kit. DNA fragments were excised from the gel using a sterile 
razorblade and dissolved in QIAquick buffer QG. One volume of isopropanol was then 
added and the solution was loaded onto a QIAquick column. The column was then 
washed with an ethanol solution (PE) and the DNA was eluted from the column using 
sterile water.
2.3.9 Alkaline phosphatase treatment of plasmid vectors
Alkaline phosphatase treatment of cut plasmid vectors was carried out to minimise re­
ligation of the vector with itself. The 5' phosphate group was removed by incubation of 
2 0 0 ng of digested vector with 2  units of the enzyme in the appropriate buffered 
conditions for 2 hours at 37°C, The plasmid was isolated from the reaction mixture by 
agarose gel electrophoresis and gel extraction as described previously.
2.3.10 DNA ligations
Ligations of vector DNA with a desired cDNA insert(s) were performed using T4 DNA 
ligase. For each ligation, a vector:insert ratio of 1:2 was used. Reactions were performed
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in a total volume of lOpl containing enzyme buffer with 1 unit of T4 ligase and 
incubated at 4°C for at least 16 hours. Ligation mixtures were used for transformation 
reactions as described in 2.3.2.
2.3.11 Polymerase chain reaction
PCR reactions were carried out in a total volume of 50pl containing 20ng of DNA 
template, 0.2mM dNTPs (dATP, dCTP, dGTP, dTTP), 25pmol of sense and antisense 
oligonucleotide primers, Ix thermophilic buffer, and 2 units of Pfu polymerase. 
Samples were overlaid with mineral oil to prevent evaporation and the reactions were 
carried out on a Hybaid Omnigene thermal cycler. The enzyme was added after the 
reaction mixtures were given an initial heat to 95 °C for 5 min.
PCR Cycles:
Dénaturation 
95°C, 1 min 
95°C, 1 min
Annealing 
50-60°C, 1 min 
50-60°C, 1 min
Extension 
72°C, 2 min 
72°C, 5 min
Cvcles
30
1
The annealing temperatures were empirically determined and were set at 50, 55, or 
60°C.
2.4 Construction of chimeric GPCR fusion cDNA
2.4.1 FLAG-IP-GFP
A BawHI-FLAG-IP-GFP-EcoRI cDNA had been generated previously in the laboratory 
and was used as template to synthesise the N terminal-TMVII DNA fragment for 
construction of the chimeric receptor fusions.
2.4.2 FLAG-IP-TRH-GFP
FLAG-IP-GFP in pcDNA3 was amplified from the N-terminal FLAG region to the end 
of the seventh transmembrane encoding region (N-TMVII). This was done using the 
following primers:
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Sense 5'-AAGGATÇÇGCCACCATG(GACTACAAGGACGACGATGATAAG)- 
GCGGATTCGTGCAGGAACC-3% where the Barnm site is underlined and the FLAG 
epitope, which was inserted after the initiating methionine, is in parenthesis.
Antisense 5'-ATAGAATTCCCTTGCGGAAAAGGATGAAGACC-3\ where the 
EcoRI site is underlined.
Wild type TRH-GFP, which had been generated previously in the laboratory, was used 
a template to PCR the sequence encoding the tail of TRH receptor with GFP linked at 
the carboxyl terminus. The primers used were:
Sense 5'-AGGGAATTCTATACAACCTCATGTCTCAGAAGTTTC-3\ where the 
EcoBl site is underlined.
Antisense 5'-GCTAîÇTAGAG(TCA)AAGCTTCTCCTGTTTGGCAGTCAAA-3', 
where the Xbal site is underlined, followed by the stop codon in parenthesis.
The 5amHI-FLAG-IP (N-TMVII)-^coRI PCR product and the EcoRI-TRH (C-tail)- 
GFP-Jfôal fi-agment were digested with the appropriate restriction enzymes and ligated 
into pcDNA3.1(+) to generate FLAG-IP-TRH-GFP.
2.4.3 FLAG-IP-P2-GFP
The N-TMVII fragment of IP-GFP was generated in the same way as in the 
construction of FLAG-IP-TRH-GFP.
Wild type pz-AR-GFP, which was a kind gift from GlaxoSmithKline, Stevenage, was 
used a template to PCR the sequence encoding the (3 2 -AR tail linked to GFP. The 
primers used were:
Sense 5'-AGGGAATTCTATACAACCTCATGTCTCAGAAGTTTC-3\ where the 
£coRI site is underlined.
Antisense 5'-GCTCTAGAG(TTA)CTTGTACAGCTC-3% where the Xbal site is 
underlined, followed by the stop codon in parenthesis.
The jBamHI-FLAG-IP (N-TMVII)-ÆcoRI PCR product and the ÆcoRI-p2“AR (C-tail)- 
GW-Xbal fragment were digested with the appropriate restriction enzymes and ligated 
into pcDNA3.1 (+) to generate FLAG-IP-P2 -GFP.
2.4.4 HA-IP
FLAG-IP-GFP was used as a template to generate a full-length IP receptor construct 
with an HA epitope tag at the amino terminus. The primers used were:
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Sense 5'-TTGGATÇÇAAAATG(TATCCCTACGACGTCCCCGATTATGCG)G- 
CGGATTCGTGCAGG-3', where the jBawHI site is underlined and the HA epitope, 
which follows the initiating methionine, is in parenthesis.
Antisense 5'-GCTCTAGAT(TCA)GCAGAGGGAGCAGGCGACGCTGGC-3', where 
the Xbal site is underlined, followed by the stop codon in parenthesis. The fragment was 
digested with the restriction enzymes and subcloned into pcDNA3.1 (+).
2.4.5 HA-IP-TRH
FLAG-IP-TRH-GFP in pcDNA3.1 (+) was used as a template to amplify the region 
encoding the amino terminus to the end of the TRH carboxyl tail. The sense primer, 
which was used to change the amino tag from FLAG to HA, was the same as used in the 
construction of the HA-IP sequence. The antisense primer introduced a stop codon at 
the end of the TRH tail coding sequence followed by 2iXbal site.
Antisense 5'-GCICTAGAGC(TCA)TATTTTCTCCTGTTTGGCAGTCAAAGA- 
ATAT-3% where the Xbal site is underlined, followed by the stop codon in parenthesis. 
The fragment was digested with BamlXl and Xbal restriction enzymes and subcloned 
into pcDNA3.1 (+).
2.4.6 HA-IP-P2
FLAG-IP-P2-GFP in pcDNA3.1 (+) was used as a template to generate the fragment 
encoding the sequence from the amino terminus to the last residue of the P2 -AR 
carboxyl tail. The sense primer that was used to change the epitope tag from FLAG to 
HA was the same as used in the HA-IP and HA-IP-TRH PCR reactions. The antisense 
primer created a stop codon at the end of the P2-AR tail coding sequence with a Xbal 
site following it.
Antisense 5'-CGTCTAGAT(TTA)CAGCAGTGAGTCATTTGTACTACAATTC-3', 
where the Xbal site is underlined and the stop codon in parenthesis. The PCR fragment 
was digested with BamUl mid Xbal restriction enzymes and subcloned into pcDNA3.1
(+)•
The Department of Genetics, University of Glasgow, sequenced all constructs generated 
before they were used for experimental analysis.
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2.5 Routine Cell Culture
2.5.1 Cell growth
The primary cell line used in this study was Human Embryonic Kidney (HEK293) cells. 
It was grown in monolayers in 75cm^ flasks in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 2mM L-glutamine and 10% Newborn Calf Serum 
(NBCS). The flasks were incubated in a humidified atmosphere of 95% air/5 % CO2 at 
37°C.
2.5.2 Passage of cells
Confluent flasks of cells were passaged using a sterile 0.25% trypsin-EDTA solution. 
Growth medium was removed from the cells and 2ml of the trypsin solution was added. 
After all the cells had detached from the surface of the flask, 8 ml of fresh medium was 
added and gently mixed to resuspend the cells. The cell suspension was split into flasks 
and dishes as required.
2.5.3 Coating plates with poly-D-lysine
50mg of poly-D-lysine was diluted with 50ml of sterile water to make a Img/ml stock 
solution. Tissue culture plates and coverslips were coated with a 1:10 dilution of the 
stock solution for 10 min. The solution was then removed and plates were left to dry for 
2 0  min before cells were added.
2.5.4 Transient transfections
Transfection of plasmid DNA into HEK293 cells was performed using Lipofectamine™ 
according to manufacturer’s instructions.
For transfection of 10cm dishes, cells were grown to 60-80% confiuency and lOpg of 
DNA was used for each dish. A typical transfection was as follows:
Tube 1 Tube 2
DNA lOpg
Optimem-1 200p.l 190pl
Lipofectamine™ - lOpl
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The DNA mix was incubated with the Lipofectamine^^ mix for 30 min at room 
temperature and then 5 ml of Optimem-1 was added to the complex. The cells were 
washed twice with Optimem-1 and the complex was added gently to the cells. 
Following an incubation period of 4-5 hours, 10ml of DMEM containing 10% NBCS 
was added and left overnight. The following day, the medium on the dish was replaced 
with fresh DMEM/NBCS and incubated for a further 24 or 48 hours before the cells 
were harvested or assayed.
For transfection of cells on coverslips in 6  well plates, the same protocol was followed 
except the amount of DNA used for each transfection was Ipg/well. For transfection of 
one coverslip the following mixes were prepared;
Tube 1 Tube 2
DNA Ipg
Optimem-1 35pl 60 pi
Lipofectamme™ - 3.5 pi
The two tubes were mixed and incubated as described previously. 1ml of Optimem-1 
was added to the incubation and then added to the appropriate well. After 4-5 hours, 
2ml of DMEM/NBCS was added to the well and left overnight. The next day the 
medium was removed and replaced by 2ml fresh NBCS/DMEM. The cells were 
incubated for a further 24 hours before they were fixed and viewed using confocal 
microscopy.
2.5.5 Generation and maintenance of stable cell lines
The generation of stable cell lines involved selecting isolated colonies of cells (clones) 
which had incorporated the transfected DNA into their chromosomes. The plasmids 
used for transfection contained an antibiotic resistance gene which conferred resistance 
to plasmid-expressing cells in the presence of the antibiotic whereas non-expressing 
cells were killed.
The transfection protocol used was the same for that of transfection in 10cm dishes. 24 
hours after transfection the cells were split 1:3 into 10cm dishes. At the same time, a 
10cm plate of untransfected parental HEK293 was split to use as a negative control to 
determine the rate of cell death. The following day the medium was changed for
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medium containing the antibiotic selection marker G418 at a concentration of 2mg/ml. 
The medium was changed every three days to maintain selection of resistant clones. 
After 7-10 days, when all the cells in the control dish were dead, isolated clones in the 
transfected plates were picked. Approximately 40 clones were picked from each 
transfection. The clones were transferred to 24 well plates and grown in medium 
containing 1 mg/ml G418. The medium was renewed every 3 days and once the clones 
were confluent they were split to 6  well dishes then 25cm  ^flasks and then finally into 
75cm^ flasks. Each of the selected clones was then assayed for expression of the 
transfected constructs. As all the stable lines generated in this study expressed GFP- 
tagged constructs, positive clones were selected by visualisation of their fluorescence 
under a fluorescent microscope.
2.5.6 Preservation of stable cell lines
Stable cell lines were preserved in the earliest passage possible. Cells were grown in 
75cm^ flasks before trypsinisation as described in 2.5.2. After the addition of 8 ml of 
medium to the cells, the suspension was added to a 15ml centrifuge tube and spun at 
lOOOg for 5 min. The cell pellet was resuspended m 1ml of NBCS containing 10% 
DMSO (as a cryo-protectant). This was then transferred to a cryovial and wrapped in 
cotton wool before being frozen overnight at -80°C and then placed in liquid nitrogen 
the following day.
Cells were regenerated by warming the cryovials at 37°C and resuspending the thawed 
cells in 10ml of growth medium. After centrifugation for 5 min at lOOOg to remove the 
DMSO, the pellet was resuspended in 10ml of medium and transferred to a 75cm^ flask.
2.5.7 Cell harvesting
Cells were harvested by first removal of the growth medium and rinsing twice with cold 
PBS. Using a cell scraper, the cells were dislodged from the bottom of the flask/dish in 
5ml of PBS. The cell suspension was collected into tubes and spun at lOOOg at 4°C for 5 
min. The cell pellets were then frozen at -80°C until required.
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2.6 Protein Biochemistry
2.6.1 BCA assay to determine protein concentration
Protein concentration in cell lysates and membrane preparations was determined using 
bincinhoninic acid (BCA) and copper sulphate solutions. Proteins reduce Cu(II) ions to 
Cu(I) in a concentration-dependent manner. BCA forms a complex with Cu(I) ions to 
form a purple coloured solution with an absorbance maximum at 562nm. The A5 6 2  value 
of the solution is directly proportional to the protein concentration. The protein 
concentration was determined using known concentrations of BSA solutions as 
standards (0.1-2mg/ml).
Reagent A Reagent B
1% (w/v) BCA 4% CUSO4
2 % (w/c) Na2C0 3
0.16% (w/v) sodium tartrate
0.4% NaOH
0.95%NaHCO3
pH 11.25
One part reagent B was added to 49 parts reagent A, and 200p,l of the working solution 
was added to 10pi of each protein sample/standard in a 96 well plate. After incubation 
at 37°C for 30 min, the absorbance was read.
2.6.2 Preparation of cell membranes
Harvested cell pellets were thawed and resuspended in TE buffer. The cells were 
ruptured with 50 strokes of a glass on Teflon homogeniser. Unbroken cells and nuclei 
were removed by spinning at lOOOrpm for 5 min in a refrigerated centrifuge. The 
supernatant fraction was then passed through a 25 gauge syringe needle 20 times and 
then centrifuged at 75 OOOrpm for 30 min in a Beckman Optima TLX Ultracentrifuge 
(Palo Alto, CA) with a TLA 100.2 rotor. The pellets were resuspended in TE buffer to a 
final concentration of l-3mg/ml and stored at -80®C until use.
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2.6.3 Sample preparation for SDS-PAGE gel electrophoresis
a) Membrane protein samples
Membrane protein samples (10-30pg) were diluted 1:1 in Laemmli buffer and boiled for 
5 min prior to loading onto SDS-PAGE gels,
b) Immunoprécipitation of samples
Cells from 60mm dishes or 6  well plates were washed 3 times with ice cold PBS and 
then lysed using 500pl radio-immune precipitation (RIPA) buffer (50mM HEPES, pH 
7.5, 150mM NaCl, 1% (v/v) Triton X-100, 0.5% deoxycholic acid, 0.1% SDS, 5mM 
EDTA, lOmM NaF, 5% (v/v) ethylene glycol) containing Ix Complete’^ '^  mini-protease 
inhibitor cocktail solution. After incubation on a rotating wheel for 1 hour at 4°C, 
insoluble material was removed by centrifugation (14 OOOrpm, 10 min, 4°C). Extracts 
were then equalised by protein assay as described in 2 .6 . 1  and precleared of non­
specific binding proteins by incubation with 20pl of protein G-Sepharose in the 
presence of 0.2% (w/v) globulin-free BSA for 1 hour at 4°C. Receptors were then 
immunoprecipitated from each precleared supernatant by incubation with 2 0 pl of 
protein G-Sepharose and the appropriate antibody (2pg anti-GFP, 4pg anti-FLAG M2, 
or Ipg 12CA5) for at least 2 hours at 4°C. The immune complexes were isolated by 
centrifugation at 14 OOOrpm for 1 min, washed twice with 1ml RIPA buffer 
supplemented with 0.2M ammonium sulphate and once with 1ml RIPA alone. The 
proteins were eluted from the protein-G Sepharose by the addition of 30-50pl Laemmli 
buffer and incubation at 37°C for 1 hour. The eluates were then loaded onto SDS-PAGE 
gels.
2.6.4 SDS-PAGE gel electrophoresis and Western blotting
Samples were resolved on NuPage® Novex pre-cast bis-tris gels from Invitrogen BV. 
The NuPage® system is based upon a bis-tris-HCl buffered (pH 6.4) polyacrylamide gel, 
with a separating gel that operates at pH 7.0. Gels with a 4-12% acrylamide 
concentration were used to achieve the best separation of the proteins of interest. 
NuPage® MOPS SDS and MES SDS buffers were used for running the gels. The gels 
were run at 200V, ~100mA, using the XCell Surelock^'^ mini-cell gel tank (Invitrogen 
BV).
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Following SDS-PAGE, the proteins were electrophoretically transferred onto 
nitrocellulose using the XCell II™ blot module (Invitrogen BV). Gels were transferred 
at 30V, -140mA, for 1 hour in transfer buffer (0.2M glycine, 25mM tris, and 20% (v/v) 
methanol). The transfer of proteins onto the nitrocellulose was checked using Ponceau 
stain (0.1% (w/v) Ponceau S, 3% (w/v) trichloroacetic acid). Membranes were then 
blocked with 5% (w/v) fat-free milk in PBS/0. l%(v/v) Tween 20 (PBS-T) for 1 hour at 
room temperature. After a brief wash in PBS-T, membranes were incubated with the 
appropriate primary antibody in blocking buffer for 1 hour at room temperature. After 
extensive washing with PBS-T, blots were treated with the required HRP-conjugated 
secondary antibody ia blocking buffer for 1 hour at room temperature. After further 
washing in PBS-T, the reactive proteins were visualised by enhanced 
chemiluminescence. For Western blot analysis the following antibody incubations were 
used:
1° Antibody 
Anti-FLAG M2 
Anti-GFP 
12CA5
Dilution 
1:2000 
1:20 000 
1:1000
2° Antibody 
Anti-mouse IgG 
Anti-sheep IgG 
Anti-mouse IgG
Dilution 
1:10 000 
1:10 000 
1:10 000
2.7 Assays
2.7.1 [^ H] Iloprost radioligand binding in membrane preparations
The expression of the IP prostanoid receptor constructs in stable cell lines was assessed 
using [^H] iloprost membrane binding studies. These were performed in borosilicate 
glass tubes in triplicates, containing the following mix:
Membrane protein (1 mg/ml) 40 pi
Assay buffer (50mM Tris, pH 7.5, 5mM MgCb) 40pl
[^H] Iloprost (-20nM) lOpl
Iloprost (1 OOpM) or assay buffer lOpl
Total Volume: lOOpl
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Reactions were incubated for 30 min at 30°C. Binding was stopped by vacuum filtration 
through GF/C filters. The filters were washed 3 times with ice cold wash buffer (50mM 
tris, pH 7.5, 0.25mM EDTA) to remove unbound radioligand from the membrane. 
Filters were inserted in vials containing 5ml liquid scintillant. The vials were then 
counted in a Beckman LS6500 scintillation counter using the [^H] counting channel. 
Specific binding was determined by subtracting the counts produced in the absence of 
unlabelled iloprost (total counts) from those with unlabelled ligand present (non­
specific counts). Receptor expression levels (finol/mg protein) were calculated from the 
known specific activity of [^H] iloprost (17 Ci/mmol) and the amount of protein used 
per tube.
The maximal binding (B m a x ) and the equilibrium dissociation constant (K d )  for iloprost 
at the various GFP-tagged prostacyclin receptor constructs was assessed using 
increasing concentrations of [^H] iloprost (O.l-lOOnM) in the absence or presence of 
20pM iloprost (to measure non-specific binding). Membrane binding was also assayed 
using homologous competitive binding experiments in which increasing concentrations 
of iloprost (1 0 '^  ^ -  lO'^ ^M) were used to displace the binding of a single concentration 
(~20nM) of the trititiated ligand.
Data were analysed using GraphPad Prism Software (San Diego, CA). Saturation 
binding data were fitted to non-linear regression curves using both one and two site 
binding models. Data were also converted to Scatchard plots to determine the Bmax and 
Kd values of the binding sites. Data from homologous displacement binding curves were 
fitted to one site competition curves.
2.7.2 Whole cell radioligand binding with [^ H] iloprost
The binding of [^H] iloprost to plasma membrane receptors in tiansiently transfected 
cells was assessed using homologous displacement binding experiments. As for 
membrane binding, cells were incubated with a single concentration of [^H] iloprost 
(~20nM). Non-specific binding was determined by incubation with excess of the 
unlabelled drug (lO'^^M). 0.4M sucrose was used in the reactions to prevent agonist- 
mediated internalisation of the receptors. The reactions were performed in borosilicate 
glass tubes in triplicates, containing the following:
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Intact cells (5x10^ -  6x10^) in assay buffer/0.4M sucrose 80(il
fH ] Iloprost (~20nM) lOpl
Iloprost (10 '^M) or buffer/sucrose 1 Opl
Total Volume: lOOpl
Reactions were carried out as described for membrane binding experiments. A 
haemocytometer was used to determine the number of cells/pl of suspension. Receptor 
number was calculated by the converting of the number of fmoles of [^H] iloprost 
bound/cell to receptors/cell using Avagadro’s constant.
2.7.3 Intact cell adenylyl cyclase assay
Whole cell adenylyl cyclase activity was determined by measuring the production of 
[^ H] cAMP in cells which had been pre-treated with [^H] adenine to label the 
intracellular adenine nucleotides. [^H] cAMP was separated from the other [^H] adenine 
nucleotides using column chromatography.
a) Column preparation
Dowex: For 100 columns, 200g of Dowex-50W was washed once with 1 litre of IM 
HCl, once with 1 litre of IM NaOH and then several times with distilled water until the 
residual wash was pH 7. The washed Dowex was then made up to 200ml with water and 
2ml of the solution was added to a glass wool stoppered column. The columns were 
washed with 2ml of IM HCl and 10ml of water prior to use. Columns were stored in 
water after use.
Alumina: For alumina columns, 0.5g of dry alumina was added to each glass wool 
stoppered column and washed once with 12ml of IM imidazole (pH 7.3), followed by 
15ml of O.IM imidazole (pH 7.3). Prior to use, the columns were washed with 10ml of 
O.IM imidazole (pH 7.3). After use they were stored in water.
b) Adenylyl cyclase dose response assays
Cells were seeded onto poly-D-lysine coated 24 well plates and incubated in medium 
containing [^H] adenine (0.5pCi/well) for 16-24 hours. The [^H] adenine was then 
removed and the cells were washed once with 1ml of HEPES/DMEM assay medium 
(Ix DMEM supplemented with 20mM HEPES, pH 7.4, 2mM L-glutamine, and ImM
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IBMX). Cells were incubated with 0.25ml assay medium containing increasing 
concentrations of iloprost (10'^  ^ -  lO'^M) for 30 minutes at 37°C. At the end of the 
incubation, the medium was aspirated and the reactions were stopped by the addition of 
0.5ml ice cold stop solution (5% (w/v) TCA, ImM ATP, ImM cAMP) to each well. 
After 30 minutes, the supernatant was removed from the cells and applied to the pre­
washed Dowex columns over scintillation vials containing 4ml of scintillant. 3ml of 
water was applied to each Dowex column to elute the non-cyclic [^H] adenine 
nucleotides. The Dowex columns were then placed over the alumina columns and 10ml 
of water was applied to wash the [^H] cAMP onto the alumina columns. The [^H] 
cAMP was eluted with 6 ml of O.IM imidazole and collected in scintillation vials 
containing 8 ml of scintillant, which had been placed over the alumina columns.
c) Adenylyl cyclase desensitisation/resensitisation/kinase inhibition assays 
For desensitisation experiments, cells were pre-incubated with assay medium containing 
IpM iloprost for periods of 10-60 min at 37^C. Cells were then washed 3 times with 
medium and re-exposed to increasing concentrations of iloprost (10'^  ^-  lO'^M) for 30 
min at 37°C. [^H] cAMP accumulation in the cells was assayed as described before. The 
net amount of [^H] cAMP generated in desensitisation experiments was determined by 
subtracting the [^H] cAMP accumulation in cells not re-challenged with agonist from 
the total [^H] cAMP generated (after re-exposure).
In resensitisation assays, cells were pre-exposed to IpM iloprost for 60 min at 37°C and 
then washed 3 times in medium and left to recover at 37°C for 30-60 min before re­
exposure to increasing concentrations of agonist. The net accumulation of [^H] cAMP in 
the cells was calculated as described for desensitisation experiments.
To assay the effects of kinase inhibitors, cells were pre-treated with lOpM H89 or 5pM 
GFI09203X for 30 min at 37°C. Cells were then challenged with IpM agonist for 
periods ranging from 0-30 min in the presence of the inhibitors and assayed for [^H] 
cAMP generation as described previously.
2.7.4 I n  vivo  phosphorylation assays
Agonist-mediated phosphorylation of the IP receptors was assessed using in vivo 
phosphorylation assays. HEK293 cells stably expressing the IP receptor constructs were 
plated onto 6  well plates at a density of approximately 1 0  ^ cells/well and cultured
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overnight. The next day the cells were washed twice with phosphate-free DMEM and 
incubated in the same medium supplemented with 0.2mCi/ml [^ ^P] orthophosphate for 
90 min. Cells were then treated with IpM iloprost for periods ranging from 30 sec to 10 
min, or with 5pM forskolin or 5p,M PMA for 10 min. To assay kinase inhibition, cells 
were pre-treated with lOpM H89 or 5pM GF109203X for 30 min prior to agonist 
exposure. The reactions were terminated by placing the cells on ice and washing 3 times 
with ice cold PBS. Cells were then solubilised for receptor immunoprécipitation with an 
anti-GFP antibody as described in 2.6.3b. After fractionation of immunoprecipitated 
receptors by SDS-PAGE, gels were dried and analysed by autoradiography. Observed 
bands were quantified by densitometric scanning of the X-ray films.
2.7.5 Receptor internalisation assay
IP receptor-expressing HEK293 cells were plated onto 6  well plates at a density of 10^  
cells/well. The next day, the cells were washed, and 1 ml/well medium was applied. 
Cells were treated with IpM iloprost for timepoints ranging from 0-60 min, or with 
5pM forskolin or 5pM PMA for 1 hour. Inhibitors of internalisation were added 30 min 
prior to stimulation with agonist. The reactions were terminated by placing the plates on 
ice and washing the cells 3 times with ice cold PBS. The alcohol groups on the cell- 
surface glycoproteins were oxidised to aldehydes by a 30 min incubation with lOmM 
sodium m-periodate. After the removal of the periodate, cells were washed once with 
PBS and twice with O.IM sodium acetate, pH 5.5, and incubated in the same buffer 
supplemented with ImM biotin-LC-hydrazide. This reacts with the newly formed 
aldehyde groups, thereby labelling all cell surface glycoproteins with biotin. Labelling 
was terminated by removal of the biotin solution and washing the cells three times with 
PBS. Cells were then solubilised for receptor immunoprécipitation with the anti-GFP or 
12CA5 antibody as described in 2.6.3b. After SDS-PAGE and the transfer of the 
proteins onto nitrocellulose membranes, cell surface biotin-labelled receptors were 
identified by incubation of the membranes with Ipg/ml HRP-conjugated streptavidin in 
5% (w/v) non-fat milk/PBS-T for 1 hour at room temperature. After several washes 
with PBS-T, reactive proteins were visualised by enhanced chemiluminescence. 
Agonist-mediated loss of cell surface receptors was quantified by densitometric 
scanning of blots.
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2.7.6 Confocal laser scanning microscopy
For all microscopic analysis in this study, fixed cell work was used. Cells were 
observed using a laser scanning confocal microscope (Ziess Axiovert 100:Zeiss 
Oberkochen, Germany) with a Ziess Plan-Apo 63 x 1.40 NA oil immersion objective, 
pinhole of 20, and electric zoom of 2-3. Typically, 10-12 optical sections were taken at 
IpM intervals through the cells. Mid-cellular sections were acquired and averaged over 
64 scans/frame. The GFP was excited using a 488nm argon/krypton laser and detected 
with a 515-540nm band pass filter. Red fluorescent protein (RFP) and the Alexa® 594 
label were excited using a 543nm argon/krypton laser and detected with a 590nm long 
pass filter.
a) Visualisation of receptor internalisation
Receptor-GFP: Cells stably or transiently expressing the GFP-tagged IP receptor 
constructs were split onto poly-D-lysine coated coverslips and incubated overnight. The 
following day, the cells were treated with or without IpM iloprost for 0-2 hours at 37°C 
and then placed on ice to terminate the reactions. Cells were then washed 3 times with 
ice cold PBS and fixed for 15 min at room temperature using 4% paraformaldehyde in 
PBS. After 2 further washes with PBS, the coverslips were mounted onto microscope 
slides with 40% glycerol in PBS.
HA-tagged receptor: HEK293 cells which had been transiently transfected with the 
HA-tagged IP receptor constructs were immunostained using an Alexa® 594-labelled 
goat anti-mouse secondary antibody to detect receptors which had been labelled with 
the 12CA5 antibody. In brief, transfected cells were plated onto poly-D-lysine coated 
coverslips and incubated overnight. The following day the medium was changed for 
DMEM supplemented with 4pg/ml 12CA5 antibody for 1 hour at 37°C. Where 
required, 1 pM iloprost was added and incubated for up to 2 hours at 37°C. Coverslips 
were then washed twice with PBS and fixed with 4% paraformaldehyde as described 
previously. Cells were then permeabilised with 0.15% Triton-X-100/3% (w/v) non-fat 
milk/PBS (TM buffer) for 10 min at room temperature. The coverslips were 
subsequently incubated with Alexa® 594-labelled goat anti-mouse secondary antibody at 
a dilution of 5pg/ml for 1 hour at room temperature and then washed twice with TM 
buffer and once with PBS. The coverslips were mounted onto microscope slides with 
40% glycerol m PBS.
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b) Receptor/arrestin colocalisation experiments
GFP-tagged receptors trafficking with p-arrestin 1 and p-arrestin 2-RFF: Cells 
stably expressing the GFP-tagged IP receptors were transfected with either p-arrestin 1 
or P-arrestin 2-RFP and split onto poly-D-lysine coated coverslips. 24 hours later, cells 
were treated with agonist for various timepoints and then fixed. For p-arrestin 2-RFP 
experiments, no immunostaining of the cells was necessary. P-Arrestin 1 was visualised 
by permeabilising the cells and incubating with an anti-p-arrestin 1 antibody (1 : 2 0 0  
dilution) for 1 hour at room temperature. The cells were subsequently incubated with an 
Alexa® 594-labelled goat anti-mouse secondary antibody as described before and then 
mounted onto microscope slides,
HA-tagged receptors trafficking with p-arrestin 1-GFP and p-arrestin 2-GFP:
HEK293 cells were co-transfected with the HA-tagged receptor constructs and P- 
arrestin-GFP cDNAs and then split onto coverslips. The next day, cells were stimulated 
with or without agonist and fixed. The cells were immunostained for the HA-tagged 
receptors as described in 2.7.6a before coverslips were mounted onto microscope slides.
c) Labelling with Texas Red® transferrin
Cells grown on coverslips were labelled with medium containing Texas Red® 
transferrin (25pg/ml) for 30 min at 37°C in 5% CO2 . Cells were then washed twice with 
medium before being treated with or without agonist for 30 min at 37®C. The cells were 
subsequently fixed and mounted onto microscope slides.
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Chapter 3
Analysis of the Pharmacology and Trafficking of GFP- and HA-tagged 
forms of the Prostacyclin Receptor in Conjunction with Receptor 
Chimeras possessing the Carboxyl Termini of the Pa-adrenergic and
TRH receptors
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Chapter 3
3.1 Introduction
Prostacyclin is an important mediator of physiological processes in a variety of tissues, 
including platelets, neuronal cells, and vascular smooth muscle. Prostacyclin acts as a 
potent mediator of vasodilation and inhibitor of platelet activation. Thus, prostacyclin 
induces smooth muscle relaxation in arterial beds as well as inhibition of platelet 
aggregation, and is, therefore, thought to be an important regulator of vascular 
homeostasis (Vane et al., 1995). Other possible roles of prostacyclin are not well 
established but include regulation of renal blood flow, hyper-immune responses, and 
lipolysis (Negishi et al., 1995; Holgate et al,, 1980; Chatzipanteli et al., 1992). In 
common with other prostaglandins, prostacyclin also evokes inflammatory responses 
such as hyperaemia, oedema, hyperanalgesia, and pyrexia primarily through its role as a 
vasodilator (Murata et al., 1997; Bley et al., 1998). Prostacyclin exerts its effects by 
activating the IP prostanoid receptor. The IP receptor couples to Gg and Gq as suggested 
by stimulation of both cAMP and IP3/DAG production (Boie et al., 1994; Namba et al., 
1994). However, stimulation of Gq in all investigated cell types occurs only at high 
concentrations of agonist.
In general, GPCRs tend to be tightly regulated by desensitisation, a phenomenon by 
which a receptor’s response to ligand is attenuated. The P2-AR has served as a prototype 
for the molecular events responsible for desensitisation (Ferguson and Caron, 1998). 
The general model for GPCR regulation involves three key mechanisms. The first and 
most rapid phase of desensitisation occurs within seconds after exposure to agonist and 
is due to receptor phosphorylation mediated by second messenger kinases and/or GRKs. 
Phosphorylation by GRKs promotes the binding of arrestins, which triggers 
desensitisation by uncoupling the receptor from its G protein. This is followed by 
sequestration of receptors away from the cell surface via clathrin coated pits by an 
arrestin-dependent process. Finally, more prolonged receptor stimulation leads to the 
redirection of internalised receptors to a lysosomal compartment with subsequent 
downregulation.
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It is likely that similar mechanisms govern IP receptor regulation. In vitro studies of the 
IP receptor, expressed in HEK293 cells, revealed that agonist stimulation leads to rapid 
receptor desensitisation, a process which seems to coincide with receptor 
phosphorylation (Smyth et a l, 1996, 1998). Internalisation of the IP receptor in 
response to agonist treatment has been observed in transfected HEK293 cells and in cell 
lines which endogenously express the receptor (Smyth et a l, 2000; Giovanazzi et a l, 
1997; Leigh and MacDermot, 1985; Krane et ah, 1994). Furthermore, downregulation 
of native IP receptors has been demonstrated in NG108-15 cells and platelets in 
response to sustained prostacyclin challenge (Giovanazzi et ah, 1997; Krane et ah, 
1994)
Clathrin-mediated endocytosis of GPCRs requires the interaction of specific receptor 
domains with components of the endocytic machinery. Data fi-om GPCR sequestration 
studies have identified several receptor domains that are involved in regulating 
internalisation. However, a common endocytic motif has not been identified. It seems 
that the determinants for endocytosis are located within multiple receptor regions which 
regulate the rate and extent of receptor sequestration in response to agonist exposure. 
For many GPCRs, the endocytic domains are found within the intracellular C-terminal 
tail. The C-tails of many GPCRs are rich in serine and threonine residues which serve as 
substrates for kinase phosphorylation, and subsequently act as sites for arrestin docking 
leading to receptor desensitisation and internalisation.
In studies of the thromboxane receptor splice variants, TPa and TPP (which differ only 
at their C-terminal tails), the longer TPp isoform was shown to be sensitive to kinase 
phosphorylation and internalised rapidly in response to agonist whereas the shorter TPa 
splice variant did not (Parent et a l, 1999). Similarly, the EP2  receptor, which possesses 
a comparatively short C-terminal tail, was found to be resistant to agonist-induced 
internalisation (Nishigaki et a l, 1996). Studies of the mammalian GnRH-R, which is 
unique among the GPCR family in that it does not possess a C-terminal tail, revealed 
that the receptor displayed exceptionally slow kinetics of receptor desensitisation and 
internalisation as compared to non-mammalian forms of the receptor which possess a 
carboxyl terminal domain (Heding et a l, 1998).
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Numerous GPCR studies have investigated the role of the C-terrainal tail in regulating 
internalisation using receptor mutants exhibiting point mutations and/or truncations 
within this region. In such investigations it has been frequently shown that the tail of the 
receptor plays an important role in internalisation and/or desensitisation.
For the histamine H2 receptor, a series of C-tail truncations identified a region between 
Glu^ "^^  and Asn^^° (ETSLRSN) as important in regulating internalisation. Furthermore, 
mutation of Th^^ to alanine, but not that at Ser^ *^’, abolished internalisation, thus 
identifying a key threonine residue of functional significance for receptor endocytosis 
(Fukushima etal., 1997).
In the parathyroid hormone receptor C-tail, 91 of the 127 residues could be deleted 
without affecting internalisation. However, further truncation of residues 475 to 494 
resulted in a 50-60% decrease in ligand internalisation. A mutant with an internal 
deletion of these 2 0  amino acids showed a similar reduction in internalisation, 
confirming the presence of a positive endocytic signal. Further truncations of the 
membrane-proximal region of the tail exhibited no fiirther loss in receptor 
internalisation, indicating the presence of only one endocytic signal within the tail 
(Huang et al., 1995).
In investigations of somatostatin receptor type 5 internalisation, 60% of cell surface 
receptors were shown to internalise after 1 hour’s agonist treatment. Truncation of the 
C-tail to 318, 328, and 338 residues reduced this to 46, 46, and 23%, respectively. 
Deletion to 347 residues slightly improved internalisation (72%), demonstrating the 
presence of both positive and negative regulators of internalisation within the domain 
(Hukovic et al., 1998).
In cells expressing C-tail mutants of the 8 -opioid receptor, those lacking the distal 15 
amino acid residues of the carboxyl terminus displayed a substantially slower rate of 
internalisation. In addition, cells expressing receptors with point mutations of any of the 
Ser/Thr residues between Ser^ "^ "^  and Ser^ ^^  in the C-terminal tail exhibited a significant 
reduction in their internalisation rate (Trapaidze et aL, 1996).
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Tyrosine-containing endocytic motifs have been identified in many single 
transmembrane receptors (Sorkin and Carpenter, 1993). Equivalent motifs in the C-tails 
of GPCRs have also been implicated in their sequestration. For the neurokinin-1 
receptor, mutation of conserved tyrosine residues (positions 331, 341 and 349) impaired 
agonist-induced endocytosis without substantially affecting agonist binding or 
signalling (Bohm et al., 1997). Tyrosine-containing motifs in the C-terminal domain of 
the ATiaR are also important for internalisation, with a 2.5 fold decrease in 
internalisation noted in cells expressing a Y318A receptor mutant (Thomas et al., 1995). 
In contrast, mutation of tyrosine residues in the cytoplasmic tail of the pi-AR (Tyr^ ^®’ 
^^ "^ ) has been shown to have no affect on receptor sequestration (Valiquette et al., 1990). 
For the pz-AR, additional structural elements within the C-tail such as dileucine repeats 
that bind AP-1 and AP-2 adapter proteins associated with clathrin coated pits seem to be 
critical for internalisation (Gabilondo et al,, 1997).
Interpretation of sequestration data from GPCR substitution/deletion studies must be 
made with caution. Since receptors exist as three-dimensional entities, the possibility of 
non-specific conformational effects have to be taken into account. Mutations of specific 
residues that are not themselves directly required for internalisation may interfere with 
conformational changes in domains that are essential for endocytosis. For instance, in 
sequestration studies of the EP4  receptor, truncations after amino acid residue 369 were 
demonstrated to markedly attenuate internalisation, whereas a receptor exhibiting 
mutations of all serine and threonine residues between residues 350 and 383 was found 
to internalise to the same extent as the wild type receptor (Desai et al., 2000). 
Additionally, modifications of the carboxyl termini of GPCRs have been shown not 
only alter the rate and extent of receptor internalisation, but also the mechanism. In 
investigations of adenosine A^g receptor sequestration it was shown that a receptor 
mutant truncated at Ser^ ^^  was unable to undergo arrestin/clathrin-dependent 
internalisation, whereas the S326A point mutant displayed an arrestin/clathrin- 
dependent internalisation phenotype identical to the wild type receptor (Matharu et ah, 
2001).
An alternative approach to deletion and substitution experiments is the creation of 
receptor chimeras. This strategy offers advantages for analysis of structure and function
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in that the expected outcome is the alteration or addition, rather than the loss of receptor 
function. Chimeric receptors have been generated to study the internalisation patterns of 
several GPCRs.
The chimeric strategy has been used to investigate the trafficking of the thrombin 
(PARI) receptor (Trejo and Coughlin, 1999). Wild type PARl-R is activated by an 
irreversible proteolytic mechanism in which thrombin binds to and cleaves the amino- 
terminal exodomain of the receptor. Receptor cleavage results in the generation of a 
new amino terminus that functions as a tethered ligand. Unlike most GPCRs, the 
activated PARl-R is sorted predominantly to the lysosomes after internalisation. To 
identify the domain(s) that specifies sorting to the lysosomes of activated PARI 
receptors, chimeras between the PARl-R and the substance P receptor were generated. 
Exchanging of the carboxyl tails of the PARl-R and the substance P receptor switched 
their trafficking behaviours after activation. The substance P chimera with the PARl-R 
tail internalised upon activation and sorted to the lysosomes like the wild type PARl-R. 
Conversely, the PARl-R bearing the cytoplasmic tail of the substance P receptor 
internalised upon activation but recycled back to the membrane thus allowing for 
‘resignalling’ of the proteolytically activated chimeric receptor even after the removal 
of thrombin.
Chimeric receptors have also been used to study the role of the carboxyl terminus in 
bombesin receptor regulation. In such studies the C-tail was switched for those of the 
m3 muscarinic (BMC) and cholecystokinin A (BCC) receptors. In CHO cells, ligand 
internalisation of the chimeric receptors generally assumed the properties of the donor 
receptors. Thus, BCC receptors internalised ligand to a similar extent as wild-type CCK 
whereas BMC receptors showed reduced ligand internalisation, like wild type m3 
muscarinic receptors (Tseng et al., 1995).
The desensitisation and internalisation kinetics of the tail-less mammalian GnRH 
receptor have also been examined using receptor chimeras. To investigate the role of a 
cytoplasmic tail in these events, a chimeric receptor was constructed where the 
intracellular tail of the TRH-R was fiised to the C-terminus of the GnRH-R. The study 
demonstrated that the addition of a functional intracellular tail to the GnRH-R
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accelerated receptor desensitisation and increased internalisation rates (Heding et al,, 
1998).
In this chapter, chimeric GPCRs were generated to examine the function of the IP 
prostanoid receptor C-terminal tail in its internalisation in response to agonist treatment. 
Chimeric receptors possessing the carboxyl terminal domains of the human p2- 
adrenergic and rat TRH-1 receptors were created. Initially, C-terminally GFP-tagged 
forms of the receptor proteins were used to directly monitor receptor trafficking using 
confocal microscopy. Experiments were then repeated using the equivalent non-GFP 
tagged forms of the receptors. Functional characterisation of the receptor constructs was 
performed at first. Receptor expression in transfected HEK293 cells was confirmed 
using radioligand binding assays, and for the GFP-tagged receptors, confocal 
microscopy was also used to visualise expression. Intact cell adenylyl cyclase assays 
were utilised to test the receptors’ coupling capacity to Gg. More extensive 
pharmacological analysis was carried out with stable cell lines expressing the GFP- 
tagged IP receptor constructs. Finally, the agonist-mediated internalisation properties of 
receptors were analysed visually by confocal microscopy and quantified by immuno­
detection of biotin-labelled cell surface receptors.
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3.2 Construction and expression of chimeric IP prostanoid receptor-green 
fluorescent protein fusion proteins.
PGR was used to link cDNAs encoding GFP-tagged versions of both the rat TRH-1-R 
and human p2-AR inti acellular carboxyl terminal tails to the distal end of TMVII of the 
IP receptor. A PGR strategy was also used to insert a FLAG (Asp-Tyr-Lys-Asp-Asp- 
Asp-Asp-Lys) epitope at the N-terminus of the protein after the initiating methionine 
residue. A full length IP receptor linked G-terminally to GFP and tagged at the amino 
terminus with a FLAG epitope, which was also used in this study, was constructed 
previously in the laboratory. Figure 3.1a is a diagrammatic representation of the GFP- 
tagged receptors which were used in this investigation. Figure 3.1b shows the amino 
acid composition of the different G-tails of the prostacyclin receptor proteins.
These cDNA constructs were transiently transfected into HEK293 cells and their 
expression was initially investigated by Western blot analysis. Immuno-detection of the 
receptors’ N-terminal FLAG epitope and G-terminal GFP moiety confirmed the 
expression of full-length proteins post transfection (Figure 3.2). Immunoblotting of 
transiently transfected membranes with both the anti-FLAG and anti-GFP antibodies 
detected broad immuno-reactive bands of molecular mass ~60-100 kDa which were not 
present in mock transfected membranes. Since the predicted molecular weight of each 
construct is approximately 6 8  kDa, it is therefore likely that the higher molecular weight 
bands corresponded to differentially glycosylated forms of the receptors.
The expression of the receptor constructs at the plasma membrane was further assessed 
by the bindmg of ~20nM [^H] iloprost to transfected whole cells (Figure 3.3). From 
these experiments it was evident that the transient expression of each construct at the 
plasma membrane was exceptionally low (IP-GFP 42 ± 9.8 fmol/10^ cells, IP-TRH- 
GFP 72 ± 8 . 8  finoFlO^ cells, and IP-P2 -GFP 39 ± 13.7 finol/10^ cells). Expression levels 
were not augmented by transfection of more receptor cDNA.
The Gs coupling capacity of each of the IP receptor constructs was determined by 
measurement of agonist-induced cAMP accumulation in transiently transfected cells 
(Figure 3.4). After 15 min incubation with agonist, the [^H] cAMP generated in
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response to IpM iloprost exposure was at best 2-3 fold higher than basal levels, which 
was further indicative of low receptor expression in the transfection assays. Direct 
activation of adenylyl cyclase with 50pM forskolin resulted in substantial second 
messenger production in the cells. In addition, a synergistic effect was observed in cells 
treated with both iloprost and forskolin.
Confocal analysis was used to visualise the GFP-tagged receptors in transiently 
transfected HEK293 cells. Figure 3.5 illustrates the confocal images generated for both 
unstimulated and agonist treated cells. In each case, it was evident that the expression of 
the receptors was predominantly localised to intracellular membranous compartments, 
thus making it impossible to detect agonist-mediated internalisation of plasma 
membrane receptors. Improper targeting of GPCRs is a commonly observed problem in 
transient expression systems. Therefore, stable cell lines of each of the chimeric 
receptors were generated in an attempt to overcome this.
Once stable cell lines expressing IP-TRH-GFP and IP-pz-GFP receptors were 
established in HEK293 cells, single clones of each were selected for study in 
conjunction with a stable cell line expressing IP-GFP receptors which had been 
generated previously in the laboratory. Screening for positive clones was carried out 
using fluorescence microscopy. Only a small number of clones generated were 
autofluorescent. Approximately 25% of the putative IP-TRH-GFP clones selected were 
positive whereas only -10% of the IP-pz.GFP clones selected fluoresced. Positive 
clones were initially analysed using radioligand binding and adenylyl cyclase assays. 
Figure 3.6 gives an approximate indication of expression levels of each clone from the 
binding of a single concentration of [^H] iloprost. The coupling efficiency of each clone 
was then assessed by measurement of cAMP generation in cells after 15 min challenge 
with IpM iloprost (Figure 3.7). From these experiments it could be seen that second 
messenger output in each clone correlated well with the receptor expression level. All 
positive clones were further examined using confocal microscopy to visualise receptor 
distribution within the cells (Figure 3.8). Although all clones showed significantly more 
plasma membrane expression as compared to transient systems, for many of the clones 
substantial amounts of the GFP-derived autofluorescence was present in intracellular 
compartments. As one of the main objectives of this study was to use GFP to directly
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visualise the trafficking of the IP receptor constructs, the clones with mainly plasma 
membrane delineated fluorescence were selected for further investigation. Of the IP- 
TRH-GFP clones, clone 19 was selected and of the IP-P2 -GFP clones, clone 17 was 
chosen.
3.3 Pharmacological characterisation of stable cell lines expressing the GFP-tagged 
IP receptor proteins.
To deteimine more accurately the receptor expression level of each of the selected 
clones, saturation binding experiments were performed by incubation of isolated 
membrane fractions with concentrations of [^H] iloprost ranging from O-lOOnM. The 
non-specific binding of [^H] iloprost was determined by incubation with 20|iM 
unlabelled iloprost (Figure 3.9 a, c, e). Saturation binding curves were converted to 
Scatchard plots (Figure 3.9 b, d, f) which revealed the presence of two binding sites 
(one high affinity and one low affinity) for each of the receptor constructs. For the IP- 
GFP receptor, a high affinity binding site with dissociation constant (K d )  of 2.6 ± 
0.25nM and maximum receptor level (Bmax) of 696 ± 53.4 fmol/mg membrane protein 
was observed. The Kd value for the low affinity binding site was 66.9 ± 5.3nM with a 
Bmax of 4806 ±106 fmol/mg. For the IP-TRH-GFP receptor, the high and low affinity 
binding sites exhibited dissociation constants of 2.9 ± 0.5nM (Bmax of 682 ± 83.7 
frnol/mg) and 33.5 ± 4.6nM (Bmax of 1591 ± 157 finol/mg) respectively. For the IP-P2 - 
GFP receptor, [^H] iloprost bound at two bindmg sites with Kd values of 1.12 ± 0.28nM 
(Bmax 168 ± 48.5 finol/mg) and 81.6 ± 25.6nM (Bmax 1780 ± 145 fmoFmg).
Practical concentrations of [^H] iloprost used in saturation binding assays were 
restricted to lOOnM at most. Consequently, the Kd values for the low affinity binding 
sites could not be calculated accurately from such experiments. Further ligand binding 
analysis of the receptor constructs was therefore carried out using homologous 
displacement binding assays (Figure 3.10). However, an intiinsic feature of competitive 
binding curves is that they are invariably unable to detect two classes of binding site 
when the same compound serves as radioligand and competitor. It is impossible to 
detect two classes of site in such experiments when the density of the low affinity site is 
less than or equal to that of the high affinity sites. Even when the low affinity site is in
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abundance, it is only possible to detect two sites when the concentration of radioligand 
is appropriate: small enough so that a reasonable fraction of the binding is to the high 
affinity site, and large enough so that some binds to the low affinity site. Increasing 
concentrations of iloprost displaced the binding of 20 nM [^H] iloprost from IP-GFP, 
IP-TRH-GFP, and IP-pz-GFP membranes with I C 5 0  values of 87.7 ± 7.5nM, 52 ± 4nM, 
and 61 ± 7nM respectively. Applying the formalisms of De Blasi and coworkers (1989), 
this produced Kd values of 67.6 ± 7.5nM for IP-GFP, 32 ± 4nM for IP-TRH-GFP, and 
42 ± 7nM for IP-P2-GFP receptors. The Hill slope coefficient for each binding curve 
suggested the presence of a heterogeneous population of receptors i.e. the receptors did 
not all bind the drug with the same affinity.
The dose-dependent effect of iloprost on adenylyl cyclase activity was studied for IP- 
GFP, IP-TRH-GFP, and IP-pz-GFP cells (Figure 3.11). After labelling overnight with 
[^H] adenine, cells were challenged with iloprost concentrations ranging from IpM to 
IpM for 30 min. Iloprost was most potent at stimulating adenylyl cyclase in IP-GFP 
cells ( E C 5 0  of 0.096 ± 0.022nM), whereas agonist potency at the chimeric receptors was 
significantly lower ( E C 5 0  values of 0.41 ± 0.07nM for IP-TRH-GFP and 0.36 ± 0.05nM 
for IP-p2 “GFP). IP-GFP and IP-P2-GFP cells displayed similar maximum levels of [^H] 
cAMP production (24.8 ± 3% and 23.5 ± 1.1% of total intracellular adenine pool 
respectively). By comparison, the maximal level of second messenger production in IP- 
TRH-GFP cells was markedly lower (13.6 ± 1.2%).
3.4 Internalisation studies of stable cell lines expressing the GFP-tagged IP 
receptor proteins.
The sequestration of the GFP-tagged receptors in the stable cell clones was initially 
monitored by direct visualisation of GFP redistribution in response to agonist treatment. 
Cells grown on glass coverslips were incubated with IpM iloprost for timepoints 
ranging from 0-60 min and then fixed before examination by confocal microscopy. 
Receptors in IP-GFP cells displayed predominantly plasma membrane expression in the 
unstimulated state. Upon exposure to agonist, receptors could be seen to translocate to 
intracellular compartments. After 30 min incubation, a significant proportion of the 
receptor population appeared to be intracellular, which became more pronounced at the
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1 hour timepoint (Figure 3.12). IP-TRH-GFP cells exhibited a more rapid time- 
dependent internalisation of receptors into discrete intracellular vesicles, with 
considerable sequestration detectable within 5 min of agonist treatment (Figure 3.13). 
After a further 15 min, the bulk of receptors appeared to have been lost from the 
plasmalemmal surface. In the IP-p2 -GFP cells, receptors were found to be equally 
distributed between the cell surface and intracellular membranes in the unstimulated 
state (Figure 3.14). After incubation with iloprost, more noticeable fluorescence could 
be detected inside the cells within 30 min.
Confocal analysis of the stable cell clones (particularly in the case of EP-P2-GFP cells) 
confirmed that in the unstimulated state significant receptor expression was localised 
intracellularly, thus making visualisation of receptor trafficking troublesome. 
Immunocytochemical experiments were undertaken to try and overcome this problem 
(Figure 3.15). Since each of the constructs possessed an amino-terminal FLAG epitope, 
live cells were incubated with an anti-FLAG antibody to label the cell surface receptors 
before treatment with agonist. Cells were then fixed and permeabilised prior to 
incubation with an Alexa^ '^^-conjugated secondary antibody to detect the FLAG 
antibody-labelled receptors at the cell surface and those which had internalised in 
response to agonist. It was anticipated that this technique could be used to highlight 
only the intracellular receptor pool which had sequestered in response to agonist. Initial 
experiments with IP-GFP cells were promising as the anti-FLAG antibody successfully 
decorated the cells (Figure 3.15a). Surprisingly, this was not the case with the chimeric 
IP receptor constructs as no specific labelling of the receptors could be seen (Figure 
3.15 b, and c). The anti-FLAG antibody had previously been shown to detect the 
epitope in membrane preparations from cells expressing the IP-TRH-GFP and IP-P2 - 
GFP constructs (Figure 3.2a) thus confirming its incorporation into the protein. The 
possibility that receptors were not being expressed at the cell surface, making them 
inaccessible to the antibody, was ruled out by assaying the binding of radioligand to cell 
surface receptors in intact cells (data not shown). It is possible that the anti-FLAG 
antibody used was ineffective at detecting the epitope in immunocytochemical 
experiments. It is also possible that switching of the IP receptor C-tail altered the 
conformation of the protein, resulting in changes in the interaction of the N-terminal
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segment with components of the extracellular matrix thus preventing epitope 
recognition by the antibody.
The confocal images of receptor internalisation suggested that each of the receptor 
constructs exhibited different rates of endocytosis over a 60 min agonist time course 
(Figures 3.12, 3.13, 3.14). To accurately determine the time courses of agonist-mediated 
internalisation, receptor biotin labelling experiments were used. After treatment of cells 
with or without 1 pM iloprost for timepoints up to 1 hour, cells were placed on ice (to 
prevent further internalisation) and the cell surface glycoproteins were labelled with a 
membrane-impermeable derivative of biotin. Receptors were extracted from the cells by 
immunoprécipitation using an anti-GFP antibody. After fractionation of 
immunoprecipitated receptors by SDS-PAGE, followed by transfer to nitrocellulose 
membranes, biotinylated proteins were detected by HRP-conjugated streptavidin. 
Agonist-induced loss of the cell surface receptor population was quantified by 
densitometi'ic scanning of the blots. For IP-GFP cells, agonist treatment induced an 
initial rapid loss of cell surface receptors in the first 5 min of agonist treatment which 
was followed by a more steady reduction in the level of cell surface receptors for the 
remainder of the time course. With cell surface receptor level in unstimulated cells set at 
100%, after 1 hour iloprost stimulation, 59 ± 7% of the biotin labelled receptors were 
detected at the plasma membrane (Figure 3.16). The IP-TRH-GFP construct internalised 
more rapidly and to a greater extent than the IP-GFP receptor (Figure 3.17). After 5 min 
agonist exposure, almost half of the total cell surface receptors had endocytosed (58 ± 
6 % at cell surface). After 15 min, the rate of internalisation decreased until it plateaued 
after 1 hour of agonist treatment (36 ± 4% at cell surface). The IP-pz-GFP construct 
internalised to a similar extent as the IP-GFP receptor. Over the 60 min time course, the 
internalisation rate appeared to be constant. After 1 hour iloprost stimulation, 59 ± 7% 
of the labelled receptors were present at the cell surface (Figure 3.18). In agreement 
with the confocal data, the biotin labelling assays confirmed that the IP-TRH-GFP 
receptor internalised the most rapidly whereas the IP-GFP and IP-P2 -GFP receptors 
behaved similarly, exhibiting slower kinetics of internalisation (Figure 3.19). In order to 
assess the effects, if any, of GFP on the internalisation rate of the receptors, the 
equivalent cDNA constructs were generated without GFP. These constructs were 
subsequently used in assays for receptor internalisation.
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3.5 Construction and pharmacological characterisation of HA-tagged IP 
prostanoid receptor fusion proteins.
A PCR based strategy was used to construct the equivalent non-GFP tagged IP receptor 
cDNAs in which the FLAG epitope tag was also removed and replaced with a sequence 
encoding an HA tag (Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala) (Figure 3.20).
The constructs were transiently transfected into HEK293 cells and their expression was 
detected by immunoblotting using the anti-HA antibody 12CA5 (Figure 3.21). Western 
blot analysis of membrane preparations from transfected cells detected broad immuno- 
reactive bands of ~35-60 kDa. The predicted molecular weight of each of the IP 
receptor proteins is 41 kDa, which would suggest that the slower migrating bands 
indicated the presence of glycosylated forms of the receptors. A non-specific reactive 
species of ~50 kDa, as detected in mock transfected cells, obscured the region of 
specific antibody binding in receptor-transfected cells.
Receptors were further characterised in transient transfections by radioligand binding 
and adenylyl cyclase assays. The plasma membrane expression of receptors was 
determined by binding of [^H] iloprost to transfected whole cells (Figure 3.22). As 
highlighted previously in binding experiments with the GFP-tagged constructs, low 
levels of binding were detected in cells expressing the HA-tagged IP receptors, 
indicating poor transfection efficiency (HA-IP 94 ± 18.6 finol/10^ cells, HA-IP-TRH 8 6  
± 24 finol/10^ cells, and HA-IP-p2  126 ± 40 fmol/1 0  ^ cells). Furthermore, cAMP 
production in response to agonist challenge in transiently transfected cells was 
exceptionally low (Figure 3.23). When treated with forskolin, to directly stimulate 
adenylyl cyclase, significant second messenger production was detected. Adenylyl 
cyclase activity was further enhanced when cells were treated with both iloprost and 
forskolin, thus confirming the expression and G protein coupling of the HA-tagged IP 
receptor constructs in HEK293 cells.
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3.6 Analysis of receptor internalisation in HEK293 cells transiently transfected 
with HA-tagged IP prostanoid receptor constructs.
An immunocytochemical approach was used to observe the trafficking of the HA- 
tagged IP receptors in cells. In contrast to earlier immunostaining analysis with the anti- 
FLAG antibody (Figure 3.15), the 12CA5 antibody effectively labelled each of the 
transiently expressed HA-receptor constructs in live HEK293 cells. Therefore, agonist- 
mediated internalisation of the HA-receptors was studied using confocal microscopy. In 
cells expressing the HA-IP construct, a 60 min time course of 1 pM iloprost treatment 
promoted the translocation of antibody labelled receptors from the cell surface to 
intracellular compartments (Figure 3.24). Within 15 min of agonist exposure, a 
significant portion of the fluorescent signal could be detected inside the cells, and at the 
1 hour timepoint, the plasma membrane appeared less defined due to the loss of 
fluorescence from the surface. For HA-IP-TRH transfected cells, most of the cells’ 
fluorescence seemed to be cytoplasmic within the first 5 min of agonist treatment 
(Figure 3.25). Prolonged exposure to agonist resulted in further loss of receptors from 
the cell surface as illustrated by the intracellular concentration of the fluorescent signal. 
In HA-IP-p2 expressing cells, the localisation of antibody labelled receptors inside the 
cells could be detected within 5 min of agonist treatment and steadily increased during 
the 60 min time course (Figure 3.26). From these experiments it could be seen that all 
three of the IP receptor constructs endocytosed in response to treatment with iloprost. 
Although such data could not be used to accurately determine the internalisation rates of 
each receptor construct, the images generated from immunocytochemical analysis 
suggested that the HA-IP-TRH receptor sequestered more quickly in response to agonist 
than the other IP receptor proteins.
Quantification of agonist-mediated internalisation for each of the constructs was carried 
out using receptor biotin labelling experiments as essentially described in section 3.4, 
except that receptors were immunoprecipitated from cell lysates using the 12CA5 
antibody. Densitometric analysis of blots from biotin labelling experiments with the 
HA-IP construct indicated that there was an initial rapid loss of receptors from the cell 
surface within the first 5 min of agonist (87 ± 2.9% receptors at the cell surface). 
Receptor internalisation continued over the rest of the time course but at a much slower
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rate (Figure 3.27). In HA-IP-TRH expressing cells, approximately 40% of the cell 
surface receptors had internalised within 5 min of iloprost treatment (Figure 3.28). Only 
a further ~10% loss in receptor cell surface expression was detected over the 60 min 
period. For the HA-IP-j32 receptor, a continuous and steady reduction in the cell surface 
expression of receptors occurred with 51 + 5.3% receptors remaining at the plasma 
membrane after 1 hour’s agonist treatment (Figure 3.29). In summary, the results 
suggest that the HA-IP-TRH receptor internalised rapidly in response to agonist while 
the HA-IP and HA-IP-132 receptors displayed much slower and essentially similar 
internalisation rates (Figure 3.30).
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Figure 3.1
a) Schematic representation of the receptor-GFP constructs used in this study.
The IP-GFP cDNA (1) was constructed previously in the laboratory. The IP-TRH- 
GFP (2) and IP-P2-GFP (3) constructs were generated by PCR as described in 
section 2.4.
b) Primary structure of the receptor carboxyl terminal sequences.
The amino acid composition of the carboxyl terminal domains of the prostacyclin 
receptor constructs.
Figure 3.2
Western blot analysis of membranes transiently transfected with the receptor- 
GFP constructs.
20pg of membrane preparations from HEK293 cells transiently transfected with the 
IP-GFP (1), IP-TRH-GFP (2), IP-P2 -GFP (3) constructs, and empty vector (4) were 
resolved on SDS-PAGE gels then transfeiTed onto nitrocellulose membranes and 
blotted with a) anti-FLAG™ and b) anti-GFP antibodies. Two further experiments 
produced similar results.
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Figure 3.3
One-point [^ H] iloprost binding in intact HEK293 cells transiently transfected 
the receptor-GFP constructs.
The specific binding of [^H] iloprost in cells transiently transfected with the 
receptor-GFP constructs was determined by incubation with 20nM [^H] iloprost as 
essentially described in section 2.7.2. Data shown are presented as specific finol 
bound/10^  cells and are means ± S.E.M., n=3.
Figure 3.4
Adenylyl cyclase activity in cells transiently expressing the receptor-GFP 
constructs.
The Gs coupling of the receptor-GFP constructs was assessed by stimulation of cells 
for 15 min with IpM iloprost. Cells were also challenged with adenylyl cyclase 
activator forskolin (50pM), or both iloprost and forskolin. The cAMP accumulation 
in the cells is expressed as a percentage of the total adenine nucleotide intracellular 
pool. The data shown represent means ± S.E.M. from a single assay performed in 
triplicate. A further two experiments produced similar results.
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Figure 3.5
The receptor-GFP constructs exhibit a diffuse pattern of expression in 
transiently transfected HEK293 cells.
Cells grown on coverslips were transfected with IP-GFP (a, b), IP-TRH-GFP (c, d) 
and IP“P2 “GFP (e, f) constructs. 48 hours post transfection, cells were treated with 
vehicle (a, c, e) or IpM iloprost (b, d, Q for 30 min, before being fixed and mounted 
onto coverslips as described in section 2.7.6. The confocal images shown are 
representative fi'om three individual experiments. Scale bar = 2.5pM.
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Fig. 3.5

Figure 3.6
One-point [^ H] iloprost binding of the stable cell clones.
An indication of the receptor expression level in each of the positive stable cell 
clones generated for this study was determined by incubation of 40pg of membranes 
with ~20nM [^H] iloprost as described in section 2.7.1. Data are means ± S.E.M. 
from a single experiment.
Figure 3.7
Whole-cell adenylyl cyclase activity of the stable cell clones.
The capacity of each of the positive stable clones to couple to Gs was assessed by 
stimulation of cells with IpM iloprost for 15 min. Data are means ± S.E.M. from a 
single experiment.
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Figure 3.8
a) Confocal analysis of the IP-TRH-GFP stable cell clones.
All the positive stable clones were imaged by confocal microscopy to determine the 
distribution of the receptors in the HEK293 cells. Each clone exhibited notable 
intracellular expression in the unstimulated state. Scale bar = lOpM.
b) Imaging of the IP p2 GFP stable cell clones.
The GFP autofluorescence of the clones was found at the cells’ plasma membrane 
but a large portion of receptor was also localised intracellularly. Scale bar = lOpM.
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Figure 3.9
Saturation pH] iloprost binding of the receptor-GFP constructs in the selected 
stably expressing clones.
a) Membranes from the IP-GFP stable clone were incubated with increasing 
concentrations of [^H] iloprost as detailed in section 2.7.1. Specific binding 
(frnoFmg) was calculated by incubation with 20pM unlabelled iloprost. The data 
shown is representative of a single experiment (means ± S.E.M) which was 
performed three times with similar results. Non-specific binding at lOnM [^H] 
iloprost was 33% of the total binding. Non-specific binding at 50nM [^H] iloprost 
was 46%.
b) Transfoimation of the non-linear curve into a Scatchard plot. Estimations of the 
K<] values from the three experiments were 2.6 ± 0.25nM (Bmax of 696 ± 53.4 
frnol/mg) and 66.9 ± 5.3nM (Bmax of 4806 ±106 fmoEmg).
c) IP-TRH-GFP cell membranes were incubated with varying concentrations of [^H] 
iloprost. A saturation curve frrom a single experiment is shown. The experiment was 
repeated twice with similar results. Non-specific binding at lOnM [^H] iloprost was 
36% of the total binding. Non-specific binding at 50nM f  H] iloprost was 49%.
d) Scatchard plot of the data fr'om the saturation curve in c). The estimated 
dissociation constants from the three experiments were 2.9 ± 0.5nM (Bmax of 682 ± 
83.7 frnol/mg) and 33.5 ± 4.6nM (Bmax of 1591 ± 157 fmoFmg).
e) Saturation binding studies of IP-P2-GFP membranes were performed to determine 
receptor expression level and ligand binding affinity. The data shown are from a 
single experiment. Two further experiments were performed with similar results. 
Non-specific binding at lOnM [^H] iloprost was 37% of the total binding. Non­
specific binding at 50nM [^H] iloprost was 54%.
f) Transformation of the data in e) into a Scatchard plot. The predicted Kd values 
from the experiments were 1.12 ± 0.28nM (Bmax 168 ± 48.5 frnol/mg) and 81.6 ± 
25.6nM (Bmax 1780 ± 145 fmol/mg).
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Figure 3.10
Homologous displacement binding of [^ H] iloprost to the receptor-GFP stable 
cell membranes.
The binding of 20nM [^H] iloprost to 40pg membrane preparations of the IP-GFP, 
IP-TRH-GFP, and IP-P2 -GFP stable cell clones was displaced by increasing 
concentrations of the imlabelled drug. The specific [^H] iloprost binding (finol/mg) 
is expressed as a percentage of the binding observed in the absence of unlabelled 
drug iloprost (set at 100%). The data shown represent means ± S.E.M. fi-om a single 
assay performed in triplicate. Similar results were obtained from two additional 
experiments. Applying the formalisms of De Blasi and coworkers (1989), the 
estimated Kd values were 67.6 ± 7.5nM for IP-GFP, 32 ± 4nM for IP-TRH-GFP, and 
42 ± 7nM for IP-P2-GFP receptors. The Hill slope coefficients for the IP-GFP, IP- 
TRH-GFP, and IP-P2 -GFP curves shown are -0.9, -1.3, and -0.9 respectively.
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Figure 3.11
Agonist stimulated adenylyl cyclase stimulation in intact cells stably expressing 
the receptor-GFP constructs.
Adenylyl cyclase dose response assays were performed as detailed in section 2.7.3. 
The IP-GFP, IP-TRH-GFP, and IP-pi-GFP clones were challenged with varying 
concentrations of iloprost for 30 min and the stimulated cAMP production was 
determined as described in section 2.7.3. The data shown represent means ± S.E.M. 
from a single assay performed in triplicate. Similar data were obtained from two 
further experiments. The average E C 5 0  values of agonist potency were 0.096 ± 
0.022nM at the IP-GFP receptor, 0.41 ± 0.07nM at the IP-TRH-GFP receptor and 
0.36 ± O.OSnM at the IP-pz-GFP receptor.
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Figure 3.12
Internalisation of the IP-GFP receptors.
Confocal microscopy of the IP-GFP stable clone was used to visualise agonist- 
mediated internalisation of the receptors. Cells were visualised prior to agonist 
tieatment (a) and after the addition of IpM iloprost for 5 (b), 15 (c), 30 (d) and 60 
(e) minutes. The images shown are representative of at least three separate 
experiments. Scale bar = lOpM.
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Figure 3.13
Confocal analysis of IP-TRH-GFP sequestration.
The ligand-induced internalisation of the IP-TRH-GFP receptor was visualised by 
confocal microscopy. Cell images were taken prior to agonist treatment (a) and after 
the addition of IpM iloprost for 5 (b), 15 (c), 30 (d) and 60 (e) minutes. The images 
are representative of at least three further experiments. Scale bar = lOpM.
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Figure 3.14
Visualisation of IP-P2-GFP internalisation.
Confocal images of IP-pi-GFP cells were taken prior to agonist treatment (a) and 
after the incubation with IpM iloprost at 5 (b), 15 (c), 30 (d) and 60 (e) minute 
intervals to visualise receptor sequestration. The images are representative of at least 
three additional experiments. Scale bar -  lOpM.
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Figure 3.15
Immunocytochemical staining of the receptor-GFP stables using an anti- 
FLAG™ antibody: non-specific binding of the antibody to receptor-GFP 
chimeras.
IP-GFP (a), IP-TRH-GFP (b), and IP-p^-GFP cells were incubated with an antibody 
against the N-terminal FLAG epitope as described in section 2.7.6 to visualise the 
cell surface receptor population. In IP-GFP cells, successful decoration of receptors 
was achieved, however, antibody labelling of the IP-TRH-GFP and IP-pa-GFP cell 
lines was non-specific. Scale bar = lOpM.
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Figure 3.16
Time course of the agonist-mediated internalisation of the IP-GFP receptors.
a) IP-GFP cells were incubated with vehicle (1) or IpM iloprost for 5 (2), 15 (3), 30
(4), and 60 (5) min at 37°C. Cell surface glycoproteins were labelled with biotin and 
the receptors were immunoprecipitated and visualised as detailed in section 2.7.5. A 
representative blot from three individual experiments is shown.
b) Blots were quantified by densitometric scanning. The values shown represent 
mean ± S.E.M. for tliree experiments, with the levels of cell surface receptors 
observed in the absence of agonist set at 100%.
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Figure 3.17
Quantification of agonist-mediated internalisation of the IP-TRH-GFP 
receptors.
a) After incubation with vehicle (1) or l|iM  iloprost for 5 (2), 15 (3), 30 (4), and 60
(5) min at 37°C, biotin-labelled cell surface IP-TRH-GFP receptors were 
immunoprecipitated and visualised. A representative blot from three separate 
experiments is shown.
b) Quantification of receptor internalisation by densitometiic analysis of the biotin 
blots. The values shown represent mean ± S.E.M. for three experiments, with the 
levels of cell surface receptors observed in the absence of agonist set at 100%.
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Figure 3.18
Quantitative analysis of agonist-stimulated internalisation of the ÏP-P2-GFP 
receptors.
a) Cells were challenged with vehicle (1) or l|iM  iloprost for 5 (2), 15 (3), 30 (4), 
and 60 (5) min at 37°C, prior to biotin-labelling of the plasma membrane receptor 
population. Receptors were immunoprecipitated and the biotin-labelled receptors 
were detected in blots. The blot shown is similar to those generated from two further 
experiments.
b) Densitometric scanning of the biotin blots was used to quantify the levels of cell 
surface receptors over the time course. The values shown represent mean ± S.E.M. 
for three experiments, with the levels of cell surface receptors observed in the 
absence of agonist set at 100%.
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Figure 3.19
A general overview of the time courses of agonist-mediated internalisation of 
the receptor-GFP constructs.
Summary of the data shown in figures 3.16, 3.17, and 3.18 to emphasise the 
different internalisation properties of the full-length and chimeric GFP-tagged 
prostacyclin receptors.
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Figure 3.20
Diagrammatical representation of the HA-tagged prostacyclin receptor 
constructs generated for this study.
The HA-IP (a), HA-IP-TRH (b), and HA-IP-pz (c) cDNAs were constructed using a 
PCR-based strategy as described in section 2.4.
Figure 3.21
Western blotting of HEK293 membranes transiently expressing the HA- 
receptors.
20fag of membrane preparations from HEK293 cells transiently transfected with the 
HA-IP (1), HA-IP-TRH (2), HA-IP-P2  (3) cDNAs, and empty vector (4) were 
resolved on SDS-PAGE gels then transfeiTed onto nitrocellulose membranes and 
blotted with the 12CA5 antibody. Similar results were obtained from two further 
experiments.
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Figure 3.22
One-point [^ H] iloprost binding in intact HEK293 cells transiently transfected 
the HA-tagged receptor constructs.
The specific binding of [^H] iloprost in intact cells transiently transfected with the 
HA-receptor constructs was determined by incubation with 20nM [^H] iloprost as 
detailed in section 2.7.2. Data shown are presented as specific finol bound/10^ cells 
and are means ± S.E.M., n=3.
Figure 3.23
Adenylyl cyclase activity in cells transiently transfected with the HA-tagged 
receptors.
The capacity of the HA-tagged IP receptor proteins to couple to Gs coupling was 
assessed by stimulation of cells for 15 min with IpM iloprost. Adenylyl cyclase 
activity in the cells was also assessed after direct activation of the enzyme with 
50pM forskolin, or after both iloprost and forskolin incubation. The cAMP 
accumulation is expressed as a percentage of the total adenine nucleotide 
intiacellular pool. The data shown represent means ± S.E.M. from a single assay 
performed in tiiplicate. A further two experiments produced similar results.
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Figure 3.24
Visualisation of agonist-stimulated HA-IP receptor sequestration in transiently 
transfected HEK293 cells by immunocytochemical staining of receptors.
Cells ti’ansfected with the HA-IP receptor construct were immunostained with the 
12CA5 antibody to label cell surface HA-IP receptors prior to agonist treatment as 
detailed in section 2.7.6. Cell images were taken before agonist treatment (a) and 
after the addition of IpM iloprost for 5 (b), 15 (c), 30 (d) and 60 (e) minutes. The 
images are representative of at least two further experiments. Scale bar = 2.5pM.
116
Fig. 3.24

Figure 3.25
Confocal analysis of agonist-stimulated HA-IP-TRH receptor internalisation in 
transiently transfected HEK293 cells.
Cells transfected with the HA-IP-TRH receptor construct were immunostained using 
the 12CA5 antibody to label plasma membrane receptors prior to agonist treatment. 
The confocal images shown are before the addition of agonist (a) and after 
incubation with IpM iloprost for 5 (b), 15 (c), 30 (d) and 60 (e) minutes. The images 
are representative of two further experiments. Scale bar = 2.5 pM
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Figure 3.26
Confocal analysis of agonist-stimulated internalisation of the HA-IP-P2 receptor 
construct in transiently transfected HEK293 cells.
Cells transfected with the HA-IP-P2 receptor construct were incubated with the 
1 2 cA5 antibody to label the cell surface receptors prior to agonist treatment. The 
confocal images were taken of cells unstrmulated (a) and after treatment with 1 |.iM 
iloprost for 5 (b), 15 (c), 30 (d) and 60 (e) minutes. The images are representative of 
two further experiments. Scale bar = 2.5pM.
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Figure 3.27
Quantification of agonist-mediated internalisation of the HA-IF receptors using 
biotin labelling receptors.
a) Ceils transiently expressing the HA-IP receptor construct were incubated with 
vehicle (1) or IpM iloprost for 5 (2), 15 (3), 30 (4), and 60 (5) min at 37°C. Cell 
surface glycoproteins were labelled with biotin and the receptors were 
immunoprecipitated and visualised as detailed in section 2.7.5. A representative blot 
from three individual experiments is shown.
b) Densitometric scanning of the biotin blots was used to quantify the levels of cell 
surface receptors over the time course. The values shown represent mean ± S.E.M. 
for three experiments, with the levels of cell surface receptors observed in the 
absence of agonist set at 100%.
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Figure 3.28
Quantitative analysis of agonist-stimulated internalisation of the HA-IP-TRH 
receptors.
a) Cells transfected with the HA-IP-TRH constructed were treated with vehicle (1) 
or IpM iloprost for 5 (2), 15 (3), 30 (4), and 60 (5) min at 37°C. Cell surface 
glycoproteins were labelled with biotin and the receptors were immunoprecipitated 
and visualised as detailed in section 2.7.5. A representative blot from three 
individual experiments is shown.
b) Blots were quantified by densitometric scanning. The values shown represent 
mean ± S.E.M. for three experiments, with the levels of cell surface receptors 
observed in the absence of agonist set at 100%.
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Figure 3.29
Quantitative analysis of agonist-stimulated internalisation of the HA-IP-P2 
receptors.
a) HEKK293 cells transiently transfected with the HA-IP-P2  construct were 
challenged with vehicle (1) or l)aM iloprost for 5 (2), 15 (3), 30 (4), and 60 (5) min 
at 37*^ C, prior to biotin-labelling of the plasma membrane receptor population. 
Receptors were immunoprecipitated and the biotinylated receptors were detected in 
blots. The blot shown is typical of blots from two further experiments.
b) Receptor internalisation was assessed by densitometric scanning of the blots. The 
values shown represent mean ± S.E.M. for three experiments, with the levels of cell 
surface receptors observed in the absence of agonist set at 100%.
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Figure 3.30
Comparison of the time courses of the agonist-mediated internalisation for each 
of the HA-receptor constructs.
An overview of the internalisation data in figures 3.27, 3.28, and 3.29. Taken 
together, the results reveal the differences in agonist-promoted internalisation 
exhibited by the full-length and chimeric HA-tagged prostacyclin receptors.
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3.7 Discussion
The majority of GPCRs undergo agonist-stimulated internalisation and therefore 
internalisation might be expected to involve a common mechanism. However, thus far, 
generalised domains and mechanisms for receptor internalisation have been difficult to 
ascertain. Many domains have been implicated in the internalisation of specific GPCRs. 
However, these domains have been localised to divergent regions of various receptors 
and often involve sequences not conserved in other members of the receptor 
superfamily. Alterations in the carboxyl terminus have been found to influence 
internalisation in the widest variety of receptors. Many studies have used point 
mutations and/or truncations of the receptor C-tail to directly study this. A complication 
of such manipulations is that it has often been difficult to discern whether the alterations 
were specific or resulted in non-specific conformational changes which indirectly 
interfered with conformational changes in actual endocytic domains. An alternative to 
deletion and substitution experiments is the creation of receptor chimeras. The 
advantage of the chimeric approach is that the predicted outcome is the retention or gain 
of function, rather than its loss, and it is unlikely that a fimction would be non- 
specifically acquired.
The chimeric approach was used to examine the internalisation properties of the IP 
prostanoid receptor, where the intracellular tail was replaced with a C-tail of similar 
length from two other GPCRs, namely the rat TRH-1 and human P2-adrenergic 
receptors. In addition, receptors C-terminally tagged with a modified form of GFP from 
the jellyfish Aequorea victoria were made, thus providing the means to directly 
visualise the expression, localisation, and redistribution of the receptors in response to 
stimuli in intact cells and in real time.
Many GPCRs have been extensively studied in both transient and stable expression cell 
systems using GFP. An important issue in an approach of this kind is whether the 
receptor-GFP conjugate maintains the ligand binding and signal transduction properties 
of the native receptor. There appears to be remarkable retention of normal receptor 
characteristics when the 27 kDa GFP protein is fused to the C-termini of GPCRs such as 
the P2 -AR, TRH-R, gastrin-releasing peptide receptor, and the lysophospholipid edgl
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receptor (Kallal et al., 1998; Drmota et al., 1998; Slice et al., 1998; Liu et al., 1999). In 
the early stages of this investigation, experiments were therefore carried out to 
determine the pharmacological properties of the IP prostanoid receptor constructs and 
whether GFP and/or the different tails altered receptor pharmacology.
Western blotting of HEK293 cell membranes transfected with the GFP- and HA-tagged 
constructs demonstrated that the receptors resolved as broad complexes which were not 
present in mock transfected cells (Figures 3.2 and 3.21). The slower migrating bands, 
which were of higher molecular weight than the native receptors, suggested that 
differential glycosylated forms of the receptors were present. It has been previously 
demonstrated that the IP receptor is expressed as a glycoprotein in HEK293 cells 
(Smyth et al., 1996). The sites for potential N-linked glycosylation are located within 
the receptor’s N-terminus and first extracellular loop (N  ^and N^^). Mutagenesis studies 
of IP receptor mutants lacking the putative glycosylation sites have highlighted the 
importance of receptor glycosylation for plasma membrane localisation, ligand binding 
and signal transduction (Zhang et a l, 2001).
One-point [^H] iloprost binding assays in intact cells confirmed the plasmalemmal 
expression of the HA- and GFP-tagged forms of the receptor constructs, but at relatively 
low levels (Figures 3.3 and 3.23). Furthermore, the coupling of the cell surface 
receptors to Gg as shown in assays of adenylyl cyclase activity, demonstrated only 
moderate agonist-stimulated second messenger production in the transiently transfected 
cells (Figures 3.4 and 3.24). A common problem with transient transfection of many 
GPCRs is that when expression is driven by a strong viral promoter, a significant 
proportion of the protein synthesised appears to be trapped in intracellular 
compartments like the Golgi membranes and is not effectively trafficked to the plasma 
membrane. The use of receptor-GFP conjugates has permitted the direct visualisation of 
this phenomenon. As suggested from the radioligand binding and adenylyl cyclase 
experiments, the receptor-GFP proteins displayed predominantly intracellular 
localisation as visualised in confocal microscopy of transiently transfected HEK293 
cells (Figure 3.5). Significant intracellular distribution has been described for cell 
expressing GPCRs such as the azc-AR (Daunt et al., 1997), aiA-AR (Hirasawa et al..
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1997), 5H T ib receptor (Langlois et al., 1996), thrombin receptor (Hein et a l, 1994), and 
dopamine D2 receptor (Prou et al., 2001).
Transient expression of GPCRs certainly overloads secretory intracellular 
compartments. However, it does not prevent a large portion of receptor pool from being 
targeted to the plasma membrane in the case of the dopamine Di (Prou et al., 2001), p- 
adrenergic (von Zastrow et al., 1993) or aib-adrenergic (Fonseca et al., 1995; Hirasawa 
et al., 1997) receptors. A feasible explanation for the intracellular retention of receptors 
could be defective glycosylation due to improper folding of the protein in the 
endoplasmic reticular membranes. As previously noted with the prostacyclin receptor, 
non/partial glycosylation has been reported to impair the plasma membrane localisation 
of GPCRs including the EPsb, TXA2 , and calcium receptors (Boer et al., 2000; Walsh et 
al., 1998; Ray et al., 1998). Constitutively active GPCRs are also known to exhibit 
predominant intracellular expression of GPCRs. Such a phenomenon has been observed 
for constitutively active dopamine D2 receptors where incubation with antibodies 
against an amino-terminal epitope tag internalised in cells in a clathrin- and dynamin- 
independent manner (Vickery and von Zastrow, 1999). Spontaneous endocytosis of 
receptors has also been demonstrated for GFP-tagged CXCR4 receptors (Tarasova et 
a l, 1998)
Confocal analysis of the transiently expressed GFP-tagged prostacyclin receptor 
constructs posed obvious difficulties for detailed analysis of agonist-stimulated 
redistribution of the receptors and therefore cell lines stably expressing the GFP- 
receptors were generated in an attempt to overcome this problem. Previous studies have 
reported that HEK293 cells stably expressed with a GFP-tagged form of the 
prostacyclin receptor displayed plasma membrane localisation in the unstimulated state 
(Smyth et al., 2000). In accordance with such findings, the IP-GFP stable cell line used 
in this investigation showed a similar cell decoration (Figure 3.12a). Surprisingly, the 
stable cell clones expressing the receptor chimeras exhibited a more diffuse pattern of 
expression (Figures 3.13a, 3.14a), thus indicating that modification of the receptor’s tail 
altered its ability to traffic to the cell surface. In investigations with a chimeric 
prostacyclin receptor possessing the equivalent C-tail region of the DP receptor it was 
demonstrated that the chimera displayed all the properties of a constitutively active
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receptor (Wise, 1999). It could therefore be argued that the loss in plasma membrane 
localisation of the IP-TRH-GFP and IP-P2 -GFP constructs was due to increased intrinsic 
activity of the receptors. However, in assays of adenylyl cyclase activity, increased 
constitutive activity was not detected; the basal level of cAMP accumulation in IP- 
TRH-GFP and IP-P2-GFP cells was in fact lower than in the IP-GFP cell line. It is 
possible that the wild type receptor contains a signal sequence within its carboxyl tail 
for targeting to the cell surface which is lost when the tail is switched. It is well known 
that GPCR mutagenesis of the C-tail can often result in poor plasma membrane delivery 
of the modified protein. In studies with GFP-tagged forms of the vasopressin V2 
receptor it was noted that the wild type receptor appeared to be plasma membrane- 
delineated while receptors with mutations in a C-tail dileucine motif and an associated 
upstream glutamate residue (a sequence thought to be important in mediating delivery 
of receptors to the cell surface) were retained in the endoplasmic reticulum (Schulein et 
aL, 1998). Mutagenesis of basic residues in the membrane proximal domain of the 
CCR5 receptor carboxyl tail has also been shown to bring about a severe reduction in 
cell surface expression (Venkatesan et al., 2001).
Scatchard analysis of the IP-GFP stable cell clone revealed the presence of two binding 
sites, one of high affinity, and one of low affinity (Figure 3.9b). It is well documented 
that a GPCR coupled to a G protein has a high degree of affinity for agonists whereas 
the uncoupled form exhibits a lower affinity (Emerit et aL, 1990). Thus, the high 
affinity iloprost binding site is indicative of ligand binding to the prostacyclin receptor 
construct in its G protein coupled state while iloprost binding to uncoupled receptors 
would account for the detection of a class of receptors of low affinity. It is also 
conceivable that the low affinity site is a result of iloprost binding to the EPi receptor 
which is endogenously expressed in HEK293 cells. Previously published data have 
shown that both the native and recombinant IP receptors exist in two affinity states. 
Boie and coworkers (1994) demonstrated that in COS cells, [^H] iloprost bound to the 
native IP receptor with high and low affinity equilibrium dissociation constants of 1 and 
44 nM respectively. Similarly, Smyth and coworkers (1996) found that an N-terminal 
HA-tagged prostacyclin receptor bound [^H] iloprost with similar affinity (high affinity 
Kd of 0.4 nM and low affinity Kj of 75 nM). The ligand binding properties of the stably 
expressed IP-GFP receptor were comparable to those already reported for the native and
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epitope-tagged forms of the receptor, indicating that neither the FLAG epitope nor the 
GFP tag altered ligand binding. Furthermore, the binding affinity of [^H] iloprost to the 
receptor was not significantly affected by the expression of the P2 -AR or the TRH-1-R 
tails (Figure 3.9d, f); both exhibited two-site binding with high and low affinity 
dissociation constants similar to those of the IP-GFP receptor. Such data would suggest 
that the C-tail of the prostacyclin receptor is not a crucial factor in the binding of ligand 
to the receptor. Indeed, ligand binding studies of the IP receptor using IP/DP receptor 
chimeras have previously demonstrated that TMs VI and VII and the first extracellular 
loop region are important in conferring the ligand binding properties of the IP receptor 
(Kobayashi et aL, 1997, 2000).
Functional characterisation of each of the stable cell lines showed that the receptors 
displayed robust coupling to adenylyl cyclase. Iloprost was most potent at stimulating 
adenylyl cyclase activity in IP-GFP cells, with an approximate 5-fold reduction in E C 5 0  
value as compared to the receptor chimeras (Figure 3.11). The potency of iloprost at the 
IP-GFP receptor was similar to that reported for both HA-tagged and native forms of 
the receptor (Smyth et aL, 1996) thus demonstrating that the fusion of GFP to the C- 
terminus of the receptor did not affect the receptor’s coupling capacity. Both the IP- 
GFP and IP-P2 -GFP cells displayed similar maximal levels of cAMP production 
whereas the intrinsic activity of IP-TRH-GFP cells was -50% lower.
In signalling systems where the effector species is quantitatively the limiting 
component, it is often observed that elevations in receptor number result in a leftward 
shift of the dose response curve i.e. decrease the E C 5 0  value. Consistent with this, earlier 
binding analysis demonstrated that the number of ligand binding sites in IP-GFP cells 
was 2-3 fold higher than in IP-TRH-GFP and IP-P2 -GFP cells. Thus, it could be argued 
that the increased receptor expression in IP-GFP cells resulted in an increased agonist 
potency. Similar observations have been reported in other GPCR studies; in functional 
assays with cell lines expressing p2 - and p3-adrenoreceptors, the potency of various 
agonists was found to be proportional to receptor density (Whaley et aL, 1994; Wilson 
et aL, 1996). Likewise, it was demonstrated that adenylyl cyclase inhibition by the 
adenosine A1 receptor exhibited a leftward shift in agonist potency of 2 orders of
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magnitude in cells expressing the receptor at relatively high levels as compared to an 
equivalent cell line in which expression was 16-fold lower (Cordeaux et aL, 2000).
Stimulation of adenylyl cyclase, but not phospholipase C, by the IP receptor has been 
shown to be unaffected by the absence of a C-tail which would suggest that this region 
of the receptor is redundant in terms of Gs coupling (Smyth et aL, 1998). The switching 
of the IP receptor tail for that of another Gs-coupled GPCR, the p2 -AR, did not alter the 
maximal response in adenylyl cyclase dose responses whereas the chimera possessing 
the C-tail region of the Gq/n-coupled rat TRH-1 receptor exhibited a much lower 
intrinsic activity. The presence of the TRH-1 tail may have inhibited Gs coupling or 
brought about conformational changes in the protein which affected its ability to couple 
efficiently to Gs. The TRH-tailed chimera may have been more effective at stimulating 
phosphoinositide turnover but this was not investigated in this study.
Earlier research into the agonist-mediated internalisation of the prostacyclin receptor 
indicated that it displayed relatively slow kinetics of internalisation and desensitisation. 
In these studies, cell lines which endogenously expressed the receptor (e.g. platelets and 
NG108-15 cells) were used. Taken together, the data revealed that the time frame of 
receptor desensitisation was between 3-10 hours which coincided with receptor 
sequestration and downregulation (Krane et aL, 1994; Giovanazzi et aL, 1998; Nilius et 
aL, 2000). Whilst in the midst of this present study, further data was published showing 
that the IP receptor, when overexpressed in HEK293 cells, undeiwent rapid agonist- 
induced desensitisation and internalisation, thus conforming to the general paradigm of 
GPCR regulation (Smyth et aL, 1998; 2000). They showed that in HEK293 cells, IP 
receptor internalisation was evident within 5 min of iloprost treatment (IqM) and 
plateaued after 30 min with 30-40% loss of cell surface receptors. Confocal analysis of 
a GFP-tagged form of the receptor seemed to exhibit similar kinetics of internalisation 
to the wild type, although the rate of internalisation was not quantified in the study 
(Smyth et aL, 2000). In addition, deletion of the carboxyl tail was shown to completely 
abolish its trafficking in response to iloprost thus confirming its critical role in 
sequestration.
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In this present study, the GFP-tagged IP receptor was shown to translocate from the cell 
surface and into the intracellular space with 5 min of agonist treatment as demonstrated 
by both confocal analysis and biotin labelling experiments (Figures 3.12, 3.16). 
Internalisation was initially rapid, but a more gradual loss of cell surface receptors 
occurred over the time course with -40% receptors internalised after 60 min of agonist 
treatment. Furthermore, similar results were obtained with HEK293 cells transiently 
expressing an N-terminal HA-tagged version of the prostacyclin receptor (Figures 3.24, 
3.27). The internalisation data are in accord with those published for HEK293 cells 
stably expressing an HA-tagged IP receptor, and add further credence to the opinion that 
fusing GFP to the receptor’s carboxyl tail does not affect its internalisation properties.
The addition of the carboxyl tail of the TRH-1 receptor to the distal end of TMVII of 
the prostacyclin receptor produced a chimera with enhanced kinetics of internalisation. 
Confocal analysis of both the GFP- and HA-tagged forms of the receptor chimera 
showed that the bulk of receptors appeared to be intracellular within 5 min of iloprost 
incubation (Figures 3.13, 3.25). Biotin labelling experiments confirmed these 
observations (Figures 3.17, 3.28).
The full length TRH receptor is a GPCR that is internalised quickly in response to 
agonist. In COS-1 cells, the wild type mouse TRH receptor was shown to be rapidly 
converted to an acid-resistant (i.e. intracellular) region of the cell upon treatment with 
TRH (Nussenzveig et al., 1993). After 1 hour agonist exposure, at room temperature, 
40% of the TRH bound became acid resistant. This rapid agonist-mediated endocytosis 
has also been noted in confocal studies of HEK293 cells stably expressing a GFP- 
tagged form of the rat TRH receptor (Drmota et al., 1998). Initially, the receptor 
appeared to be localised to the plasma membrane but within 5-10 min of agonist 
exposure most of receptors appeared to be located in intracellular vesicles.
By a series of C-terminal truncations of the mouse and rat forms of the TRH receptor, 
the carboxyl tail has been shown to be an important regulator of its sequestration 
(Nussenzveig et aL, 1993; Drmota and Milligan, 2000). In studies of the murine TRH 
receptor, two domains between residues 335-368 within the intracellular tail were found 
to be involved in internalisation. First, a domain between residues 360-367 was 
identified using a mutant truncated at codon 360 which exhibited a 50% reduction in the
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level of internalisation to that of the wild type whereas truncation at codon 368 
internalised to the same extent as the wild type. A second domain was uncovered by 
truncations at codons 335 and 338, and the substitutions of the cysteine residues at 
positions 335 and 337. The C335Stop truncation severely compromised the steady-state 
level of internalisation whereas lengthening the receptor by the three amino acids 
partially restored internalisation. The need for the proximal cysteine residues within this 
domain was demonstrated by their substitution which diminished internalisation by 
approximately 50% (Nussenzveig et aL, 1993). For the rat TRH-1 receptor, truncation 
studies uncovered a relatively short sequence in the C-tail involved in internalisation of 
the receptor. Truncation of the 93 amino acid tail to at least 50 amino acids in length 
had no effect on the agonist-induced internalisation of the receptor. However, further 
truncation to 45 or 46 amino acids dramatically reduced internalisation to 36% of that of 
the full length receptor, thus narrowing the region of a key internalisation signal to a 
four amino acid stretch (Drmota and Milligan, 2000).
From the observations made in studies of wild type TRH receptor sequestration, it could 
be argued that the addition of the rat TRH-1 receptor carboxyl tail to the IP receptor 
confers the internalisation properties of the donor to the recipient. Consistent with this 
hypothesis, in studies of the tail-less mammalian GnRH-R it has been reported that a 
GnRH/TRH tail chimera exhibited accelerated desensitisation and internalisation 
kinetics as compared to the wild type GnRH-R (Heding et aL, 1998).
Both the HA- and GFP-tagged forms of the IP receptor chimeras possessing the tail of 
the P2 -AR displayed similar internalisation patterns (Figures 3.18, 3.29), with notable 
receptor sequestration occurring after 30 min agonist treatment as determined both 
confocally and quantitatively. These data indicated that the internalisation 
characteristics of the P2 -AR tailed chimera were more similar to the full-length IP 
receptor than the IP/TRH tail fusion proteins.
The exact role of the wild type p2 -AR’s carboxyl tail in regulating internalisation 
remains unclear. Neither truncation of the P2 -AR tail nor mutation of putative 
phosphorylation sites blocked internalisation (Hausdorff et aL, 1989; Ferguson et aL,
130
1995, 1996). In contrast, sequestration was markedly inhibited by a mutation of a 
dileucine motif in the intracellular tail (Gabilondo et aL, 1997).
In HEK293 cells, the rate and extent of internalisation of both GFP-conjugated and 
native p2 -ARs was shown to be similar; both exhibited a rapid loss of receptors from the 
cell surface, with -60% of receptors being sequestered within 30 min of agonist 
exposure (Barak et aL, 1997a). The IP chimeras with the p2 -AR tail appended, at best, 
exhibited a -30% reduction in cell surface receptor number after 30 min agonist 
treatment, therefore indicating that the P2 -AR C-tail fusion protein did not acquire the 
internalisation properties of the donor receptor. In accord with this, chimeric studies 
with the mtemalisation-resistant Ps-AR demonstrated that all of the receptor’s 
intracellular domains had to be switched with the equivalent sequences of the P2 -AR in 
order to establish a sequestration phenotype similar to that of the native P2 -AR (Jockers 
et aL, 1996). It is therefore conceivable that the P2-AR C-tail alone is insufficient to 
confer its rapid internalisation properties to the prostacyclin receptor and the 
substitution of multiple intracellular domains would be required.
In summary, the results show that the introduction of different cytoplasmic tails to the 
prostacyclin receptor has the capacity to alter the rate and extent of the receptor 
internalisation and these characteristics are maintained when GFP is added to the C- 
terminus. In accordance with previously published findings, the data further highlight 
the crucial role that the intiacellular carboxyl tail domain plays in regulating 
prostacyclin receptor sequestration.
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Chapter 4
Examination of the Endocytic Pathways Utilised 
by the Prostacyclin Receptor Constructs
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Chapter 4
4,1 Introduction
An important aspect of GPCR regulation is the sequestration of agonist-occupied 
receptors from the plasma membrane to intracellular compartments. Intensive 
investigations into the underlying mechanisms of GPCR internalisation have uncovered 
multiple pathways of receptor endocytosis for various members of the superfamily.
Phosphorylation of agonist-activated receptors was first suggested as a candidate for 
inducing internalisation by Sibley and coworkers in 1986 when it was noted that 
sequestered p2 -ARs exhibited lower stoichiometry of phosphorylation (-0.75 mol/mol), 
compared to the whole cellular pool of P2 -ARS (-2.1 mol/mol). However, initial 
experiments with P2 -AR mutants lacking sites for both PKA- and GRK-mediated 
receptor phosphorylation, did not support this theory (Bouvier et al., 1988; Hausdorff et 
al., 1989). More recently, the role of phosphorylation in P2 -AR internalisation was 
confirmed by experiments demonstrating that overexpression of GRKs facilitated the 
endocytosis of a phosphorylation- and internalisation-defective mutant, p2-AR-Y326A 
(Ferguson et al., 1995, Menard etal., 1996).
Internalisation studies of other GPCR subtypes have further highlighted the importance 
of phosphorylation for endocytosis. Early experiments of m2 muscarinic receptor 
internalisation demonstrated that sequestration was reduced by mutation of the putative 
phosphorylation sites within the third intracellular loop of the receptor (Moro et al., 
1993). Furthermore, Tsuga and coworkers (1994) were the first to show that, upon 
overexpression of GRK 2, both the rate and maximal extent of m2 muscarinic receptor 
sequestration were accelerated, whereas expression of a dominant-negative GRK 2 
mutant led to a decrease in receptor phosphorylation and internalisation. Overexpression 
of GRKs has now been shown to promote internalisation for an array of GPCRs 
including the endothelin A (Bremnes et a l, 2000), follitropin (Lazari et al., 1999), ATia 
(Smith et al., 1998) and chemokine CXCRl (Barlic et al., 1999) receptors.
133
Some studies have indicated that phosphorylation is not an absolute requirement for 
internalisation. Indeed, P2-AR mutants lacking GRK phosphorylation sites were shown 
to readily internalise in response to agonist (Hausdorff et al., 1989; Bouvier et al., 
1988). It has now become evident that GRK phosphorylation promotes the interaction 
of the receptor with other intracellular components which are directly involved in 
receptor sequestration. In fact, GRK-mediated phosphorylation of GPCRs increases the 
affinity of the receptor to bind p-arrestins. P-Arrestins not only uncouple receptors from 
G proteins but act as adapters for the targeting of GPCRs for internalisation via clathrin 
coated pits (Zhang et al., 1996; Ferguson et al., 1996). The sequestration of the P2 -AR- 
Y326A mutant was rescued by overexpression of both P-arrestins 1 and 2, and this 
effect was enhanced by GRK 2 coexpression (Ferguson et al., 1996). Moreover, P- 
arrestins facilitated the endocytosis of P2 -AR mutants lacking either carboxyl terminal 
tails or putative GRK phosphorylation sites (Menard et al., 1997).
Investigations, primarily with the P2 -AR, have delineated a general pathway for receptor 
internalisation by which GRK-mediated phosphorylation of agonist-activated receptors 
promotes the recruitment of P-arrestins, uncoupling the receptor-G protein complex and 
facilitating endocytosis via clathrin coated vesicles (CCVs). However, a large volume of 
published data would suggest that this pathway is not universally observed.
In some instances, it has been reported that GPCR internalisation can be arrestin- 
independent. In HEK293 cells, it was shown that internalisation of the m2 muscarinic 
receptor could proceed via a GRK-dependent, arrestin-independent pathway (Pals- 
Rylaarsdam et al., 1997). Furthermore, agonist-induced internalisation of the m l, m3, 
and m4 subtypes was neither altered by overexpression of p-arrestins nor transfection 
with a dominant negative mutant arrestin (Lee et al., 1998). Similarly, internalisation of 
agonist-activated 5HT2a receptors in HEK293 cells appeared to be insensitive to arrestin 
dominant negative mutants, although receptor stimulation did promote the translocation 
of arrestins to the plasma membrane which was accompanied by differential sorting of 
the arrestins and receptors into distinct intracellular compartments (Bhatnagar et al., 
2001). It has also been reported that the maximal extent of A T ia receptor endocytosis in 
C0S7 cells (GRK- and arrestin-deficient) was indistinguishable from that found in 
HEK293 cells which endogenously express GRKs and arrestins at relatively high levels
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(Zhang et al., 1996; Menard et al., 1997). It could be argued that the prefeired 
internalisation pathway of GPCRs is GRK- and p-arrestin-dependent and that the 
presence of dominant negative inhibitors drives internalisation via alternative endocytic 
pathways. Indeed, it has been observed that sequestration of the m2 muscarinic and 
ATia receptors was augmented by overexpression of GRKs and arrestins (Zhang et al., 
1996; Schlador and Nathanson, 1997).
The idea that GPCRs sequester via clathrin coated pits was initially suggested by early 
investigations of P2-AR internalisation, in which agents which disrupted clathrin coat 
assembly (e.g. hypertonicity treatment, cytosolic acidification, intracellular K+ 
depletion, temperature reduction, and reduced cellular ATP) blocked internalisation 
(Chuang et al., 1980). This hypothesis was further established with the development of 
immunocytochemical techniques which revealed the subcellular localisation of agonist- 
occupied p2-ARs with the transferrin receptor (von Zastrow and Kobilka, 1992). More 
recently, the use of GTPase defective dynamin mutants (which inhibit the budding off 
of CCVs) has proved to be effective in blocking the p-arrestin-dependent internalisation 
of GPCRs such as the ATiaR and P2 -AR (Zhang et al., 1996). The discovery that p- 
arrestins possess domains for binding clathrin and the p2-adaptin subunit of the clathrin 
adapter, AP-2, has provided further evidence for a p-arrestin/clathrin internalisation 
pathway (Goodman etal., 1997; Laporte et a l, 1999, 2000).
Although it seems that the majority of GPCRs use a clathrin pathway for internalisation, 
which is either dependent or independent of arrestin, some exceptions have been noted. 
Internalisation of the N-formyl peptide receptor was shown to be independent of 
arrestin, dynamin, and clathrin in HEK293 cells (Gilbert et ah, 2001), Sequestration via 
non-coated vesicles such as caveolae has also been observed for the endothelin A 
receptor in transfected COS cells (Chun et al., 1994), the B2 bradykinin receptor in 
DDTl MF-2 cells (de Weerd and Leeb-Lundberg, 1997), and for the muscarinic 
receptors in human fibroblasts (Raposo et a l, 1987).
Recent research into p-arrestin dependent internalisation of GPCRs has also revealed 
striking differences in the ability of the P-arrestin isoforms to bind GPCRs. Initially 
these findings were observed in in vitro binding assays with purified proteins. Studies
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with translated visual arrestin protein demonstrated that it bound rhodopsin in 
preference to the (32-adrenergic and m2 muscarinic receptors, whereas purified p- 
arrestins bound the p2-AR and m2 muscarinic receptor in preference to rhodopsin 
(Attramadal et a l, 1992; Lohse et al., 1992; Gurevich et a l, 1993, 1995). Moreover, p- 
arrestin 1 was shown to exhibit a 2.5-fold greater binding affinity to the p2 -AR than p- 
arrestin 2, and p-arrestin 2 bound to the m2 muscarinic receptor with a 1.5-fold greater 
affinity than p-arrestin 1 (Gurevich et al., 1995). More recently, Oakley and coworkers 
(2000) showed that the specificity in the interactions of arrestins with GPCRs could also 
be observed in intact cells. They identified two classes of GPCRs, designated A and B, 
that differed in their affinities for the arrestin isoforms. Class A receptors, such as the 
p2 -AR, p-opioid receptor, endothelin A receptor, DIA dopamine receptor, and the om- 
AR, bound p-arrestin 2 with higher affinity than P-arrestin 1, and did not interact with 
visual arrestin. Conversely, class B receptors (ATjaR» neurotensin receptor 1, 
vasopressin V2 receptor, TRH receptor, and substance P receptor) bound both p-arrestin 
isoforms with similar high affinities and also interacted with visual arrestin. The 
different physiological roles of the p-arrestin isoforms were further defined in 
experiments examining the internalisation of the class A receptor, p2 -AR, and the class 
B receptor, ATiaR, in mouse embryonic cell lines lacking expression of p-arrestin 1, p- 
arrestin 2, or both (Kohout et aL, 2001). Analysis of agonist-stimulated pz-AR 
sequestration in the P-arrestin 2 knockout cells was significantly impaired (87% 
reduction) compared to wild type cells, whereas internalisation in the p-arrestin 1 
knockout cells was not compromised. Comparison of the ability of the two p-arrestin 
proteins to sequester the p2 -AR revealed that P-arrestin 2 bound to the receptor with a 
100-fold higher affinity than P-arrestin 1. Investigation of ATia receptor internalisation 
showed that p-arrestins 1 and 2 could be substituted for each other in the sequestration 
of the receptor, and internalisation was only significantly impaired when the receptor 
was expressed in cells lacking both p-arrestin isoforms (82% reduction).
The binding of p-arrestin isoforms to agonist-activated, GRK-phosphorylated GPCRs is 
thought to involve the simultaneous interaction of the p-arrestin protein with two 
regions of the receptor (Gurevich et al., 1993; 1995). The amino-terminal activation 
recognition domain of p-arrestin recognises the agonist-activated state of GPCRs while
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the amino-terminal phosphorylation-récognition domain is thought to interact with the 
GRK-phosphorylated serine and threonine residues of the intracellular loops and 
carboxyl termini.
Extensive investigation has identified the carboxyl tail as the main site of P-arrestin 
binding for many GPCRs, although direct interaction between the third intracellular 
loop and p-arrestin has been reported for the m2 and m3 muscarinic receptors, the a 2 A- 
AR (Wu et al., 1997), and the 5HT2a receptor (Gelber et al., 1999). There does not 
appear to be a universal consensus sequence for p-arrestin binding although the 
phosphorylation of key serine and threonine residues seems to be an important 
prerequisite for P-arrestin binding. Mutation or serial truncation of putative 
phosphorylation sites has been shown to correlate well with loss of p-arrestin 
association for GPCRs such as the ATiaR (Qian et al., 2001), CCR5 receptor (Kraft et 
ah, 2001), and parathyroid hormone receptor (Vilardaga et al., 2002).
The role of the intracellular tail in p-arrestin-dependent internalisation has been 
eloquently demonstrated in studies using a GnRH/TRH tail receptor chimera. Agonist- 
activation of the wild type tail-less GnRH receptor does not induce phosphorylation or 
interaction with p-arrestin, which seems to account for its exceptionally slow kinetics of 
desensitisation and internalisation (Vrecl et aL, 1998; Heding et aL, 1998; Willars et aL, 
1999). In contrast, the rapid sequestration of the native TRH receptor is P-arrestin 
sensitive (Groarke et aL, 1999; Yu and Hinkle, 1999), and truncation of the receptor’s 
C-tail abolished internalisation (Nussenzveig et aL, 1993; Yu and Hinkle, 1999; Drmota 
and Milligan, 2000), thus highlighting the importance of this domain in the receptor’s 
interaction with P-arrestin. The fusion of the TRH receptor C-tail to the mammalian 
GnRH receptor was sufficient to switch its internalisation to a P-arrestin-dependent 
phenotype (Willars et aL, 1999; Heding et aL, 2000). More recently, the sequence 
determinants within the TRH receptor tail responsible for p-arrestin binding have been 
identified as three casein kinase II (CKII) phosphorylation sites. In the GnRH/TRH 
chimera, mutation of the CKII sites resulted in a loss of P-arrestin binding. Similarly, 
incubation with a CKII inhibitor produced the same effect (Hanyaloglu et aL, 2001).
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The carboxyl tails of GPCRs have also been suggested to play a role in the determining 
the stability of receptor/p-arrestin complexes and the cellular distribution of P-arrestins. 
In response to agonist stimulation of the p2 -adrenergic, DIA dopamine, and endothelin 
type A receptors, p-arrestin 2 was observed to translocate to the plasma membrane but 
did not traffic along with the activated receptors. In contrast, activated ATia and 
neurotensin receptors co-intemalised with p-arrestin 2 in endocytic vesicles. The 
switching of the p2 -AR tail for that of the ATiaR, and vice versa, was capable of 
reversing the p-arrestin redistribution pattern of each receptor (Zhang et aL, 1999). 
Moreover, Oakley and coworkers (2000) demonstrated that the differential affinities of 
visual arrestin and the P-arrestins isoforms for class A and class B GPCRs could be 
switched by exchanging their carboxyl tails.
In this chapter, experiments were carried out in an effort to determine the molecular 
mechanisms involved in the agonist-mediated sequestration of both GFP-tagged and 
non-GFP-tagged forms of the prostacyclin receptor. In addition, the chimeric 
prostacyclin receptors possessing the tails of the TRH and p2 -adrenergic receptors were 
used to examine the functional importance of the carboxyl terminal region in regulating 
the pattern of sequestration. The internalisation pathway of each of the IP receptor 
constructs was delineated using various biochemical and immunocytochemical 
techniques.
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4.2 The effect of inhibitors of clathrin-mediated endocytosis on agonist-mediated 
sequestration of the prostacyclin receptor constructs.
Receptor endocytosis via CCVs can be pharmacologically blocked by pre-treatment of 
cells with concanavalin A and hyperosmolar sucrose. Concanavalin A, a plant lectin, 
blocks GPCR endocytosis by binding to cell surface glycoproteins and impairing their 
mobility within the lipid bilayer, without affecting ligand binding or receptor signalling 
(Pippig et aL, 1995; Luttrell et aL, 1997). Hypertonic sucrose inhibits clathrin-mediated 
internalisation by inducing abnormal clathrin polymerisation into empty micro-cages on 
the membrane (Heuser and Anderson, 1989). The effect of these biochemical agents on 
iloprost-induced internalisation of the prostacyclin receptor proteins was examined 
visually by confocal microscopy and quantitatively using biotin labelling experiments. 
Confocal analysis of the immunostained HA-tagged IP receptors, transiently expressed 
in HEK293 cells, demonstrated that pre-treatment of cells with 0.4M sucrose or 
0.25mg/ml concanavalin A effectively blocked agonist-mediated sequestration of each 
construct (Figure 4.1). In the stable cell clones expressing the receptor-GFP proteins, 
the effect of the endocytosis inhibitors was measured quantitatively. Pre-treatment of 
the stable cell clones with sucrose and concanavalin A prior to 1 hour’s challenge with 
IpM iloprost, significantly attenuated receptor endocytosis in each clone (Figure 4.2). 
In IP-GFP cells, agonist alone resulted in a ~40% loss of cell surface receptors after 60 
min, whereas the fi’action of receptors remaining at the plasma membrane after agonist 
treatment in cells pre-exposed to 0.4M sucrose and 0.25mg/ml concanavalin A was 91 ± 
3% and 80 ± 6% respectively. In the IP-TRH-GFP clone, approximately half of the total 
cell surface receptors had internalised after incubation with IpM iloprost alone, whereas 
in cells pre-treated with sucrose and concanavalin A, the proportion of receptors present 
at the cell surface was 98 ± 10% and 95 + 11% respectively. For the IP-Pa-GFP cell line, 
70 ± 2% of the plasma membrane receptors remained at the cell surface after 60 min 
agonist treatment. In cells pre-incubated with sucrose, 99.6 + 4% of receptors remained 
at the cell surface after agonist treatment, while after concanavalin A treatment 92 ± 6% 
of receptors were at the plasmalemmal surface.
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4.3 Colocalisation of internalised prostacyclin receptor constructs with transferrin 
receptors in endosomal compartments.
To further characterise the internalisation pathway of the prostacyclin receptor proteins 
in HEK293 cells, the receptor-GFP stable cell clones were incubated with Texas Red® 
labelled transferrin, a well known endosomal marker of clathrin-mediated endocytosis 
(Woods et aL, 1989), to determine whether the agonist-internalised receptors 
colocalised with vesicles containing transferrin. In the unstimulated state, the GFP- 
tagged receptors were seen mainly at the cell surface, whereas the transferrin receptors 
localised predominantly to small punctate intracellular compartments which were 
indicative of their presence in endosomal membranes (Figure 4.3a). After 30 min 
incubation with IpM iloprost, a more pronounced green fluorescent signal could be 
detected within the cells in each of the clones. The intracellular distribution of the 
receptors appeared to be similar- to those intracellular vesicles which contained 
transferrin. Dual imaging revealed that many of these vesicles contained both receptor 
and transferrin as seen by the convergence of the green and red fluorescent signals to 
produce yellow fluorescence (Figure 4.3b). Such findings therefore suggested that the 
prostacyclin receptor constructs internalise via clathrin coated pits.
4.4 Association of the p-arrestin isoforms with the GFP-tagged prostacyclin 
receptor fusion proteins.
In order to determine the functional significance of P-arrestins in the agonist-induced 
endocytosis of the prostacyclin receptor, the IP-GFP stable cell clone was transfected 
with native p-airestin 1 (and subsequently immunostained with an anti-p-arrestin 1 
antibody and complementary Alexa^^"^-conjugated secondary antibody) or with a RFP- 
conjugated form of P-arrestin 2. Confocal microscopy was used to study the interaction 
of these proteins in the cells at various timepoints in a 60 min time course of agonist 
stimulation. In addition, the same experiments were performed with the IP-TRH-GFP 
and IP-P2 -GFP cell lines to determine whether the presence of a different carboxyl 
terminal tail altered the receptor’s affinity for the arrestin proteins.
140
In IP-GFP cells, both arrestin isoforms were distributed uniformly throughout the 
cytoplasm in the unstimulated state (Figmes 4,4a and 4.5a). However, the RFP moiety 
which was used to tag p-arrestin 2 displayed a tendency to aggregate, and as a result, 
red puncta of p-arrestin 2 expression were frequently seen in the cells. Upon the 
addition of agonist, the receptor translocated from the plasma membrane to intracellular 
compartments with pronounced cytoplasmic expression after 30 min. The agonist- 
activation of the IP-GFP receptor did not appear to induce a redistribution of p-arrestin 
1 localisation during the time course (Figure 4.4a). Analysis of the separate red and 
green fluorescent images confirmed this; p-arrestin 1 did not translocate to the plasma 
membrane or co-interaalise with the receptor. It could therefore be argued that P- 
arrestin 1 is not involved in IP-GFP internalisation in HEK293 cells. Detecting 
colocalisation of the receptor with P-arrestin 2-RFP was more difficult due to the 
presence of RFP aggregates in the cells. However, iloprost treatment stimulated the 
movement of receptors from the cell surface into intracellular vesicles via a pathway 
which appeared to be independent of p-arrestin 2 (Figure 4.5a). Intracellular vesicles 
containing agonist-induced receptors were readily observed in the cells but none of 
these vesicles could be seen to overlap those containing the RFP-tagged arrestin. The 
possible existence of a p-arrestin 2-specific pathway of IP-GFP internalisation in 
HEK293 cells therefore seems unlikely. Taken together, the data suggested that an 
arrestin-independent mechanism is involved in the sequestration of the receptor in 
HEK293 cells.
In IP-TRH-GFP cells, no change in p-arrestin 1 localisation was detected during the 
time course of agonist stimulation, whereas the receptors rapidly internalised in 
endocytic vesicles (Figure 4.4b). The merged images show that the expression patterns 
of the receptor and arrestin were distinct, indicating that IP-TRH-GFP receptor 
internalisation is independent of p-arrestin 1. Repeating the experiments with p-arrestin 
2-RFP revealed that the agonist-stimulated receptors co-internalised with vesicles 
containing arrestin (Figure 4.5b). Colocalisation could be seen within 5 min of iloprost 
treatment and was maintained throughout the time course. The confocal data therefore 
suggested that IP-TRH-GFP internalisation is p-arrestin 1-independent/p-arrestin 2- 
dependent.
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Analysis of the confocal pictures of IP- Pi-GFP/p-arrestin colocalisation suggested that 
receptor endocytosis proceeded via a pathway not involving p-arrestin 1 (Figure 4.4c). 
Agonist stimulation of the cells induced a diffusion of receptors from the cell surface to 
the cytoplasm while the distribution of p-arrestin 1 expression remained unaffected. In 
cells transfected with P-arrestin 2-RFP, no obvious translocation of arrestin was 
detected during the time course. The internalised receptors appeared to be located in 
vesicles distinct from those containing p-arrestin 2. Accordingly, it would seem that that 
IP-p2 -GFP receptor sequestration is independent of p-arrestins.
4.5 Interaction of the HA-tagged IP receptor constructs with p-arrestin-GFF 
conjugates.
The data from the p-arrestin/receptor-GFP colocalisation experiments were somewhat 
unexpected and it was evident that further analysis was necessary. As previously noted, 
some of the stable cell clones exhibited significant intracellular receptor expression in 
the basal state and this may have obscured the espial of any receptor/p-arrestin 
associations. Additionally, it is possible that the GFP moiety fused to the carboxyl tail 
of the receptors may have altered their affinities for P-arrestins. In an effort to more 
accurately analyse receptor/arrestin interactions, HEK293 cells were co-transfected with 
the N-terminally HA-tagged IP receptors and C-terminally GFP-tagged forms of P- 
arrestin 1 and 2.
In the absence of agonist, expression of the HA-IP receptor was localised primarily to 
the plasma membrane (as detected by the 12CA5 antibody and reciprocal Alexa^^^- 
labelled secondary antibody) whereas p-arrestin 1-GFP was distributed evenly 
throughout the cell cytoplasm. Upon agonist addition, large punctate spots of 
internalised receptor were evident while the scattering of p-arrestin 1-GFP remained 
unaltered (Figure 4.6a). The decoded images show that agonist treatment did not 
promote arrestin translocation or stimulate its co-intemalisation with the receptor, and 
when merged, the red and green signals did not overlap. When the experiments were 
repeated using the p-arrestin 2-GFP construct, no obvious colocalisation could be seen 
with the receptor and arrestin upon agonist stimulation of the cells. p-Arrestin 2-GFP 
appeared to remain localised to the cytoplasm and did not traffic with the HA-IP
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receptor (Figure 4.7a). Small puncta of green fluorescence could be seen in the cells, but 
they did not seem to overlay any of the red spots of endocytosed receptor. The 
requirement of p-arrestin 2 in prostacyclin receptor endocytosis therefore seems 
dubious. The data, in conjunction with the previous observations from the IP- 
GFP/arrestin colocalisation experiments, indicated that p-arrestins are not a prerequisite 
for prostacyclin receptor internalisation in HEK293 cells.
In cells co-expressing p-arrestin 1-GFP and the HA-IP-TRH construct, agonist- 
mediated internalisation of receptor did not appear to have an effect on the cytoplasmic 
diffusion of the arrestin isoform (Figure 4.6b). Examination of the separate red and 
green images revealed that no overlay of the two proteins occurred, thus demonstrating 
that HA-IP-TRH receptor sequestration is independent of p-arrestin 1. In receptor- 
expressing cells transfected with p-arrestin 2-GFP, no obvious agonist-induced 
plasmalemmal localisation of arrestin was observed, but large clusters of green 
fluorescence could be seen in the cells. The spots of arrestin appeared to associate with 
those containing receptor, producing a yellow fluorescent signal when the images were 
merged (Figure 4.7b). It would therefore seem likely that p-arrestin 2 is involved in 
sequestration of the TRH-tailed chimera.
Agonist-mediated internalisation of the HA-IP-P2 receptor did not appear to stimulate 
any noticeable shift in P-arrestin 1-GFP localisation fi’om the cytoplasm to the plasma 
membrane (Figure 4.6c). Moreover, no obvious receptor/arrestin interactions were 
observed, therefore suggesting that HA-IP-P2 receptor sequestration is independent of 
P-arrestin 1. In receptor cells expressing p-arrestin 2-GFP no obvious movement of the 
GFP signal was detected in response to iloprost incubation. None of the red spots of 
internalised receptor appeared to colocalise with the arrestin isoform (Figure 4.7c). It 
would therefore seem unlikely that P-arrestin 2 plays a role in the sequestration of the 
prostacyclin receptor chimera with the P2-AR carboxyl tail. It could therefore be 
proposed that HA-IP-P2 receptor endocytosis in HEK293 cells does not require p- 
arrestins.
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4.6 p-Arrestin colocalisation experiments with full-length TRH and Pz-adrenergic 
receptors.
Control experiments of receptor/arrestin colocalisation were performed using the full- 
length p2 -adrenergic and TRH receptors; two GPCRs which internalise via an arrestin- 
dependent pathway. In confocal studies of HEK293 cells transiently expressing a VSV 
epitope-tagged form of the rat TRH 1 receptor and GFP-conjugated forms of the p- 
arrestin proteins, significant colocalisation could be seen between the receptor and each 
of the arrestin isoforms in response to agonist treatment (Figure 4.8). As anticipated, 
after a 30 min incubation of the cells with lOpM TRH, the receptors sequestered into 
endocytic vesicles containing p-arrestin. In equivalent experiments with the wild type 
p2-AR, a 5 min incubation with lOpM isoproterenol promoted the rapid redistribution of 
P-arrestins from the cytosol to the receptor at the plasma membrane (Figure 4.9). 
Previously published observations have demonstrated that the agonist-activated p2 -ARs 
recruit P-arrestins to the plasma membrane but the receptor/p-arrestin complex 
dissociates at or near the plasma membrane, and the P-arrestins are excluded from the 
receptor-containing vesicles (Oakley et aL, 1999, 2000; Zhang et aL, 1999). In contrast, 
the TRH receptor forms a stable complex with p-arrestins and traffics with them into 
early endosomes upon agonist stimulation (Groarke et aL, 1999; Oakley et aL, 2000).
4.7 Association of P-arrestins with the prostacyclin receptor constructs as 
determined by co-immunoprecipitation experiments.
The potential physical interaction between p-arrestin and the prostacyclin receptor 
proteins in HEK293 cells was further assessed in co-immunoprecipitation assays. The 
HA-tagged forms of the receptor constructs were co-expressed in HEK293 cells with p- 
arrestin 1-GFP or p-arrestin 2-GFP. Transfected cells were then treated with vehicle or 
1 pM iloprost for 5 min before being lysed and immunoprecipitated with the anti-GFP 
antibody. Subsequent immunoblotting with the 12CA5 antibody was performed to 
detect receptor/arrestin co-precipitations. As shown in Figure 4.10a, the association of 
both p-arrestin isoforms with the full-length prostacyclin receptor was detected in both 
unstimulated and agonist treated cells. Somewhat surprisingly, the interaction did not
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appear to be enhanced by iloprost treatment. No co-precipitations were detected when 
the cells were transfected with only vector, receptor, or p-arrestin, thus demonstrating 
that the immuno-reactivities of the two antibodies were specific. Similar results were 
produced when the experiments were repeated with the HA-IP-TRH (Figure 4.10b) and 
HA-IP-P2  (Figure 4.10c) receptors. No obvious agonist-enhanced association of P- 
arrestin with receptor was detected with any of the constructs. Any observed variability 
in the amount of receptor/arrestin co-precipitated seemed merely to reflect the slight 
differences in protein loading on the gels.
Agonist-specific interactions of p-arrestins with GPCRs in intact cells can be difficult to 
assess using standard immunoprécipitation techniques but can be readily determined 
with the use of chemical cross-linking agents which stabilise the complexes prior to 
immunoprécipitation. This approach has been used successfiilly in the study of the 
association of p-arrestins with GPCRs such as the P2 -AR and lutropin receptor (Min et 
aL, 2002; Zhang et aL, 1997). In this study, however, chemical cross-linkers did not 
augment receptor/p-arrestin complex formation in agonist treated cells (data not 
shown). It therefore seemed likely that the receptor/p-arrestin interactions observed in 
this investigation were non-specific. To test this, various control experiments were 
performed. First, the co-immunoprecipitation assays were repeated using less plasmid 
DNA in the transfections to lower expression of the receptor and p-arrestin constructs in 
the cells, and therefore reduce the likelihood of the receptor and P-arrestin proteins 
forming non-specific interactions. An approximate 5-fold reduction in receptor and p- 
arrestin expression (as detected by Western blot analysis of cell lysates) did not 
however prevent receptor/arrestin co-precipitation (data not shown). Secondly, co- 
immunoprecipitation assays were performed using a pooled mixture of receptor-only 
and p-arrestin-only transfected cells to determine whether the receptor/p-arrestin 
complexes were forming in the cell lysate. This did not seem to be the case as no co­
precipitates were detected in these cells (data not shown) suggesting that the receptor/p- 
arrestin complexes formed only in intact cells.
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4.8 Sequestration of the HA-tagged prostacyclin receptor constructs in COS7 cells.
The extent of agonist-mediated GPCR internalisation can be regulated by the cellular 
milieu in which it is expressed. For GPCRs which utilise arrestin-dependent 
mechanisms for internalisation, the rate and extent of internalisation can be affected by 
the cellular levels of endogenous GRKs and P-arrestins (Menard et aL, 1997). For the 
p2 -AR, sequestration was ablated when expressed in cell lines with relatively low levels 
of endogenous GRKs and P-arrestins e.g. COS7 cells. Sequestration could be enhanced 
to levels comparable in HEK293 cells by overexpression of P-arrestin (Menard et aL, 
1997). Conversely, ATia receptor sequestration in COS7 cells and HEK293 cells is 
similar, an observation which suggested that ATiaR internalisation proceeded via an 
arrestin-independent mechanism (Zhang et aL, 1996; Menard et aL, 1997).
The HA-tagged prostacyclin constructs were transiently transfected into COS7 cells to 
determine whether reducing the endogenous complement of GRKs and P-arrestins could 
impede receptor internalisation. Post transfection, the cells were incubated with the 
12CA5 antibody to label the cell surface receptors before being treated with vehicle or 
IpM iloprost for 1 hour and then fixed. Confocal analysis of the immunostained cells 
revealed that the agonist-activated receptors translocated from the cell surface to 
intracellular membranes (Figure 4.11). After 60 min, sequestration comparable to levels 
seen in HEK293 cells was observed with each of the constructs, which indicated that 
GRKs and P-arrestins are not of functional significance in the internalisation of the 
prostacyclin receptors. The transfection efficiency of the COS7 cells with each of the 
constmcts (as determined visually using confocal microscopy) was exceptionally low 
which made it impossible to quantify the extent of receptor sequestration in the cells 
using biotm labelling assays. On the basis of the confocal data, internalisation of the 
prostacyclin receptor proteins seemed unaltered when expressed in COS7 cells.
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4.9 The effect of overexpression of dominant negative dynamin on internalisation 
of the prostacyclin receptors.
Another important tool which has been used to dissect the pathway of GPCR 
internalisation is the expression of dominant negative mutant dynamin proteins. 
GTPase-deficient dynamin mutants such as dynamin-1-K44A have been shown to 
inhibit clathrin-mediated endocytosis in many systems (Zhang et aL, 1996; Lee et aL, 
1998; Gaborik et aL, 2001). To study the potential role of dynamin in internalisation of 
the prostacyclin receptors, the stable cell clones expressing the GFP-tagged receptor 
constructs were transfected with a myc epitope-tagged form of the K44E dynamin 
mutant. The successful expression of the construct in cells was demonstrated by 
Western blot analysis of cell lysates with an anti-myc antibody (Figure 4.12b). The 
effect of the mutant dynamin on receptor sequestration was determined using biotin 
labelling assays; cells transfected with either vector or the mutant dynamin construct 
were treated with vehicle or IpM iloprost for 60 min before biotinylation of the cell 
surface receptors. An inhibitory effect on iloprost-induced sequestration by the dynamin 
mutant was not demonstrable for any of the receptors as seen in the immunoblots 
(Figure 4.12a). These data therefore suggested that internalisation of the prostacyclin 
receptor constructs is dynamin-independent.
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Figure 4.1
Visualisation of the HA-tagged prostacyclin receptors in HEK293: the effects of 
inhibitors of clathrin-mediated transport on receptor sequestration.
Cells were pre-ti'eated with vehicle (a, b), 0.4M sucrose (c), or 0.25mg/ml 
concanavalin A (d) for 30 min prior to treatment with IpM iloprost (b, c, d) for 60 
min at 37°C. Receptors were visualised by immunostaining with the 12CA5 
antibody. The confocal images shown are from a single experiment which was 
repeated twice. Scale bar = 2.5pM.
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Figure 4.2
Quantification of agonist-mediated internalisation of the GFP-receptor proteins 
in the presence of hyperosmolar sucrose and concanavalin A.
a) The stable cell clones were pre-incubated with vehicle (1,2), 0.4M sucrose (3), or 
0.25mg/ml concanavalin A (4) prior to IpM iloprost exposure (2, 3, 4) for 60 min at 
37°C. Cell surface glycoproteins were subsequently labelled with biotin and the 
receptors were immunoprecipitated and visualised as detailed in section 2.7.5. A 
representative blot from three individual experiments is shown.
b) Densitometric scanning of the biotin blots was used to quantify the levels of cell 
surface receptors. The values shown represent mean ± S.E.M. for three experiments, 
with the levels of cell surface receptors observed in the absence of agonist set at 
100%.
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Figure 4.3
Internalisation of GFP-tagged prostacyclin receptors into vesicles in close 
apposition to those containing transferrin.
The stable cell clones were pre-labelled with Texas Red® transferrin for 30 min to 
allow for uptake into transfenin receptor-containing vesicles. After washing, cells 
were treated with vehicle (a) or IpM iloprost (b) for 30 min at 37°C. Imaging of 
each cell clones revealed that the receptor (green) and transferrin (red) signals 
overlapped after the addition of agonist (observed as yellow). Similar results were 
obtained fi*om two further experiments. Scale bar -  lOpM.
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Figure 4.4
Interaction of the stably expressed prostacyclin receptor-GFP fusion proteins 
with transiently introduced p-arrestin 1 in response to agonist exposure.
a) The tiafficking of the IP-GFP receptors (green) over a 60 min time course of 
agonist treatment was monitored in cells transiently expressing native p-arrestin 1, 
immunologically stained red. Merging of the fluorescent signals showed that the 
proteins localised in separate cellular compartments. The confocal images shown are 
representative of three separate experiments.
b) Examination of the merged confocal images revealed no detectable colocalisation 
between the sequestered IP-TRH-GFP receptors (green) and the transiently 
expressed p-arrestin 1 (red) during the time course. Similar results were produced 
with two further experiments.
c) IP-P2-GFP receptor (green) sequestration proceeded via a pathway which 
appeared to be independent of P-arrestin 1 (red). As shown in the confocal images 
for all the timepoints of iloprost incubation, the red and green signals were 
differentially located. The images shown were similar to those produced from two 
further experiments.
Scale bar = 2.5pM.
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Figure 4.5
Agonist-mediated interactions of the stably expressed prostacyclin receptor- 
GFP fusion proteins with transiently introduced P-arrestin 2-RFP.
a) Agonist-stimulated trafficking of IP-GFP receptors (green) was observed in cells 
transiently transfected with p-arrestin 2-RFP (red). No obvious colocalisation of the 
proteins was observed during the 60 min agonist incubation as determined from 
analysis of the merged images. Two further experiments produced similar data.
b) Following transient expression of p-arrestin 2-RFP (red) into the IP-TRFI-GFP 
cells (green), colocalisation of the two proteins (yellow) was observed upon the 
addition of agonist and was maintained for the duration of the time course.
c) Agonist stimulation of the IP-P2 -GFP cells (green) did not seem to induce a 
redisti'ibution of p-arrestin 2-RFP (red) to the receptors. The merged images reveal 
that the sequestered receptors were located in vesicles distinct from those which 
contained the airestin protein at all timepoints of agonist stimulation. The confocal 
data shown are representative of three individual experiments.
Scale bar = 2.5pM.
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Figure 4.6
Confocal analysis of HEK293 cells transiently expressing the HA-tagged 
prostacyclin receptor constructs in conjunction with GFP-Iabelled p-arrestin 1.
a) In cells co-expressing the HA-IP receptor (red) and P-arrestin 1-GFP (green) 
constructs, agonist-activated receptors sequestered into intracellular compartments 
distinct from those containing P-arrestin 1-GFP. The images from one 60 min 
agonist time course is shown. Similar data was produced from two additional 
experiments.
b) Agonist stimulation of HA-IP-TRH receptors (red) did not trigger the recruitment 
of P-arrestin 1-GFP (green) to the plasma membrane. The confocal images reveal 
that the two signal did not overlap during the 60 min time course. Two further 
experiments produced similar results.
c) Sequestered FIA-IP-P2 receptors (red) did not form any noticeable interaction with 
the co-transfected P-arrestin 1-GFP construct (green). The merged confocal images 
of the 60 min agonist incubation demonstrate that the signal localised in differential 
intraceliulai' structures. The images shown represent one experiment which was 
performed three times.
Scale bar = 2.5pM.
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Figure 4.7
Confocal analysis receptor/arrestin interactions in HËK293 cells co-expressing 
the HA-tagged prostacyclin receptor constructs and p-arrestin 2-GFP.
a) HA-IP receptors (red) showed no obvious colocalisation with P-arrestin 2-GFP 
(green) upon agonist activation of the receptors. The dual images of the various 
agonist timepoints reveal that the two proteins did not associate. Similar 
obsei-vations were made with two further experiments.
b) Visualisation of the distiibution of agonist-sequestered HA-IP-TRH receptors 
(red) reveal that receptors co-internalised with p-arrestin 2-GFP (green). Significant 
colocalisation of the two signals (yellow) can be seen at all timepoints of agonist 
treatment. The images shown are representative of one experiment which was 
performed three times.
c) Agonist-mediated internalisation of the HA-IP-P2  receptors (red) proceeded via a 
pathway which was independent of p-arrestin 2-GFP (green). Analysis of the 
confocal images showed that no visible association of the two proteins was evident 
during the agonist time course. Two further experiments produced similar 
obsei*vations.
Scale bar = 2.5 pM.
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Figure 4.8
Control experiments: Cellular trafficking of the rat TRH-1 receptor with P~ 
arrestins.
a) HEK293 cells were co-transfected with a VSV-tagged TRH receptor (red) and p- 
aiTestin 1-GFP (green). In the unstimulated state, the two signals were differentially 
localised. After a 30 min exposure to lOpM TRH, the sequestered receptors co- 
intemalised with p-arrestin 1-GFP (yellow). A further experiment produced similar 
findings.
b) In cells co-expressing the VSV-tagged TRH receptor (red) and p-arrestin 2-GFP 
(gieen), significant colocalisation of the two proteins in intracellular vesicles could 
be seen after 30 min of agonist treatment. Similar observations were made in one 
further experiment.
Scale bar = 2.5pM.
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Figure 4.9
Control experiments: Agonist-activation of the pi-AR promotes translocation of 
p-arrestins to the plasma membrane.
a) In the basal state, the immunostained P2 -AR (red) was localised at the plasma 
membrane whereas p-arrestin 1-GFP (green) was distributed diffusely throughout 
the cytoplasm. Within 5 min of treatment with 10 pM isoproterenol, agonist- 
activated receptors had triggered the translocation of p-arrestin 1-GFP to the 
plasmalemmal surface. A similar result was produced when the experiment was 
repeated.
b) In unstimulated cells the P2 -AR (red) and p-arrestin 2-GFP (green) were 
differentially located. Agonist stimulation of the P2-AR induced the redistribution of 
P-airestin 2-GFP from the cytoplasm to the agonist-activated receptors within 5 min. 
One additional experiment produced similar results.
Scale bar = 2.5pM.
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Figure 4.10
Co-immunoprecipitation of the HA-tagged prostacyclin receptors with p- 
arrestins.
HEK293 cells were transfected with the HA-IP (a), HA-IP-TRH (b), and HA-IP-pz 
(c) receptor constructs in conjunction with either the p-arrestin 1-GFP or P-arrestin 
2-GFP plasmids. Cells were incubated with or without IpM iloprost for 5 min at 
37°C. Cells were then lysed and the p-arrestin constructs were immunoprecipitated 
with the anti-GFP antibody and the presence of receptor in the immunoprecipitates 
was detected with the 12CA5 antibody following SDS-PAGE and immunoblotting. 
Co-precipitated receptors were detected as immuno-reactive species of ~40 kDa. No 
signal was detected in cells transfected with receptor, P-arrestin, or empty vector 
alone.
165
Figure 4.10
Mr(x 10^)
a)
IP: Anti-GFP 
Blot: 12CA5
Receptor mm— 50— 35
Receptor + 
P-Arrestin 1-GFP 
p-Arrestin 2-GFP 
Agonist (5 min)
+ +  
+ + + s ?f
b)
IP: Anti-GFP 
Blot: 12CA5
Receptor
Receptor 
P-Arrestin 1-GFP 
P-Arrestin 2-GFP 
Agonist (5 min)
EHEU:
+ + + +
+ + -  -
-  +  +  
-  +  -  +
+
n
2.
I
c)
IP: Anti-GFP 
Blot: 12CA5
Receptor brf ‘ ■ 50
— 35
Receptor + 
p-Arrestin 1-GFP 
P-Arrestin 2-GFP 
Agonist (5 min)
+ + + +
+ + -  -
-  +  +  
-  +  -  +
+
n
&
•S'
»

Figure 4.11
Agonist-mediated internalisation of the HA-tagged prostacyclin receptors in the 
GRK- and P-arrestin-defîcient COST cell line.
COST cells were transiently transfected with the HA-IP, HA-IP-TRH, and the HA- 
IP-p2 receptor constructs. Cell surface receptors were antibody labelled with the 
12CA5 antibody prior to treatment with vehicle or IpM iloprost for 60 min. 
Confocal analysis of the immunostained receptors revealed that each of the 
consti'ucts exhibited significant intracellular localisation in response to agonist. The 
images shown are from one experiment which was repeated twice with similar 
results.
Scale bar = 2.5pM.
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Figure 4.12
Effects of K44E-dynamin overexpression on agonist-induced sequestration of 
the prostacyclin receptor-GFP fusion proteins.
a) The stable cell lines transiently tiansfected with empty vector (1, 2) or K44E- 
dynamin (3) were stimulated with either vehicle (1) or IpM iloprost (2, 3) for 60 
min. The cell surface receptor expression was detected using biotin labelling assays 
as described in section 2.7.5. The immunoblots shown are representative of two 
separate experiments.
b) A representative Western blot of lysates from receptor-expressing cells 
transfected with empty vector (1) or myc-tagged dynamin-K44E (2) and 
immunoblotted with an anti-myc antibody.
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4.10 Discussion
Agonist-induced GPCR internalisation is a multi-step process. In the “classical” 
pathway of GPCR internalisation, GRK- and/or second messenger kinase-mediated 
phosphorylation of the receptor facilitates the binding of p-arrestins thereby uncoupling 
the receptor from G protein and promoting receptor sequestration via clathrin coated 
vesicles (Ferguson and Caron, 1998). To date, it appears that most GPCRs studied 
follow this paradigm, but notable exceptions have been observed. Numerous 
investigations have proposed that the pathway by which a given GPCR internalises is 
not only governed by receptor structure and activity, but by the cellular environment in 
which it is expressed. In this investigation, various biochemical assays in concert with 
immunocytochemical techniques were used to delineate the endocytic pathway used by 
the prostacyclin receptor, and its chimeric forms, in HEK293 cells. Whilst in the midst 
of this investigation, Smyth and coworkers (2000) reported that the native prostacyclin 
receptor exhibited a clathrin-dependent, arrestin-independent internalisation pattern in 
HEK293 cells. Similar findings are reported in this chapter.
Pharmacological agents such as hyperosmolar sucrose and concanavalin A are known to 
disrupt receptor internalisation via clathrin coated pits (Heuser and Anderson, 1989; 
Pippig et al.y 1995). Pre-treatment of HEK293 cells transiently expressing the HA- 
tagged IP receptor constructs with sucrose or concanavalin A significantly reduced 
agonist-mediated internalisation of the receptors as monitored confocally (Figure 4.1). 
A similar result was observed with the GFP-tagged forms of the receptors; biotin- 
labelling experiments showed that receptor internalisation was substantially reduced in 
the presence of sucrose and concanavalin A (Figure 4.2). To further investigate the 
nature of the vesicles into which the receptors were internalised, the receptor-GFP 
stable cell clones were incubated with Texas Red® transfeiTin. Transferrin is 
internalised constitutively, along with the transferrin receptor, via clathrin coated pits 
into early endosomes through a recycling pool and then back to the plasma membrane 
(Woods et a l, 1989; Ghosh et a l, 1994). In unstimulated cells the receptors and 
transferrin were compartmentalised separately. After 30 min of iloprost exposure, an 
overlap of the red and green signals was evident as demonstrated by the appearance of 
yellow fluorescence (Figure 4.3) thus indicating the vesicles containing the two proteins
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were in close proximity. Taken together, these data suggested that the receptors traffic 
via a clathrin coated vesicular pathway.
Evidence from numerous GPCR studies has indicated that clathrin-mediated 
endocytosis of receptors proceeds primarily via an arrestin-dependent pathway. It 
therefore seemed likely that similar molecular mechanisms were involved in the CCV 
trafficking of the prostacyclin receptors. Direct monitoring of fluorescently-labelled 
GPCRs and P-arrestins in intact cells has been used to study the arrestin-dependent 
sequestration of GPCRs including the P2 -AR, proteinase-activated receptor, TRH 
receptor, and chemokine CXCR4 receptor (Barak et ah, 1997b; Dery et ah, 1999; 
Groarke et al., 1999; Orsini et al., 1999).
A similar approach was used to characterise the endocytic pathway of the prostacyclin 
receptor; confocal microscopy was used to visualise the interactions of the p-arrestin 
isoforms with the receptor constructs in intact cells. In colocalisation studies, agonist- 
mediated internalisation of the full-length GFP- and HA-tagged forms of the receptor 
did not promote the redistribution of either P-arrestin isoforms in the cells, thus 
demonstrating that receptor sequestration was primarily arrestin-independent (Figures 
4.4a, 4.5a, 4.6a, 4.7a). Smyth and coworkers (2000) reported similar findings; they 
noted that co-transfection of receptor-expressing HEK293 cells with p-arrestin 1 did not 
increase iloprost-stimulated sequestration. Moreover, expression of a dominant negative 
mutant form of p-anestin 1 did not reduce receptor endocytosis. They concluded from 
these observations that prostacyclin receptor internalisation is likely arrestin- 
independent. The group did not, however, investigate the role of P-arrestin 2 in receptor 
sequestration. Therefore, the data cannot rule out the possible involvement of an 
anestin-dependent pathway altogether. Similar to data presented in this chapter, Smyth 
et al. (2000) did report that reagents such as hyperosmotic sucrose or concanavalin A 
could inhibit endocytosis thus demonstrating that prostacyclin receptor internalisation is 
clathrin-mediated.
To ascertain the functional importance of the carboxyl terminal domain in conferring 
arrestin insensitivity to the prostacyclin receptor, arrestin colocalisation studies were 
performed with the chimeric prostacyclin receptors which possessed the intracellular C-
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tail sequences of the rat TRH-1 and human p2 -adrenergic receptors. The agonist- 
induced internalisation of the native TRH and p2 -adrenergic receptors has been shown 
to be p-arrestin-mediated (Groarke et aL, 1999; Yu and Hinkle, 1999; Zhang et al., 
1996; Ferguson et al., 1996). Furthermore, the carboxyl terminal domains of the 
receptors appear to contribute to the receptor/arrestin interactions (Willars et al., 1999; 
Heding et al., 2000; Zhang et al., 1999; Oakley et al., 1999, 2000). It is therefore likely 
that the switching of the carboxyl tail would direct receptor trafficking via an arrestin- 
dependent pathway.
In the IP-TRH-GFP cells, autofluorescent detection of the receptor and p-arrestin 2 
isoform revealed significant colocalisation of the signals upon the addition of agonist to 
the cells (Figure 4.5b). Similarly, the GFP-tagged form of p-arrestin 2 co-internalised 
with the HA-tagged receptor in intracellular vesicles after iloprost exposure (Figure 
4.7b). However, the chimeric receptor did not appear to exhibit any capacity to interact 
with the P-arrestin 1 isoform; no visible mobilisation of the cytoplasmic p-arrestin 1 
isoform could be seen in the confocal images for the duration of agonist treatment 
(Figures 4.4b, 4.6b). Taken together, the data were somewhat unexpected. The TRH tail 
has been shown to confer its p-arrestin sensitivity to the mammalian tail-less GnRH 
receptor (Willars et al., 1999; Heding et al., 2000). Furthermore, Oakley and coworkers 
(2000) identified the TRH receptor as a class B GPCR, which bind both p-arrestin 
isoforms with similar high affinities. Using chimeric receptor models, they also 
demonstrated that the C-tail played an important role in regulating p-arrestin binding. 
Contrary to Oakley’s model, the TRH-tailed prostacyclin receptor chimeras did not 
exhibit the TRH receptor’s affinity for binding both P-arrestin proteins as readily 
observed in control experiments with a VSV-tagged form of the TRH receptor (Figure 
4.8). Intriguingly, Hanyaloglu and coworkers (2001) reported a similar anomaly with a 
chimeric form of the mammalian GnRH receptor expressing the C-tail sequence of the 
p-arrestin-sensitive catfish GnRH receptor. They noted that the sequestration properties 
of GnRH/catfish-GnRH tail chimera were the same as the wild type mammalian 
receptor i.e. it internalised independently of P-arrestins. Presumably, the carboxyl 
terminal domain in conjunction with other intracellular receptor domains determines the 
GnRH receptor’s capacity to bind arrestin. It could therefore be argued that multiple
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intracellular domains would have to be swapped in order to switch the endocytic 
phenotype of the prostacyclin receptor to that of TRH receptor.
The confocal data of the receptor/p-arrestin interactions with the p2 -AR-tailed chimeras 
demonstrated that there was no apparent agonist-induced redistribution of arrestins to 
the plasma membrane. Moreover, the internalised receptors were located in endocytic 
vesicles which were distinct from those containing the arrestins (Figures 4.4c, 4.5c, 
4.6c, 4.7c). It could therefore be concluded that the presence of the p2 -AR carboxyl 
terminal domain failed to confer arrestin binding to the receptor. Confocal analysis of 
native p2 -AR trafficking has revealed that agonist stimulation triggers the translocation 
of both P-arrestin isoforms to the plasma membrane. However, the redistributed P- 
arrestins are confined to the periphery and do not co-intemalise with the receptor 
(Zhang et al., 1999). A similar pattern of receptor/arrestin interactions was observed in 
the control experiments with the wild type p2 -AR and GFP-tagged p-arrestins in this 
chapter (Figure 4.9). Using chimeric receptor strategies, some studies have suggested 
that the p2-AR C-tail is the critical domain in determining the association and stability 
of receptor/arrestin complexes (Zhang et al., 1999, Oakley et al., 1999, 2000), whereas 
several investigators have intimated that p-arrestin interactions with the P2 -AR involve 
multiple receptor domains including the receptor carboxyl terminus; Jockers et al. 
(1996) showed that several intracellular domains including the first and second 
intracellular loops and the carboxyl tail of the P3-AR had to be swapped with the 
equivalent domains of the P2-AR to establish a sequestration phenotype of the wild type 
P2-AR. Furthermore, p-arrestins have been shown to facilitate the sequestration of P2 - 
AR mutants lacking the carboxyl tail sequences (Ferguson et al., 1996). The data from 
the colocalisation experiments would suggest that the P2 -AR C-tail has little functional 
importance in augmenting the prostacyclin receptor’s affinity for P-arrestin. It remains 
to be seen whether the substitution of further intracellular domains would transform 
receptor endocytosis to a p2 -AR-like phenotype.
The interpretation of confocal data can be subjective. It therefore seemed appropriate to 
use an additional method to further analyse arrestin interactions with the prostacyclin 
receptor constructs. Co-immunoprecipitation assays were carried out to detect the 
association of the HA-tagged prostacyclin receptors with the arrestin-GFP constructs in
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intact cells. This approach has been used successfully to determine the agonist-enhanced 
binding of p-arrestins to various GPCRs. In this study, each of the IP receptors could be 
co-precipitated with the arrestins, but somewhat surprisingly, these complexes formed 
in an agonist-independent manner, which suggested that these formations were merely 
experimental artefacts (Figure 4.10). Consequently, no significance could be ascertained 
from the co-immunoprecipitation data. Presumably, a more sensitive technique such as 
fluorescence resonance energy transfer (FRET) would be needed to monitor the specific 
interactions of p-arrestins with the prostacyclin receptor proteins. FRET technology is 
an extremely sensitive method for determining the relative proximity of labelled protein 
partners. Recently, it has been used to monitor the real-time interaction of p-arrestins 
with wild type and phosphorylation-deficient chemokine CCR5 receptors in live cells 
(Kraft et ah, 2001).
The cellular complement of P-arrestins and GRKs can significantly affect GPCR 
internalisation. Menard et ah (1997) showed that the extent of pg-AR internalisation in 
various cell lines correlated well with the endogenous levels of GRKs and p-arrestins. 
In COS7 cells which express these proteins at very low levels, Pz-AR sequestration was 
severely attenuated (Zhang et ah, 1996; Menard et ah, 1997) thus demonstrating that 
GRKs and P-arrestins were essential for normal sequestration of the receptor. In this 
investigation, the sequestration of the prostacyclin receptor constructs was examined in 
HEK293 cells which have a much higher endogenous complement of GRKs and p- 
arrestins (Menard et ah, 1997). To determine whether receptor sequestration was altered 
by a reduction in the cellular levels of these endocytic proteins, COS7 cells were 
transiently transfected with the HA-tagged receptors. Confocal analysis of the 
immunostained receptors demonstrated that substantial levels of receptor sequestration 
occurred upon agonist exposure (Figure 4.11). It could therefore be postulated that 
internalisation of the receptor constmcts proceeds via an arrestin-independent 
mechanism, at least when expressed in a p-arrestin-deficient environment. Whether or 
not the main endocytic pathway of the prostacyclin receptor proteins is arrestin- 
independent remains uncertain. The development of cell lines from p-arrestin knockout 
mice have proved to be better models for studying p-arrestin-mediated GPCR 
sequestration (Kohout et ah, 2001). From earlier studies of ATiaR sequestration, it had 
been reported that internalisation in COS 7 cells was identical to that in HEK293 cells
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which suggested that the receptor internalised via an arrestin-independent mechanism 
(Zhang et a l, 1996; Menard et al., 1997). When expressed in the p-arrestin knockout 
cell lines, ATiaR sequestration was not significantly affected in either the p-arrestin 1 - 
knockout or p-arrestin 2-knockout cell lines. However, internalisation in cells lacking 
both P-arrestin isoforms was severely impaired (Kohout et al., 2001) thus demonstrating 
that ATiaR sequestration is primarily via a P-arrestin-dependent pathway, but to a lesser 
extent, it can internalise independently of p-arrestin. Attempts to use these p-arrestin 
knockout cell lines to examine prostacyclin receptor sequestration proved to be 
ineffectual as the cell lines died post transfection.
Clathrin-mediated internalisation of GPCRs requires dynamin. This has been 
demonstrated most effectively with a GTPase-defective K44A-dynamin mutant which 
was found to block internalisation of GPCRs including the p2 -AR, 5 HT2aR, and the 
PARl-R (Zhang et al., 1996; Bhatnagar et al., 2001; Trejo et al., 2000). Co-expression 
of a myc-tagged form of K44E-dynamin in the stable cell lines expressing the IP 
receptor-GFP fusion proteins did not appear to have any noticeable effect on agonist- 
mediated internalisation of the receptors as determined by biotin labelling experiments 
(Figure 4.12a). Thus, the data suggested receptor internalisation was dynamin- 
independent. In a similar investigation, Smyth et al. (2000) reported that trafficking of 
the wild type prostacyclin receptor was only partially reduced by overexpression of the 
K44A-dynamin mutant, indicating that dynamin-independent pathways may also be 
involved in prostacyclin receptor sequestration. Using a K44A-dynamin mutant to 
examine whether GPCR internalisation is dynamin-dependent can, however, be 
unsuitable: early experiments with the m2  muscarinic and ATia receptors showed that 
receptor internalisation proceeded irrespective of K44A-dynamin expression, suggesting 
that internalisation of these receptors was dynamin-independent (Vogler et al., 1998; 
Zhang et al., 1996). However, upon fiirther examination of these findings with a N272 
mutant dynamin, which lacks the complete GTP-binding domain (residues 1-271), and a 
K535M mutant which lacks PIP2 -stimulated GTPase activity, it was finally established 
that both the m2  muscarinic and ATia receptors internalise via a dynamin-dependent 
route (Werbonat et al., 2000). More recently, Gaborik and coworkers (2001) revealed 
that overexpression of the K44A-dynamin mutant could inhibit ATiaR receptor 
endocytosis at physiological concentiations of agonist, but the effects were reversed at
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saturating concentrations of the ligand. In light of these observations, the possible 
involvement of a dynamin-dependent pathway in prostacyclin receptor sequestration 
cannot be ruled out. Further analysis with different dominant negative dynamin mutants 
would be needed to better characterise the endocytic pathways of the prostacyclin 
receptor and its chimeric forms.
In this chapter, the data presented would suggest that the internalisation of the 
prostacyclin receptor proceeds primarily via a clathrin-mediated, P-arrestin- and 
dynamin-independent pathway. Exchanging the carboxyl tail for the equivalent P2 -AR 
domain did not alter the trafficking properties of the receptor. However, p-arrestin 2 did 
appear to contribute to the endocytosis of the TRH-tailed chimeras. Taken together, it 
would seem that the P2 -AR C-tail sequence is not sufficient to confer P-arrestin binding 
to the prostacyclin receptor whereas the TRH receptor carboxyl tail alone can increase 
receptor/p-arrestin interactions. The binding of P-arrestins to GPCRs is thought to partly 
involve an interaction with phosphorylated Ser/Thr residues in the carboxyl termini 
(Kieselbach et al., 1994). Sequence comparison of the different carboxyl tails has 
revealed that the TRH tail sequence has 21 potential phosphate acceptor sites whereas 
the p2 “AR and wild type C-tails have 14 and 16 respectively. Presumably, the TRH- 
tailed prostacyclin receptors exhibited an increased affinity for p-arrestin due to an 
increase in phosphorylation of the carboxyl tail. Considering that p-arrestin binding to 
agonist-activated, phosphorylated GPCRs is thought to involve the simultaneous 
engagement of the p-arrestin molecule with two distinct regions of the receptor 
(Gurevich et al., 1995), it could be postulated that additional intracellular domains 
would have to be exchanged in order for chimeric prostacyclin receptors to assume the 
endocytic properties of the donor receptors.
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Chapter 5
Signal Regulation of the Prostacyclin Receptor 
and its Chimeric Forms
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Chapter 5 
5.1 Introduction
Agonist binding to GPCRs not only results in G protein activation, but also initiates 
signalling cascades which lead to a reduction in GPCR responsiveness. Receptor 
desensitisation, the waning of GPCR activity in the presence of continuous agonist 
exposure, is an important negative feedback mechanism which protects against acute 
and chronic over-stimulation of receptors. The process of desensitisation can be 
subdivided into homologous and heterologous events. Homologous desensitisation is 
characterised by the attenuation of receptor responsiveness to agonist only, whereas 
heterologous desensitisation is characterised by the loss of receptor responsiveness 
following activation of a heterologous GPCR. The mechanisms of desensitisation 
include the uncoupling of GPCR/G protein interactions, receptor internalisation and 
downregulation (Ferguson and Caron, 1998).
The uncoupling of GPCRs from their cognate G proteins occurs within seconds of 
receptor activation and is mediated through the covalent modification of the receptor’s 
cytosolic domains by protein kinases. The involvement of covalent modification in 
GPCR desensitisation was initially suggested upon notice of the decreased 
electrophoretic mobility of desensitised (3 2 -ARs (Stadel et al., 1982). The modification 
was later identified as phosphorylation as agonist exposure was shown to increase 
receptor phosphorylation. Moreover, the kinetics of desensitisation appeared to mimic 
those of phosphorylation (Stadel et al., 1983a; Strasser et al., 1986). The possible 
involvement of kinases other than second messenger kinases in homologous 
desensitisation of the receptor was first suggested when it was revealed that 
desensitisation of the p2-AR could still proceed in kin" S49 lymphoma cells (which lack 
PKA) (Strasser et al., 1986). The purification of a kinase and the subsequent cloning of 
the cDNA encoding the protein from kin" S49 lymphoma cells, revealed an enzyme 
capable of phosphorylating and desensitising agonist-bound p2 “ARs (Benovic et al., 
1986, 1989). The kinase, termed P-adrenergic receptor kinase, was later identified as a 
member of the GRK family (Pitcher et al., 1998). It has since been well established that 
second messenger-dependent kinases (e.g. PKA and PKC) and/or GRKs play important
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regulatory roles in receptor desensitisation by catalysing the phosphorylation of key 
serine and threonine residues within the intracellular domains of GPCRs (Ferguson and 
Caron, 1998).
For most GPCRs, the third intracellular loop and the carboxyl terminal tail domains 
contain multiple serine and threonine residues which function as substrates for agonist- 
mediated phosphorylation. Some GPCRs such as the a 2-adrenergic and the m2 
muscarinic receptors have relatively short carboxyl tails containing only a few Ser/Thr 
residues but have enlaiged third intracellular loops which are Ser/Thr-enriched. In 
contrast, some receptors including the p2 -AR and rhodopsin have relatively short third 
intracellular loops but have long carboxyl tails with many Ser/Thr sites. Numerous 
investigators have shown that mutation or deletion of these putative phosphorylation 
sites severely impairs receptor desensitisation, a phenomena which has been reported 
for an array of GPCRs including the bradykinin B2 (Blaukat et al., 2001), dopamine D1 
(Lamey et al., 2002), N-formyl peptide (Maestes et al., 1999) and ATia (Smith et al., 
1998) receptors.
Phosphorylation alone is insufficient to mediate receptor desensitisation (Pfister et al., 
1985; Benovic et al., 1987). The arrestin proteins function as co-factors in GPCR 
desensitisation whereby phosphorylation of agonist-occupied receptors promotes 
arrestin binding thus sterically hindering receptor/G protein interactions (Benovic et al., 
1987; Lohse et al., 1990a, b; Pippig et al., 1993). Arrestins preferentially bind to 
agonist-activated and GRK-phosphorylated GPCRs as opposed to second messenger 
kinase-phosphorylated or non-phosphorylated receptors (Lohse et al., 1990a; 1992). For 
the p2 -AR, GRK phosphorylation within the carboxyl tail promotes p-arrestin binding 
whereas PKA-phosphorylated receptors do not bind arrestins (Ferguson et al., 1996; 
Lohse e/ûf/., 1990a, 1992).
In addition to uncoupling receptors from heterotrimeric G proteins, the P-arrestins act as 
endocytic adapter proteins targeting receptors for internalisation. Sequestration was 
originally thought to be the primary mechanism of GPCR desensitisation as it leads to a 
reduction in cell surface receptor population and spatial separation of receptors from its 
effectors (Sibley and Lefkowitz, 1985). However, since desensitisation proceeds more
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quickly than receptor endocytosis, sequestration is now thought to play only a minor 
role in the acute desensitisation of most GPCRs. In A431 cells, pz-AR sequestration 
alone was found to contribute to approximately 20-30% of receptor desensitisation 
while other studies have revealed that blocking receptor internalisation does not affect 
the p2 -AR’s ability to desensitise (Lohse et a l, 1992; Yu and Lefkowitz, 1993; Pippig et 
al, 1995).
Upon prolonged or repeated agonist activation of GPCRs, receptor downregulation 
occurs. The process is characterised by a reduction in the total cellular complement of 
receptors thereby mediating long-term desensitisation. The main pathway of 
downregulation involves the targeting of receptors for degradation via a lysosomal or 
proteasomal mechanism (von Zastrow, 2001) although receptor number can also be 
regulated at the level of gene expression and biosynthesis. In P2-AR downregulation 
studies, a reduction in gene transcription and mRNA translation has been observed in 
response to agonist challenge (Collins et al., 1989; Tholanikunnel and Malbon, 1997). 
In contrast to the processes of G protein uncoupling and sequestration, downregulation 
proceeds over prolonged time frames ranging from hours to days and is also 
characterised by slow or partial reversibility after agonist removal.
Following desensitisation, it is necessary for GPCRs to regain responsiveness to 
extracellular stimuli in order to maintain cellular homeostasis. Receptor internalisation 
appears to be a prerequisite for resensitisation since pharmacological agents which 
block internalisation have been shown to inhibit resensitisation without affecting 
desensitisation (Pippig et al., 1995; Garland et al., 1996; Hasbi et al., 2000). Agonist- 
internalised receptors are thought to traffic via endosomes enriched with a GPCR- 
specific phosphatase (Sibley et al., 1986; Pitcher et al., 1995b) which dephosphorylates 
the receptors prior to their return to the cell surface in the pre-ligand exposed state. In 
the case of the protease-activated receptor family, internalised receptors are targeted to 
the lysosomes for degradation. In this instance, receptor resensitisation is mediated by 
alternative mechanisms including de novo synthesis of receptors and the maintenance of 
an intracellular pool of naïve receptors (Shapiro et al., 1996; Shapiro and Coughlin,
1998),
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The recycling rate of resensitised GPCRs varies, with some internalised receptors 
recycling rapidly to the plasma membrane in a fully sensitised state while others recycle 
relatively slowly. Dephosphorylation appears to be the critical molecular event 
governing the recycling rate (Pippig et al., 1995; Garland et al., 1996). An event 
necessary for dephosphorylation to proceed is the release of bound P-arrestins (Oakley 
et al., 1999). Recent studies have shown that the ability of P-arrestins to co-intemalise 
with desensitised GPCRs regulates the rate of receptor resensitisation. Receptors which 
internalise in vesicles without P-arrestin, such as the p2-AR, were shown to be rapidly 
dephosphorylated and recycled back to the plasma membrane while receptors which 
form stable endocytic complexes with p-arrestin, such as the vasopressin V2  receptor, 
exhibited a slower recycling and resensitisation profile (Zhang et al., 1999; Oakley et 
al., 1999). Switching of the carboxyl tails of the p2 -AR and the vasopressin V2 receptor 
reversed their dephosphorylation, recycling, and resensitisation kinetics (Oakley et al.,
1999). Moreover, the specific determinants within the carboxyl terminal domains which 
mediate the association of P-arrestins with endocytosed receptors were identified as 
clusters of phosphorylated serine residues (Oakley et al., 1999). For the vasopressin V2 
receptor, a cluster of three serine residues located in the carboxyl terminus serve as the 
principle site for GRK-mediated phosphorylation and determine the stability of the 
receptor/p-arrestin complexes. In the p2-AR, which forms only transitory interactions 
with P-arrestin, these putative phosphorylable clusters are notably absent from the 
carboxyl terminal domain (Oakley et al., 1999).
In this chapter, the regulation of prostacyclin receptor signalling was examined. Assays 
of G protein coupling and sequestration were used to determine the desensitisation and 
resensitisation properties of the GFP-tagged form of the receptor. Furthermore, the role 
of receptor phosphorylation in desensitisation and sequestration was investigated. To 
assess the role of the receptor’s carboxyl terminal tail in these processes, identical 
experiments were performed with the chimeric prostacyclin receptors possessing the 
carboxyl tails of the TRH and p2 -adrenergic receptors.
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5.2 Agonist-mediated desensitisation of the GFP-tagged prostacyclin receptor
constructs.
To examine the agonist-mediated desensitisation properties of the prostacyclin receptor- 
GFP fiision proteins, the cell lines were pre-exposed to vehicle or lOOnM iloprost for 10 
min, in the presence of ImM IBMX, and then re-exposed to increasing concentrations 
of iloprost for 30 min (Figure 5.1). For the IP-GFP receptor, desensitisation was 
characterised by an approximate 80% reduction in maximal adenylyl cyclase activity 
with no observable change in ECso value compared to non-desensitised cells. In the IP- 
TRH-GFP receptor-expressing cells, after pre-treatment with iloprost, maximal adenylyl 
cyclase activity decreased by -40% with no significant shift in ECso value compared to 
control cells. For the IP-(3 2 -GFP receptor, modest attenuation of adenylyl cyclase 
activity was observed after iloprost pre-exposure; agonist pre-treated cells exhibited 
only a 1 0 -2 0 % reduction in maximal signalling output without any notable rightward 
shift in the dose response curve.
From these initial experiments it was evident that the IP-GFP receptor rapidly 
desensitised as demonstrated by the almost complete termination of receptor signalling 
within 10 min of iloprost pre-treatment. For the chimeric receptor proteins, by 
comparison, the loss of receptor responsiveness was less substantial. To determine 
whether the signalling responses of the desensitised receptor chimeras could be further 
diminished, the cells were pre-exposed to lOOnM iloprost for 30 and 60 min intervals 
prior to assays of adenylyl cyclase activity (Figure 5.2). Indeed, in the IP-TRH-GFP cell 
line, a more notable reduction in maximal output (-35% of control values) was 
observed for receptors pre-exposed to iloprost for 30 min. In cells pre-treated with 
agonist for an additional 30 min, no fiirther receptor desensitisation was achieved. 
Similarly, for the IP-p2 -GFP receptor, maximal adenylyl cyclase activity was reduced to 
approximately 50% of control cell values after 30 min pre-treatment with iloprost. A 
more prolonged period of agonist pre-treatment did not induce further signal 
attenuation. The data therefore suggested that desensitisation of the receptor chimeras is 
much slower and less pronounced in comparison to the IP-GFP receptor.
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5.3 The effects of second messenger kinase inhibitors on agonist-mediated 
desensitisation of the prostacyclin receptor-GFP proteins.
The rapid agonist-induced desensitisation of the prostacyclin receptor in HEK293 cells 
has previously been shown to involve PKC phosphorylation of the carboxyl tail (Smyth 
et ah, 1998). Therefore, the effects of second messenger kinase activation on the 
desensitisation of the GFP-tagged prostacyclin chimeras were examined using the PKA 
inhibitor, H89 (Figure 5.3), and the PKC inhibitor, GF109203X (Figure 5.4). Cells, 
incubated in culture medium containing the phosphodiesterase inhibitor IBMX, were 
pre-treated with vehicle or kinase inhibitor prior to challenge with IpM iloprost for 
various timepoints over a 60 min period. Subsequent measurement of cAMP 
accumulation in the stable clones was used to monitor receptor desensitisation. Pre­
treatment of cells with lOpM H89 for 30 min significantly augmented the cAMP 
responses elicited by each of the receptors. In IP-GFP cells, cAMP accumulated rapidly 
within minutes of agonist treatment and reached a plateau after 20 min. In cells pre- 
tieated with H89, intracellular cAMP levels were approximately twice those of non­
treated cells after the 60 min period of iloprost incubation. Similarly, in IP-TRH-GFP 
receptor-expressing cells, H89 treatment induced an approximate twofold increase in 
cAMP accumulation within 60 min of iloprost challenge compared to non-treated cells. 
For IP-P2-GFP cells, a more striking amplification of agonist-mediated cAMP 
production was demonstrated with H89 incubation. In control cells cAMP accumulation 
plateaued within 15 min of iloprost exposure whereas in H89-treated cells intracellular 
cAMP levels continued to rise steadily before reaching a plateau after the 50 min 
timepoint. Overall, an approximate 3.5-fold increase in cAMP generation was 
observable in IP-P2 -GFP cells treated with H89 compared to non-treated cells.
In contrast to previous reports of prostacyclin receptor desensitisation (Smyth et aL, 
1998), PKC inhibition failed to attenuate desensitisation of the IP-GFP receptor. 
Somewhat surprisingly, pre-treatment of IP-GFP cells with 5qM GF109203X did not 
alter the agonist-mediated adenylyl cyclase activity of the receptor (Figure 5.4a). 
Moreover, identical observations were made with the IP-TRH-GFP and IP-P2-GFP 
constructs with GF109203X-treated cells eliciting cAMP responses paralleling those of 
the non-treated cells (Figure 5.4b and Figure 5.4c). Taken together, the data suggested
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that receptor phosphorylation by PKA, but not PKC, is involved in the desensitisation of 
the GFP-tagged prostacyclin receptor constructs.
5.4 The effects of inhibition and activation of PKA and PKC on sequestration of 
the prostacyclin receptor constructs.
For most GPCRs, phosphorylation is a prerequisite for rapid receptor internalisation 
(Ferguson and Caron, 1998). To determine whether second messenger kinase 
phosphorylation is involved in the endocytosis of the prostacyclin receptor proteins, 
receptor trafficking was monitored in the presence of inhibitors and activators of PKA 
and PKC. Confocal analysis of the immunostained HA-tagged IP receptors, transiently 
expressed in HEK293 cells, demonstrated that cells pre-treated with lOpM H89 or 5pM 
GF109203X exhibited receptor sequestration levels comparable to those in non-treated 
cells after 60 min of IpM iloprost exposure (Figure 5.5). Similarly, in the stable cell 
clones expressing the receptor-GFP constructs, quantitative measurement of receptor 
internalisation revealed that neither H89 nor GF109203X pre-exposure blocked agonist- 
stimulated internalisation of the receptors (Figure 5.6).
Heterologous activation of second messenger kinases has been shown to trigger 
internalisation of GPCRs such as the am-AR and 0-opioid receptor in the absence of 
agonist (Awaji et aL, 1998; Xiang et aL, 2001). To determine the effects of PKA and 
PKC activation in promoting sequestration of IP receptor constructs, cells were 
challenged with 5pM forskolin or 5pM PMA for 60 min (Figures 5.7 and 5.8). Confocal 
imaging of the antibody-labelled HA-tagged IP receptors, transiently expressed in 
HEK293 cells, showed that forskolin treatment did not stimulate receptor internalisation 
whereas each of the constructs exhibited modest levels of endocytosis upon treatment 
with PMA. Biotin labelling assays which were used to measure sequestration of the 
GFP-tagged forms of the receptor proteins, revealed that forskolin-treated cells 
exhibited minimal receptor internalisation; the proportion of IP-GFP receptors 
remaining at the cell surface after forskolin challenge was 102% + 3% while for the IP- 
TRH-GFP and IP-P2 -GFP receptors the cell surface receptor populations were 104% ± 
9% and 98% ± 6 % respectively. Cells treated with PMA showed considerable levels of 
receptor internalisation. In IP-GFP cells, 72% ± 5% of the receptor population remained
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at the plasmalemmal surface after 60 min of PMA treatment. Similarly, for the IP-TRH- 
GFP and IP-p2-GFP cell lines, the fraction of cell surface receptors remaining was 65% 
±3%  and 74% ± 6 % respectively.
5.5 Phosphorylation of the GFP-conjugated prostacyclin receptor constructs.
The data from sections 5.3 and 5.4 indicated that second messenger kinase activation 
was of functional importance in the desensitisation and internalisation of the 
prostacyclin receptor proteins. It therefore seemed appropriate to determine whether the 
prostacyclin receptor-GFP constructs were phosphorylated upon agonist binding and if 
second messenger kinases contributed to this process. Earlier investigations by Smyth 
and coworkers (1996) demonstrated that an HA-tagged form of the native receptor, 
expressed in HEK293, underwent rapid agonist-mediated phosphorylation. 
Furthermore, it was shown that the process was, in part, mediated by PKC. Figure 5.9 
shows the time course of phosphorylation of the GFP-tagged IP receptor proteins with 
IpM iloprost. Each of the receptors underwent rapid phosphorylation in response to 
agonist. The kinetics of phosphorylation of each construct were similar; significant 
phosphorylation was detectable within 30 seconds of agonist incubation and was 
maximal within approximately 5 min. In the absence of agonist, a basal level of 
phosphorylation was evident for each receptor. Agonist-mediated phosphorylation of 
the receptors was further examined using inhibitors of PKA and PKC (Figure 5.10). The 
cells were stimulated with IpM iloprost for 10 min in the presence of either lOpM H89 
or 5pM GF109203X. Both inhibitors were found to modestly decrease the agonist- 
induced phosphorylation signals of the three receptor constructs thus indicating that 
agonist-mediated phosphorylation of the receptors may, in part, be mediated by PKA 
and PKC. Furthermore, receptor-independent activation of PKA by forskolin (5qM) and 
PKC by PMA (5pM) also induced phosphorylation of the receptors (Figure 5,10). 
Taken together, the phosphorylation data indicated that each of the prostacyclin 
receptor-GFP proteins are substrates for PKA and PKC phosphorylation.
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5.6 Resensitisation of the prostacyclin receptor-GFP constructs.
The mechanisms responsible for receptor resensitisation are namely recycling of 
intracellular receptors back to the plasma membrane and/or de novo synthesis of 
receptor protein. Both of these mechanisms have been shown to contribute to the 
resensitisation of the prostacyclin receptor in various cell lines. While in platelets and 
HEK293 cells the IP receptor recycles, resensitisation in human fibroblasts and NO 108- 
15 cells requires de novo synthesis (Smyth et aL, 2000; Fisch et aL, 1997; Nilius et aL, 
2000; Krane et aL, 1994). The capacity of the GFP-tagged prostacyclin receptors to 
resensitise after agonist removal was therefore examined. The receptor-expressing 
HEK293 cells were treated with vehicle (control) or lOOnM iloprost for 30 min and 
allowed to recover for either 30 or 60 min in agonist-free medium before adenylyl 
cyclase activity was measured for each condition (Figure 5.11). For the IP-GFP 
receptor, a rapid restoration of Gs coupling occurred after agonist removal in 
desensitised cells. After a 30 min recovery period, the maximal adenylyl cyclase 
stimulation was approximately two thirds of the activity in non-desensitised cells. 
Further resensitisation was evident in cells which were left to recover for an additional 
30 min. After 60 min recovery, the maximal signalling capacity of the receptors was 
~80% of control cell values. In contrast, resensitisation of the receptor chimeras was 
undetectable. In IP-TRH-GFP cells, no obvious restoration of adenylyl cyclase activity 
was seen within 60 min of agonist removal. The level of agonist responsiveness after 60 
min agonist-fr ee conditions was approximately 40% of the maximal activity observed in 
non-desensitised cells. For the IP-pi-GFP receptor, agonist withdrawal failed to bring 
about any amelioration in signalling of the desensitised cells. In fact, a further reduction 
in adenylyl cyclase activity was apparent. The maximal signalling output after the 60 
min recovery period was ~25% of the activity in control cells. Earlier assays had shown 
that desensitisation of the IP-P2 -GFP receptor was characterised by a ~50% reduction in 
maximal adenylyl cyclase activity after 30 min of agonist incubation (Figure 5.2).
To assess whether the differential resensitisation responses of the prostacyclin receptor 
constructs was related to the receptors’ recycling efficiency, biotin labelling 
experiments were used to monitor the return of receptors to the plasma membrane after 
agonist removal. Cells were incubated with IpM iloprost for 60 min to promote
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receptor internalisation. Agonist was then removed and the return of intracellular 
receptors to the cell surface was determined after 30 and 60 min intervals (Figure 5.12). 
Recycling of the IP-GFP receptors was rapid. Setting the level of cell surface receptors 
in non-treated control cells as 100%, the ftraction of receptors at the cell surface after the 
30 and 60 min agonist withdrawal periods was 90% ± 7% and 95% ± 9% respectively. 
By comparison, recycling of internalised receptors back to the cell surface following 
iloprost treatment was not detected for either of the chimeric constructs. The 
plasmalemmal expression of IP-TRH-GFP and IP-P2 -GFP receptors after the 60 min 
recovery period was 45% ± 4% and 68% ± 7% respectively. The results therefore 
indicated that the differences in ability of the prostacyclin receptor constructs to recycle 
is a determining factor in their ability to re-establish agonist responsiveness following 
desensitisation.
The data from the recycling experiments would suggest that the prostacyclin receptor 
proteins exhibit differential intracellular sorting patterns upon activation by agonist. The 
failure of the IP-TRH-GFP and IP-P2-GFP receptors to recycle would indicate that the 
sequestered proteins are retained within endosomal compartments and possibly targeted 
for degradation. On this basis, experiments were carried out to assess the receptors’ 
capacity to be downregulated upon prolonged agonist exposure. The stable cell clones 
were incubated with or without 1 pM iloprost for 8 hours and then lysed. The level of 
receptor protein in the cell lysates was determined by quantitative Western blot analysis 
(Figure 5.13). In IP-GFP cells, 8 hour’s agonist treatment induced a -30% reduction in 
receptor protein. For each of the chimeric receptors, a more substantial decrease in 
receptor protein levels was observable. In iloprost-stimulated IP-TRH-GFP cells an 
approximate 60% reduction was noted while in IP-P2 -GFP cells, receptor protein levels 
were diminished by -70%. Taken together, these findings suggested that the agonist- 
activated chimeric prostacyclin proteins are predominantly sorted via a pathway which 
leads to their eventual degradation whereas the full-length receptor is primarily recycled 
back to the plasma membrane after agonist challenge.
185

Figure 5.1
Desensitisation of the IP-GFP receptor, and IP-TRH-GFP and IP-p2-GFP 
chimeras in intact cells following 10 min agonist pre-exposure.
The IP-GFP (a), IP-TRH-GFP (b) and IP-pa-GFP (c) stable clones were challenged 
with vehicle or lOOnM iloprost for 10 min at 37°C. Cells were then washed three 
times with medium and then re-exposed to increasing concentrations of iloprost for 
30 min at 37°C. The net cAMP accumulation in desensitised cells was calculated by 
subtracting the cAMP accumulation (after pre-exposure) measured at zero time. 
Results for each receptor were normalised to the maximal cAMP accumulation of 
non-desensitised cells. Maximal cAMP accumulation was designated as 100%, The 
data represent the mean ± S.E.M. of three independent experiments which were 
performed in triplicate.
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Figure 5.2
Desensitisation of the chimeric IP receptors in intact cells after prolonged 
iloprost pre-treatment.
The IP-TRH-GFP (a) and IP-p2 -GFP (b) cell lines were challenged with or without 
lOOnM iloprost for 30 or 60 min intervals. The cAMP generated in desensitised cells 
was calculated by subtracting the cAMP accumulated after iloprost pre-exposure at 
zero time. Results for the receptor constructs were normalised to the maximal cAMP 
accumulation of non-desensitised cells with maximal output being set at 100%. The 
data shown are representative of three independent experiments which were 
performed in triplicate.
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Figure 5.3
The effects of FKA inhibition on agonist mediated cAMP accumulation in cell 
lines expressing the GFP-tagged IP receptor proteins.
Cells expressing the IP-GFP (a), IP-TRH-GFP (b) and IP-P2 -GFP (c) constructs 
were incubated in medium containing the phosphodiesterase inhibitor IBMX 
(ImM), prior to treatment with vehicle or lOpM H89 for 30 min. Cells were then 
challenged with 1 pM iloprost for 0-60 min. The cAMP responses are expressed as a 
fraction of the cAMP accumulation in non-treated cells at 60 min (assigned as a 
value of 1). Data are means ± S.E.M. from one experiment which was performed 
thi’ee times.
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Figure 5.4
The effects of PKC inhibition on the agonist-mediated adenylyl cyclase activity 
of the GFP-tagged IP receptors.
In the presence of ImM IBMX, the IP-GFP (a), IP-TRH-GFP (b), and IP-pa-GFP (c) 
cells were pre-treated with or without 5juM GF109203X for 30 min prior to 
challenge with IpM iloprost for up to 60 min. Intracellular cAMP levels are 
normalised to those in non-treated cells at the 60 min timepoint (set as 1). Data 
shown are representative of one experiment which was performed three times.
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Figure 5.5
The effects of second messenger kinase inhibitors on agonist-mediated 
sequestration of the HA-tagged prostacyclin receptor constructs.
Cells were pre-treated with vehicle (a, b), lOpM H89 (c), or 5pM GF109203X (d) 
for 30 min prior to ti*eatment with IpM iloprost (b, c, d) for 60 min at 37°C. 
Receptors were visualised by immunostaining with the 12CA5 antibody. The 
confocal images shown are from a single experiment which was repeated twice. 
Scale bar = 2.5pM.
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Figure 5.6
Quantitative analysis of the effects of PKA and PKC inhibition on iloprost- 
induced internalisation of the GFP-tagged IP receptor constructs.
a) The stable cell clones were pre-incubated with vehicle (1, 2), lOpM H89 (3), or 
5pM GF109203X (4) prior to IpM iloprost exposure (2, 3, 4) for 60 min at 37°C. 
Cell surface glycoproteins were subsequently labelled with biotin and the receptors 
were immunoprecipitated and visualised as detailed in section 2.7.5. Representative 
blots are shown. Similar results were obtained from two further experiments,
b) Densitometi'ic scanning of the biotin blots was used to quantify the levels of cell 
surface receptors. The values shown represent mean ± S.E.M. for three experiments, 
with the levels of cell surface receptors observed in the absence of agonist set at 
100%.
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Figure 5.7
Confocal visualisation of the effects of second messenger kinase activation on 
the sequestration of the HA-tagged IP receptor proteins.
Cells transiently expressing the HA-tagged receptor constructs were incubated with 
vehicle (a), IpM iloprost (b), 5|aM forskolin (c), or 5pM PMA (d) for 60 min at 
37°C. Receptors were visualised by immunostaining with the 12CA5 antibody. The 
confocal images shown are representative of a single experiment which was repeated 
twice. Scale bar = 2.5pM.
195
Figure 5.7
HA-IP HA-IP-TRH HA-IP-P2
a)
b)
c)
d)

Figure 5.8
Quantitative analysis of the effects of exogenous second messenger kinase 
activation on the internalisation of the GFP-receptor proteins.
a) Cells were incubated with vehicle (1), IpM iloprost (2), 5pM forskolin (3), or 
5pM PMA (4) for 60 min at 37°C. Cell surface glycoproteins were subsequently 
labelled with biotin and the receptors were immunoprecipitated and visualised as 
detailed in section 2.7.5. Representative blots are shown. Similar results were 
obtained from two further experiments.
b) Densitometi'ic scanning of the biotin blots was used to quantify the levels of cell 
surface receptors. The values shown represent mean ± S.E.M. for three experiments, 
with the levels of cell surface receptors observed in non-treated cells set at 100%.
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Figure 5.9
Iloprost-induced phosphorylation of the GFP-tagged prostacyclin receptor 
constructs.
Cells were incubated with vehicle (1), or IjiM iloprost for 30 seconds (2), 1 min (3) 
2 min (4), 5 min (5) or 10 min (6). Receptors were then immunoprecipitated as 
described in 2.6.3b. Dried gels were analysed by autoradiography. Data shown are 
representative of one experiment which was repeated twice.
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Figure 5.10
Effects of second messenger kinases on phosphorylation of the IP receptor-GFP 
conjugates.
Cells were pre-ti-eated with vehicle (1, 5, 6), lOpM H89 (3) or 5pM GF109203X (4) 
prior to stimulation with IpM iloprost (2, 3, 4), 5pM forskolin (5) or 5[iM PMA (6) 
for 10 min at 37°C. Representative autoradiographs of the immunoprecipitated 
receptors are shown. Similar results were produced with two further experiments.
198
Figure 5.10
IP-GFP
M r (Xl0‘^ )
—75
—50
1 2 3 4 5 6
IP-TRH-GFP
-5 0
1 2 3 4 5 6
IP-P2-GFP
—75
—50
1 2 3 4 5 6

Figure 5.11
Resensitisation of the GFP-tagged IP receptor proteins following agonist 
removal.
The IP-GFP (a), IP-TRH-GFP (b), and IP-P2 -GFP (c) stable cell clones were 
incubated for 60 min at 37°C in the absence (control) or presence of lOOnM iloprost. 
Cells were then washed to remove agonist and maintained in fresh medium for 30 or 
60 min intervals at 37°C. Adenylyl cyclase activity in cells was then assessed in the 
presence of increasing concentrations of agonist. Net accumulation of intracellular 
cAMP in recovered cells was measured by subtracting the cAMP accumulation 
(after pre-exposure) measured at zero time. Results for each receptor are expressed 
as a percentage of the maximal cAMP accumulation in control cells. The data 
represent the mean ± S.E.M. of thiee independent experiments which were 
performed in triplicate.
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Figure 5.12
Recycling of the sequestered IP receptor-GFP fusion proteins to the plasma 
membrane.
a) Cells were treated with vehicle (1) or IpM iloprost for 60 min at 37°C (2, 3, 4) 
followed by a recovery period of 0 min (2), 30 min (3) or 60 min (4) in agonist-free 
conditions. Cell surface glycoproteins were subsequently labelled with biotin and 
the receptors were immunoprecipitated and visualised as detailed in section 2.7.5. 
Representative blots are shown. Similar results were obtained from two further 
experiments.
b) Densitometric scanning of the biotin blots was used to quantify the levels of cell 
surface receptors. The values shown represent mean ± S.E.M. for three experiments, 
with the levels of cell surface receptors observed in the absence of agonist set at 
100%.
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Figure 5.13
Western blot analysis of IP receptor-GFP constructs: the effects of receptor 
protein expression upon prolonged iloprost incubation.
a) The stable cell clones were treated with vehicle (control) or 1 pM iloprost for 8 
hours at 37°C. Cell lysates were then prepared and subjected to Western blot 
analysis using an anti-GFP antibody. The immunoblots shown are from a single 
experiment which was repeated twice with similar results. Molecular masses are in 
kDa.
b) Densitometric scanning of the immunoblots was used to quantify the levels of cell 
surface receptors. The values shown represent mean ± S.E.M. for three experiments, 
with the levels of cell surface receptors observed in the absence of agonist set at 
100%.
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5.7 Discussion
The GPCR carboxyl terminal domain is primarily a site of agonist-mediated 
phosphorylation and p-arrestin interaction. Therefore, for many receptors, the process of 
desensitisation is dependent upon the integrity of the intracellular C-tail. In this chapter, 
the functioning of the carboxyl domain in the desensitisation of a GFP-tagged form of 
the prostacyclin receptor was examined using the C-tail receptor chimeras, IP-TRH- 
GFP and IP-pz-GFP. Whole-cell adenylyl cyclase assays, which were used to monitor 
Gs coupling, showed that the IP-GFP receptor underwent rapid agonist-mediated 
desensitisation. Thus, the fusion of the GFP moiety to the receptor’s C-terminus did not 
affect the receptor’s ability to desensitise. The degree of receptor desensitisation 
induced in each cell line seemed to correlate well with the potency of iloprost at the 
receptors. For the IP-GFP receptor, at which iloprost was found to be the most potent, 
substantial abrogation of signalling was observed in cells after 10 min iloprost pre­
exposure (Figure 5.1). By comparison, the IP-TRH-GFP and IP-pz-GFP receptors (at 
which iloprost was approximately one order of magnitude less potent) exhibited a more 
modest attenuation of signalling after 10 min agonist pre-treatment (Figure 5.1). 
Therefore, it could be suggested that the reduction in Gg coupling efficiency of the 
chimeric receptors affected the receptors’ capacity to induce full receptor 
desensitisation. The adenylyl cyclase responses of the IP-TRH-GFP and IP-P2-GFP 
receptors were further reduced after a more prolonged period of iloprost pre-exposure 
(Figure 5.2). This increase in desensitisation may have been due to the onset of receptor 
sequestration. It could therefore be argued that the mechanisms involved in acute 
desensitisation of the IP-GFP receptor differ firom those of the receptor chimeras.
Earlier prostacyclin receptor studies have demonstrated that mutant receptors lacking 
the putative PKC phosphorylation sites in the carboxyl terminal domain exhibit minimal 
agonist-mediated desensitisation in HEK293 cells (Smyth et al., 1998). From this 
observation it was suggested that PKC is the major desensitising kinase of the 
prostacyclin receptor. In this chapter, the role of second messenger kinases in the 
iloprost-mediated desensitisation of the GFP-tagged prostacyclin receptor proteins was 
analysed in time courses of cAMP formation in the absence and presence of H89 (a 
PKA inhibitor) and GF109203X (a PKC inhibitor). For each of the constructs, an
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increased accumulation of intracellular cAMP was evident in H89-pre-treated cells 
(Figure 5,3). Surprisingly, PKC inhibition did not appear to have any effects on the 
agonist-mediated adenylyl cyclase activation of the receptors (Figure 5.4). Taken 
together, the data indicated that PKA, and not PKC, is of functional significance in the 
desensitisation of the GFP-tagged prostacyclin receptor and its chimeric forms. The 
explanation for these unexpected observations is unclear. In the studies of Smyth and 
coworkers, prostacyclin receptor desensitisation was assessed in membrane preparations 
while in this investigation the process was examined in live cells. The discrepancy 
between the results reported here and the observations made by Smyth et al. (1998) may 
therefore simply reflect the different experimental conditions which were used to assay 
receptor desensitisation. The ineffectiveness of GF109203X in blocking desensitisation 
of the GFP-tagged prostacyclin receptors may be indicative of the receptors’ inability to 
stimulate PI hydrolysis, and subsequently, activate PKC. Measurement of the receptors’ 
coupling capacity to G q/G n would have to be performed to test this. It could be 
suggested that H89’s effects on the desensitisation responses elicited by the prostacyclin 
receptor constructs were not due to the loss of PKA phosphorylation of the receptors. 
Rather, the inhibition of PKA phosphorylation of downstream effectors such as G 
proteins and/or adenylyl cyclase isoforms may account for the increased cAMP 
production seen in the presence of H89. It is also possible that the GFP adjunct alters 
prostacyclin receptor desensitisation. The fusion of GFP to the receptor’s C-terminus 
may affect receptor signalling by inducing conformational changes in the receptor, 
indkectly altering kinase phosphorylation of key residues within the intracellular 
domains.
While in the midst of this investigation Smyth et ah (2000) reported that second 
messenger kinase phosphorylation was not a requirement for sequestration of the 
prostacyclin receptor. Similarly, in this study, pre-treatment of cells with the kinase 
inhibitors H89 and GF109203X failed to attenuate iloprost-stimulated sequestration of 
the HA- and GFP-tagged forms of the receptors when assessed both visually (by 
confocal analysis) and quantitatively (in biotin labelling assays) (Figures 5.5 and 5.6). 
The data therefore indicated that second messenger kinase phosphorylation plays only a 
minor role in mediating sequestration of the IP receptors. Nevertheless, the data cannot 
rule out a possible involvement of GRKs in receptor sequestration. Previous published 
findings have suggested that prostacyclin receptor sequestration is independent of GRK-
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mediated phosphorylation since overexpression of GRKs did not increase internalisation 
(Smyth et aL, 2000). On this basis, it could be argued that trafficking of the IP receptor 
and the chimeras proceeds primarily via a phosphorylation-independent mechanism. For 
many GPCRs, phosphorylation is a prerequisite for receptor sequestration (Ferguson 
and Caron, 1998). However, phosphorylation-independent trafficking has been reported 
for GPCRs including the rat follitropin receptor (Nakamura et aL, 1998) and chemokine 
CXCR2 receptor (Fan et a/., 2001).
Heterologous desensitisation of GPCRs can involve the phosphorylation of unoccupied 
as well as agonist-bound receptors by second messenger kinases. The process may also 
be associated with an increase in receptor internalisation. Indeed, heterologous 
activation of second messenger kinases has been shown to trigger internalisation of the 
aiB-adrenergic and 8-opioid receptors in the absence of ligand (Awaji et al., 1998; 
Xiang et al., 2001). To determine whether heterologous activation of PKA and/or PKC 
regulated the agonist-independent activities of the prostacyclin receptor constructs, 
receptor sequestration was monitored after pre-treatment of cells with forskolin or PMA 
(Figures 5.7 and 5.8). In confocal experiments and biotin labelling assays, exogenous 
stimulation of PKA by forskolin did not alter the plasmalemmal distribution of 
unoccupied IP receptor proteins. In contrast, exogenous PKC activation by PMA 
promoted considerable internalisation of each of the receptor constructs. The data 
therefore indicated that PKC phosphorylation of the receptors is sufficient to promote 
internalisation. Why GF109203X did not at least partially inhibit iloprost-mediated 
internalisation of the receptors is unclear. It is possible that the diacylglycerol formed 
upon iloprost stimulation of the receptors induces only modest PKC activation. Thus, 
the contribution of PKC to agonist-stimulated receptor sequestration may be 
insignificant. It could also be argued that a GF109203X-insensitive PKC isoform directs 
internalisation of the prostacyclin receptor constructs. Contrary to the hypothesis of 
Smyth et al. (2000), the data presented here cannot rule out the possibility that 
phosphorylation is a pre-requisite for the sequestration of the prostacyclin receptor 
proteins. Notably, the extent of PMA-induced receptor internalisation was less than the 
response mediated by iloprost incubation, indicating that receptor phosphorylation alone 
is unable to elicit a maximal endocytic response. Receptor occupancy may therefore 
promote conformational changes which are essential for endocytosis.
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The prostacyclin receptor, expressed in HEK293 cells, is rapidly phosphorylated in 
response to agonist stimulation (Smyth et al., 1996; 1998). Similarly, the GFP-tagged 
form of the receptor was shown to undergo rapid phosphorylation in response to iloprost 
challenge (Figure 5.9). The presence of the large GFP group at the carboxyl terminus of 
the receptor might have been expected to inhibit agonist-mediated receptor 
phosphorylation but this was not the case. The maintenance of agonist-dependent 
phosphorylation has also been shown for other GPCR-GFP conjugates including the p2 “ 
AR and cAMPl receptor (Barak et al., 1997a; Xiao et al., 1997). As anticipated, a time- 
dependent increase in receptor phosphorylation was also exhibited by the IP-TRH-GFP 
and IP-p2 "GFP constructs m response to agonist treatment (Figure 5.9). Furthermore, 
the time courses revealed that the constructs exhibited similar phosphorylation kinetics. 
In order to determine the role of second messenger kinases in receptor phosphorylation, 
agonist-stimulated phosphorylation was examined in the presence of H89 and 
GF109203X (Figwe 5.10). Pre-treatment with H89, as well as GF109203X, 
significantly diminished agonist-mediated phosphorylation of the GFP-tagged 
prostacyclin receptor. A similar effect was also seen with the receptor chimeras. Thus, 
the data indicated that both PKA and PKC phosphorylate the receptor proteins. In 
further support of these findings, exogenous activation of PKA by forskolin and PKC 
by PMA also induced phosphorylation of the receptors independently of agonist 
activation (Figure 5.10). Previous reports of prostacyclin receptor phosphorylation by 
Smyth and coworkers (1996) suggested that IP receptor phosphorylation is primarily 
catalysed by PKC and not PKA. The reasons for the apparent discrepancy between the 
data reported here and the findings of Smyth et al. (1996) are unclear although the 
presence of GFP at the receptor C-terminus may have modified receptor 
phosphorylation. It could be postulated that GFP itself is acting as a substrate for the 
second messenger kmases. It is impossible to determine from the phosphorylation 
experiments the sites of kinase action, though sequence analysis has shown that each of 
the receptor constructs contains multiple consensus sites for PKA (R-X1.2 -S/T-X) and 
PKC (X-S/T-X-R/K) phosphorylation within their intracellular domains. While it 
appears that second messenger kinases account for a sizeable proportion of the agonist- 
induced phosphorylation response of the receptors, the data does not rule out the 
possibility that other kinases, such as GRKs, regulate the responsiveness of the receptor 
proteins.
206
The fine balance between receptor resensitisation and downregulation of desensitised 
GPCRs determines the magnitude and endurance of a cell’s response to further agonist 
exposure. The fate of the agonist-activated prostacyclin receptor-GFP proteins was 
examined to further characterise receptor regulation. Upon withdrawal of agonist, 
adenylyl cyclase activity in IP-GFP cells was restored to levels comparable to those in 
control cells within a 60 min recovery period (Figure 5.11). Resensitisation of the IP- 
GFP receptor appeared to coincide with the recycling of sequestered receptors back to 
the plasma membrane therefore indicating that a significant number of the recycled 
receptors were fully functional (Figure 5.12). However, no obvious recovery of G» 
coupling was evident in IP-TRH-GFP and IP-P2 -GFP cells after 60 min of agonist-free 
conditions (Figure 5.11). The slow resensitisation of the chimeric receptors was 
associated with their failure to recycle (Figure 5.12). Earlier investigations by Oakley 
and coworkers (1999) revealed that stable association of desensitised receptors with (3- 
arrestins protects the receptor from phosphatases, blocking dephosphorylation and 
resulting in slowed receptor resensitisation. The data from Chapter 4, together with 
published findings by Smyth et ah, (2000), have indicated that prostacyclin receptor 
sequestration occurs independently of (3-arrestins. Therefore consistent with Oakley’s 
hypothesis, it could be argued that P-arrestin-independent trafficking of the IP receptor 
allows for rapid association with the GPCR phosphatases, enabling dephosphorylation 
and the rapid recycling of receptors back to the plasma membrane. Likewise, it could be 
postulated that long-term association of the p-arrestin proteins with the IP-TRH-GFP 
construct impedes receptor resensitisation. In support of this hypothesis, confocal 
experiments demonstrated that the TRH-tailed IP receptors endocytose in complexes 
with p-arrestin 2 (Chapter 4). Furthermore, numerous investigations have confirmed the 
role of TRH carboxyl tail in mediating high affinity binding with P-arrestins (Willars et 
a l, 1999; Heding et a l, 2000; Zhang et a l, 1999; Oakley et a l, 1999,2000). For the IP- 
P2-GFP construct, which was shown to exhibit p-arrestin-independent sequestration 
(Chapter 4), the pattern of receptor resensitisation does not fit the model proposed by 
Oakley and coworkers (1999). The biochemical explanation for this unanticipated result 
remains undetermined. It is known that dephosphorylation is a prerequisite for the 
exocytosis of GPCRs including the P2 -adrenergic, 6-opioid and vasopressin V2 
receptors (Shih et a l, 1999; Hasbi et a l, 2000; Innamorati et a l, 2001). Therefore it 
could be suggested that sequestered IP-P2 -GFP receptors exhibit incomplete
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déphosphorylation. Interactions between the p2-GFP tail and the body of the receptor 
may induce conformational changes which affect the access of phosphatases to 
desensitised receptors. Another possibility is that the internalised IP-P2-GFP receptors 
deviate to an organelle that is not pait of the recycling pathway. For the non-recycling 
vasopressin V2 receptor, sequestered receptors have been shown to diverge from the 
sorting endosomes to the perinuclear compartment where they are retained (Innamorati 
et aL, 2001).
The retention of sequestered GPCRs intracellularly has been suggested to promote 
routing of receptors to the lysosomes (Bremnes et aL, 2000). Consistent with this 
hypothesis, an increased downregulation of the non-recycling IP-TRH-GFP and IP-P2 - 
GFP receptor proteins was detected in comparison to the recycling IP-GFP receptor 
after 8 hour’s of agonist challenge. (Figure 5.13). The different intracellular trafficking 
routes of the full-length prostacyclin receptor and it chimeric forms may be an 
important mechanism underlying the distinct physiological responses mediated by the 
receptors.
In summary, the results show that the GFP-tagged prostacyclin receptor exhibits rapid 
iloprost-induced desensitisation which is reversible upon agonist withdrawal. 
Examination of the underlying mechanisms governing IP-GFP signalling has 
highlighted the critical roles of PKA and PKC in the processes of desensitisation and 
sequestration. Similarly, for the TRH- and p2 -AR-tailed receptor chimeras, second 
messenger kinase phosphorylation was found to be of functional importance in receptor 
regulation. However, comparative analysis of the receptors’ Gs coupling clearly 
demonstrated that the presence of the different carboxyl tails altered the receptor’s 
ability to elicit desensitisation and resensitisation responses. The data would therefore 
suggest that the carboxyl terminal domain of the prostacyclin receptor contributes to 
these processes.
In contrast to findings in this study and those previously reported by Smyth et al. 
(1998), in which prostacyclin receptor desensitisation was analysed in overexpression 
systems, all studies performed with cells naturally expressing the IP receptor describe a 
much slower time course of desensitisation occurring over a period of several hours
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(Krane et aL, 1994; Mimdell and Kelly, 1998; Giovanazzi et aL, 1997; Nilius et aL, 
2000). The slow desensitisation kinetics in natural systems suggest that mechanisms 
different from those described for the cloned prostacyclin receptor are likely to be 
involved. The mechanisms of long-term attenuation of the endogenously expressed IP 
receptor are much less understood although the process is thought to be independent of 
receptor phosphorylation and sequestration (Nilius et aL, 2000). The signalling 
responses of the IP receptor in HEK293 cells may therefore be artefacts of the 
transfection system.
209
Chapter 6
Final Discussion
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Chapter 6
The GPCR superfamily constitutes one of the largest protein families in nature with the 
identification of approximately 2000 members to date. Despite binding and transducing 
signals of a wide range of ligands, all GPCRs share the same basic structure comprising 
an extracellular amino terminal domain followed by a central core domain of seven 
transmembrane helices (connected by three extracellular and three intracellular loops), 
and an intracellular caihoxyl terminal domain. GPCRs mediate their intracellular 
actions through the activation of one or more class of heterotrimeric G protein. As well 
as initiating receptor signalling, agonist binding to GPCRs activates a series of 
signalling events which lead to receptor desensitisation, a process which is characterised 
by a reduction in GPCR responsiveness. The molecular mechanisms of receptor 
desensitisation are primarily the uncoupling of receptors from G proteins and 
sequestration of plasma membrane receptors to intracellular compartments. To maintain 
cellular homeostasis, GPCR responsiveness to extracellular stimuli is restored by the 
process of receptor resensitisation which is achieved mainly through the recycling of 
receptors back to the cell surface in the pre-ligand exposed state and/or shuttling of 
newly synthesised receptors to the plasma membrane. Thus, a co-ordinated balance 
between receptor desensitisation and resensitisation regulate GPCR activity (Ferguson 
and Caron, 1998).
In addition to determining G protein coupling and specificity, the intracellular domains 
of GPCRs are also involved in GPCR regulation. Agonist-mediated phosphorylation of 
residues within the receptor’s cytosolic loops and/or C-tail domain promotes the binding 
of p-arrestins which uncouple GPCR/G protein interactions and target receptors for 
endocytosis in clathrin-coated pits, thereby inducing receptor desensitisation. 
Conversely, the release of bound P-arrestin and dephosphorylation of the receptor’s 
intracellular regions are considered to be essential processes for the resensitisation of 
ligand-activated GPCRs.
For many GPCRs the carboxyl terminal domain is the primary site of agonist-mediated 
phosphoiylation and p-arrestin interaction. Thus, alterations within this region have 
been shown to influence the processes of desensitisation (Blaukat et al., 2001; Lamey et
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al, 2002; Maestes et al., 1999; Smith et al., 1998), sequestration (Fukushima et al., 
1997; Huang et al., 1995; Hukovic et al., 1998), and resensitisation (Oakley et a l, 1999; 
Innamorati et al., 2001). In many of these investigations, point mutations and/or 
receptor truncations have been the most common strategies adopted in the study of C- 
tail function. An alternative strategy is the generation of chimeric receptors. With this 
approach the predicted outcome is either the retention of receptor function or the 
conferment of properties of the donor receptor to the recipient. In this study, chimeric 
GPCRs possessing the intracellular tail regions of the human p2 -adrenergic and rat 
TRH-1 receptors were constructed in order to examine the role of the carboxyl terminal 
region in prostacyclin receptor regulation. Furthermore, C-terminally GFP-tagged forms 
of each receptor were generated, thus providing the opportunity to directly monitor the 
localisation, and trafficking of receptors in response to extracellular stimuli. Earlier 
investigations by Smyth and coworkers (1998, 2000) with a recombinant IP receptor 
construct, overexpressed in HEK293 cells, indicated that the processes of receptor 
desensitisation and sequestration were dependent upon the integrity of the carboxyl tail.
In chapter 3 experiments were performed to characterise the pharmacological properties 
and agonist-mediated trafficking of each receptor construct. Ligand binding analysis 
revealed the GFP-tagged receptors exhibited similar binding affinity for [^H] iloprost 
thus demonstrating that the IP receptor’s carboxyl tail was not a critical factor in agonist 
binding. The ability of the constructs to mediate intracellular signalling was confirmed 
in assays of adenylyl cyclase activity. Moreover, the addition of GFP to the C-terminal 
region did not appear to affect Gg coupling. Iloprost was most potent at the IP-GFP 
receptor, exhibiting an E C 5 0  value similar to that reported earlier for both native and 
epitope-tagged forms of the receptor (Smyth et al., 1996). The lower receptor 
expression in the IP-TRH-GFP and IP-p2 -GFP cell lines may account for the 
observation that iloprost was less potent at stimulating adenylyl cyclase in these stable 
clones. The relationship between agonist potency and receptor density has previously 
been established for GPCRs such as the adenosine A1 and P2 -adrenergic receptors 
(Cordeaux et al., 2000; Whaley et al., 1994). Further desensitisation studies with stable 
cell lines expressing similar receptor densities would be necessary to test this 
hypothesis.
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Agonist-induced sequestration of the receptor-GFP conjugates was initially determined 
by confocal analysis. Direct visualisation of sequestered receptors proved to be 
problematic since each of the selected clones exhibited varying amounts of intracellular 
GFP-derived autofluorescence in the unstimulated state. Despite this, significant 
translocation of plasmalemmal receptors to intracellular compartments could be 
detected in each of the stable cell lines upon agonist incubation. Confocal data 
suggested that the IP-TRH-GFP receptor displayed enhanced internalisation kinetics 
whereas the IP-GFP and IP-P2 -GFP receptors internalised more slowly. Quantification 
of receptor internalisation in biotin labelling experiments further supported these 
observations, demonstrating that internalisation of the p2 -tailed chimera was comparable 
to that of the full-length receptor whereas receptor sequestration was augmented by the 
presence of the TRH receptor carboxyl tail. In internalisation studies of the HA-tagged 
receptor proteins similar results were obtained. Therefore, the presence of a C-terminal 
GFP tag did not alter the internalisation kinetics of the receptors, a phenomena which 
has been reported for other GFP-conjugated GPCRs including the P2 -AR and edgl 
receptor (Kallal et al,, 1998; Liu et a i, 1999).
The native TRH receptor rapidly internalises in response to agonist (Nussenzveig et al., 
1993). From various mutational studies, the determinants of receptor sequestration were 
localised to regions within the receptor’s carboxyl domain (Nussenzveig et al., 1993; 
Drmota and Milligan, 2000). On this basis, it would appear that the fusion of the TRH 
carboxyl tail to the IP receptor created a receptor chimera possessing the trafficking 
behaviour of the donor receptor. In accord with such an assumption, internalisation of 
the mammalian GnRH receptor was reported to be enhanced by the addition of the TRH 
carboxyl tail to the receptor C-terminus (Heding et al., 1998).
Expression of the P2 -AR carboxyl sequence was unable to switch the sequestration 
phenotype of the prostacyclin receptor to that of the donor. Rather, the internalisation 
kinetics remained unaltered fi-om that of the full-length receptor. The role of the 
carboxyl tail in the sequestration of the P2 -AR is uncertain since mutations of potential 
phosphorylation sites and C-tail deletions did not inhibit internalisation (Hausdorff et 
al., 1989; Ferguson et al., 1995, 1996) whereas a dileucine motif within this region was 
identified as a positive regulator of receptor endocytosis (Gabilondo et al., 1997). In this
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study, the internalisation assays revealed that there was no acquisition of function by the 
expression of the P2 -AR C-tail. It would therefore appear that multiple domains would 
have to be switched in order to gain p2 -AR-like internalisation properties.
To further characterise the molecular mechanisms governing sequestration of the 
prostacyclin receptor, in chapter 4 various techniques were employed to identify the 
pathway involved in its sequestration. The role of the receptor’s carboxyl terminal 
domain in this process was examined using the chimeric receptor constructs. 
Pharmacological agents which block endocytosis via clathrin coated pits were effective 
at inhibiting sequestration of each of the receptor constructs. Furthermore, the receptors 
were shown to traffic in vesicles in close apposition to those containing transferrin. 
Taken together, these initial data identified the main pathway of internalisation of each 
of the constmcts as clathrin-dependent.
Clathrin-mediated endocytosis of GPCRs invariably displays a dependence on P- 
arrestin. Therefore, confocal microscopy was used to monitor the association of p- 
arrestin proteins with the receptors in intact cells. In accordance with previously 
published reports by Smyth et al. (2000), sequestration of the full-length prostacyclin 
receptors did not appear to be mediated via a p-arrestin dependent route. Switching of 
the carboxyl domain for the equivalent TRH receptor region increased the receptor’s 
affinity for P-arrestins as revealed by confocal imaging in which the chimeric receptor 
could be seen to co-intemalise with p-arrestin 2. In contrast, the P2-AR tailed chimeras 
trafficked independently of P-arrestins, assuming the same pattern of internalisation as 
the full-length receptor. Confocal analysis also revealed that the prostacyclin receptor 
proteins were capable of mediating significant levels of agonist-induced internalisation 
in a cellular milieu deficient of GRKs and arrestins. The predominant endocytic 
pathway utilised by the receptor constructs may therefore be arrestin-independent, 
although better cell models would be needed to confirm this.
The colocalisation experiments indicated that the addition of the TRH receptor C-tail 
sequence conferred P-arrestin sensitivity to the prostacyclin receptor. In support of this, 
earlier research suggested that the TRH receptor carboxyl domain was the main site of 
p-arrestin interaction, mediating high affinity binding with both p-arrestin 1 and 2 (Yu
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and Hinkle, 1999; Willars et a l, 1999; Heding et a l, 2000; Oakley et a l, 2000). 
Moreover, the carboxyl tail alone was reported to be sufficient to increase the binding 
affinity of P-arrestins to various receptor chimeras (Willars et a l, 1999; Oakley et a l, 
2000). Although an increase in the prostacyclin receptor’s affinity to p-arrestin was 
produced by the expression of the TRH carboxyl sequence, the failure of the IP/TRH 
chimeras to interact with p-arrestin 1 would suggest that, in this instance, the 
substitution of further intracellular domains would be necessary to reproduce a TRH- 
like sequestration phenotype.
The wild type P2 -AR receptor has been demonstrated to internalise in a p-arrestin- 
dependent manner (Zhang et a l, 1996; Ferguson et a l, 1996; Oakley et a l, 2000). 
Some investigators have suggested that the determinants which regulate the P2 -AR’s 
interactions with P-arrestin are located within the receptor’s carboxyl tail (Zhang et a l, 
1999, Oakley et a l, 1999, 2000) while others have intimated that other receptor 
domains contribute to the process (Jockers et a l  1996; Ferguson et a l, 1996). The data 
reported in this study would seem to be in accord with the latter postulation. The 
exchange of the intracellular loop regions may therefore also be required to generate a 
p-arrestin-sensitive receptor.
In the final results chapter, the desensitisation and resensitisation properties of the 
prostacyclin receptors were examined. In overexpression systems, the prostacyclin 
receptor has been shown to undergo rapid agonist-mediated desensitisation, a process 
which coincides with receptor phosphorylation (Smyth et a l, 1998). Desensitisation 
studies with the IP-GFP receptor produced similar results, demonstrating that the GFP 
tag did not prevent signal attenuation. Agonist-stimulated IP-TRH-GFP and IP-P2-GFP 
receptors exhibited a similar pattern of phosphorylation. However, the desensitisation 
responses elicited by the chimeras were more modest in comparison to that of the full- 
length receptor. The reason for these apparent differences in receptor responsiveness is 
unclear although it could be suggested that the reduced coupling efficiency displayed by 
the chimeric proteins was a contributory factor.
PKC has been reported to be the main desensitising kinase of the prostacyclin receptor 
(Smyth et a l  1998). However, experiments performed in this study indicated that PKA,
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and not PKC, was involved in the desensitisation of the IP-GFP receptor. Moreover, 
PKA was found to contribute to the desensitisation of the receptor’s chimeric forms. 
The explanation for the apparent discrepancy between results from this study and the 
observations made by Smyth et al. (1998) is uncertain. The GFP adjunct may alter 
receptor phosphorylation, and thus affect the signalling processes which induce receptor 
desensitisation. Consistent with this, the phosphorylation data reported here revealed 
that both second messenger kinases could stimulate phosphorylation of the constructs 
whereas Smyth and coworkers (1998) concluded that the IP receptor was not a substrate 
for PKA phosphorylation. It is possible that GFP may be modifying receptor 
phosphorylation and desensitisation by acting as a substrate for kinase action. It has 
been suggested that GRKs do not contribute to the desensitisation of the prostacyclin 
receptor (Smyth et al., 2000). It remains to be determined whether this is also the case 
for the GFP-tagged form of the receptor, and if the different carboxyl tails are GRK 
substrates.
The role of phosphorylation in receptor sequestration has been established for many 
GPCRs. For the prostacyclin receptor, however, it has been reported that 
phosphorylation is not a prerequisite for internalisation (Smyth et al., 2000). Contrary to 
this, the internalisation data in chapter 5 suggested that PKC phosphorylation may be of 
importance in the sequestration of the prostacyclin receptors; PMA-induced PKC 
activity stimulated the endocytosis of unoccupied cell surface receptors. Nevertheless, 
PKC’s involvement in the sequestration of agonist-activated receptors may be minimal 
since PKC inhibition failed to inhibit internalisation of iloprost-stimulated receptors. 
The data in this study cannot therefore rule out a link between receptor phosphorylation 
and sequestration for the IP receptor and its chimeric forms.
Upon the removal of agonist, the sequestered IP-GFP receptors were found to rapidly 
recycle back to the plasma membrane with a concomitant recovery of receptor 
responsiveness. In contrast, the agonist-activated chimeric receptors did not recycle. 
The retention of receptors intracellularly coincided with the receptors’ failure to 
resensitise. Various studies have intimated that dephosphorylation is a prerequisite for 
receptor recycling and resensitisation (Pippig et al., 1995; Shih et al., 1999; Hasbi et al., 
2000; Innamorati et al., 2001). The dissociation of the receptor/p-arrestin complexes has
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been reported to be the rate-limiting step for receptor dephosphorylation (Oakley et al., 
1999). Consistent with this, it could therefore be argued that the p-arrestin-independent 
trafficking of the IP-GFP receptor allows for rapid association of the sequestered 
receptors with the phosphatase, enabling rapid recycling and resensitisation. This model 
may also be applicable to IP-TRH-GFP receptor sequestration; the high affinity P- 
arrestin interactions mediated by the TRH carboxyl tail may prevent receptor 
dephosphorylation and recycling. The recycling and resensitisation profile of the pz-AR 
tailed chimera did not fit the model proposed by Oakley et al. (1999). Although it has 
been shown that the construct internalises independently of p-arrestin, it is conceivable 
that conformational effects induced by the presence of the P2-AR carboxyl domain 
impede phosphatase access or possibly direct receptor trafficking via a non-recycling 
pathway. Assessment of the receptors’ phosphorylation status after agonist withdrawal 
would be required to accurately determine the rate of dephosphorylation for each 
construct, and whether the dephosphorylation step dictates the receptors’ resensitisation 
kinetics. Investigation of the long-term fate of the agonist-stimulated prostacyclin 
receptor constructs revealed that the non-recycling chimeric receptors underwent 
downregulation more rapidly compared to the recycling full-length receptor. From this 
observation, it could therefore be assumed that the retention of receptors intracellularly 
increases sorting via a degradative pathway, a proposal which has been suggested by 
other investigators (Oakley et al., 1999; Bremnes et al., 2000).
In conclusion, with the use of receptor chimeras, the carboxyl terminal domain of the 
prostacyclin receptor has been shown to be of functional significance in various aspects 
of receptor regulation including desensitisation, sequestration, and resensitisation. The 
results indicate that the different carboxyl sequences modulate distinct receptor 
interactions with intracellular signalling components. Although switching of carboxyl 
tail domain was found to have profound effects on receptor activity, the chimeric 
receptors did not assume the GPCR characteristics typical of the carboxyl terminal 
donors. It therefore seems likely that the carboxyl tail, in concert with other intracellular 
domains, regulate receptor activity.
The use of GFP to directly visualise the trafficking of the prostacyclin receptors in cells 
provided crucial insight into the mechanisms involved in GPCR regulation.
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Nevertheless, it is clear from this investigation that whilst many of the pharmacological 
properties of the prostacyclin receptor were retained following the C-terminal fusion of 
the GFP moiety, the IP-GFP receptor elicited discernible differences in receptor activity 
in comparison to those reported for the non-GFP-tagged form of the protein (Smyth et 
ah, 1996 1998). Therefore, data from GPCR-GFP studies should be viewed with 
caution.
It is evident from the data presented in this study that further research is required to 
better characterise the role of the carboxyl terminal domain in prostacyclin receptor 
signalling. Future work with the prostacyclin receptor constructs would include 
investigating the G q/G n coupling efficiency of the receptors to determine the role of 
PKC activation in receptor desensitisation and internalisation. It would also be of 
interest to examine the possible role of GRK-mediated phosphorylation in homologous 
desensitisation of these receptor proteins. Viable p-arrestin knockout cell lines would 
also be useful tools to delineate the sequestration pathways utilised by the receptors. 
Furthermore, assessment of the intracellular localisation and phosphorylation status of 
the agonist-activated receptors would provide greater insight into the mechanisms 
involved in the resensitisation of the full-length receptor and the carboxyl tail chimeras. 
Further understanding of prostacyclin receptor regulation could also be achieved by the 
generation of a series of prostacyclin receptor chimeras in which additional intracellular 
domains are switched.
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